Chronic hepatitis B infection in the immigrant communities of East London by Dias, Aruna







The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 





Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For






CHRONIC HEPATITIS B INFECTION IN THE IMMIGRANT COMMUNITIES OF 
EAST LONDON 
Dr Aruna Dias 
BSc MBBS MRCP 
 
Submitted in partial fulfilment of the requirements of the Degree of 
Doctor of Medicine (MD RES) 
2 
 
Statement of Originality 
I, Aruna Dias, confirm that the research included within this thesis is my own work or 
that where it has been carried out in collaboration with, or supported by others, that this 
is duly acknowledged below and my contribution indicated. Previously published 
material is also acknowledged below. 
I attest that I have exercised reasonable care to ensure that the work is original, and does 
not to the best of my knowledge break any UK law, infringe any third party’s copyright or 
other Intellectual Property Right, or contain any confidential material. 
I accept that the College has the right to use plagiarism detection software to check the 
electronic version of the thesis. 
I confirm that this thesis has not been previously submitted for the award of a degree by 
this or any other university. 
The copyright of this thesis rests with the author and no quotation from it or information 
derived from it may be published without the prior written consent of the author. 
 






Worldwide there are 350 million people with chronic hepatitis B infection and globally it 
causes up to half of the liver cancer deaths and one third of deaths from cirrhosis. Only a 
fraction of sufferers will develop these complications. Various studies have implicated 
socio-demographic, biochemical and viral factors in disease progression but research has 
been limited to local populations in endemic countries. Our aim was to study the 
prevalence and factors associated with advanced disease of hepatitis B infection in 
immigrants living in East London.  
I completed a retrospective analysis of notes and electronic health records of 1209 
immigrant patients attending hospitals in East London, 217 of whom were from 
Bangladesh and Pakistan. Screening of volunteers attending local mosques using oral 
mucosal transudate swabs and national statistics data allowed us to calculate prevalence 
rates in these populations. Those 13 patients from Bangladesh and Pakistan admitted 
over 30 months with decompensated disease were men aged >40. Age, sex, ALT, 
smoking, alcohol and diabetes were significant predictors for cirrhosis and 
decompensated disease but not viral markers. Similar analyses were performed for other 
ethnicities with similar outcomes.  The scale of under diagnosis of hepatitis B for all 
ethnicities was estimated and the reasons explored. This work has scrutinised the 
epidemiology of chronic hepatitis B in East London and the difficulties encountered 
exploring it. We provide differing results to published studies and suggestions for how 
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1.1 Classification of human hepatitis viruses  
Many viruses affect the liver such as Cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
Herpes Simplex virus (HSV), human immunodeficiency virus (HIV), yellow fever virus and 
Dengue fever virus but they do not have the liver as their primary target of infection.  
The human hepatitis viruses are hepatotrophic with the liver being the primary target of 
cellular damage and viral replication. There are five main human hepatitis viruses and 
these are defined virologically into RNA and DNA viruses. Hepatitis A and E are 
transmitted via the faecal-oral route, whilst hepatitis B, C, and D are transmitted 
parenterally. Hepatitis B (HBV) differs from the other parenterally transmitted hepatitis 
viruses in that it is a DNA virus, whilst the others are RNA viruses.  
HBV belongs to the Hepadnaviridae family of viruses. Human HBV shares a degree of 
structural, genomic and clinical sequelae with other animal hepatitis viruses from the 
same family: ground squirrel hepatitis virus (GSHV),1 woodchuck hepatitis virus (WHV),2 
and duck hepatitis B virus (DHBV).3 In all these species, presence of the virus can 
ultimately lead to the development of chronic liver disease and hepatocellular carcinoma 
albeit with differing degrees of oncogenic potential. 
 
1.2 Discovery of HBV 
Hepatitis B was first isolated by Baruch Blumberg and his co-workers in Philadelphia in 
1965. They identified a viral antigen in serum that was "introduced by transfusions". As 
this virus originally came from the sera of an Australian Aborigine it was termed Australia 
Antigen (AuAg).4 In 1970, David Dane and colleagues described the structure of the 
complete HBV particle.5 In 1973 the world health organisation (WHO) renamed AuAg as 
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hepatitis B antigen (HBAg) and this subsequently was known as hepatitis B surface 
antigen (HBsAg). 
 
1.3 Structure of HBV 
The infectious HBV virion is 42-47 nm in diameter and is also known as the Dane particle 
after its discoverer (see Figure 1-1). It is composed of an outer envelope and inner 
icosahedral nucleocapsid. The outer envelope is composed of a lipid bilayer and 
embedded within are the surface proteins which may or may not be glycosylated. There 
are 3 types of surface proteins which are also known as surface antigens: small, medium, 
and large, and are typically found in a ratio of 4:1:1 in Dane particles.6 As the small 
antigen is present on the surface of all HBV particles it is termed hepatitis B surface 
antigen (HBsAg). The role of medium proteins has not been fully determined yet. Large 






Figure 1-1 Structure of HBV virus (taken from Lai CL, Locarnini S, editors. Hepatitis B 
Virus. 2 ed. London: International Medical Press; 2008.) 
 
The main structural protein of the inner nucleocapsid is the phosphorylated C or core 
protein. This was originally detected serologically and referred to as hepatitis B core 
antigen (HBcAg).8 Within this core is found the P or polymerase protein, the viral DNA 
and a protein kinase. In vitro studies have shown that the protein kinase is involved with 
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phosphorylating C protein9;10 but that recombinant C and P proteins do not possess this 
enzyme which suggests that it is derived from the host. 
In addition to producing the Dane particle, HBV also releases 2 types of sub-viral particles 
which exist as 20 nm spheres or filaments (see Figure 1-2). They are composed entirely of 
S proteins and lipid membrane derived from the host11;12 with no inner nucleocapsid. The 
S proteins are mainly small surface proteins with some medium proteins but very few 
large proteins. Whilst these particles are non-infectious due to the lack of nucleic acid, 
they are highly immunogenic and efficiently induce a neutralizing anti-HBs antibody 
response. There may be as many as 10,000 to a 1,000,000 fold excess of these spheres 
compared to Dane particles. Filaments are produced in smaller numbers than spheres 
and have the same diameter but are of variable length. The reason for there being so 
many spheres produced when they are not infectious has not been fully ascertained but 
one theory maybe that they absorb neutralizing antibody and so shield the virions from 
the host defences.13  
 
Figure 1-2 Schematic diagram of HBV Dane particle and sub-viral particles (taken from 
Kann M. Structure and Molecular Virology. In: Lai CL, Locarnini S, editors. Hepatitis B 
Virus. 2 ed. London: International Medical Press; 2008. 2.1-2.15)7 
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1.4 Viral Genome 
HBV has a relatively short genome of 3200 kilobases arranged as relaxed, circular, 
partially double stranded DNA (dsDNA).14 The DNA consists of a complete negative 
strand that is paired with an incomplete complimentary positive strand that is of variable 
length. The structure is kept circular by base pairing between the 2 strands. The 5’ end of 
the negative strand is covalently attached to the viral polymerase protein, whilst the 
5’end of the positive strand is covalently linked to a RNA oligonucleotide. Both of these 
additional structures are essential for initiating DNA synthesis. In addition to these, there 




Figure 1-3 Structure of viral genome (taken from Ganem D, Schneider RJ. 
Hepadnaviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, editors. 





The genetic information within the small HBV genome is organised in a very compact 
fashion. All of the nucleotides are functionally arranged within the coding region or 
reading frame.13 There are four major proteins in HBV: surface (S), core (C), polymerase 
(P) and X protein (X) and each of these has their own open reading frame (ORF). This 
compactness is maximised by having overlapping ORFs that utilise more than half of the 
nucleotides in different ORFs so that they can transcribe different messenger RNAs 
(mRNAs). These mRNAs can then subsequently be translated into more than one viral 
protein. For instance, from Figure 1-3, it can be seen that whilst the S gene encodes for 
HBsAg, the entire length of its sequence is used in another ORF to encode part of the P 
gene. This has implications for the development of mutations as any changes to the S 
gene will invariably have an effect on the P gene. 
Another feature of the HBV genome is having ORFs with multiple start sites. The surface 
ORF codes for the surface proteins but it is elongated upstream at its 5’ end by a 400 
nucleotide preS region.15 This region can be subdivided further into preS1 and preS2 
regions each of which has its own AUG initiation codon. Translation of just the S region 
results in small protein production; translation of preS2 and S results in medium protein 
formation; and translation of preS1, preS2 and S is necessary to form large surface 
proteins. 
A similar phenomenon exists with the core ORF which has a C region and a 33 nucleotide 
region upstream from its 5’ end called preC.16 Translation of the combined C and preC 
regions results in a protein that is similar to but different from core protein both 
structurally and functionally called hepatitis B e antigen (HBeAg). The precore sequence 
directs the protein to the endoplasmic reticulum and Golgi where proteases cleave part 
of the C-terminus peptide residues before it gets secreted out of the host cell. The 
specific function of HBeAg is not fully understood but it is not essential for viral assembly, 
replication or infection.17 It may play a role with immune regulation and inducing 
“tolerance” of the host defences towards HBV infection.18 
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Core protein is translated from the C region of the core ORF but it is transcribed by a 
different mRNA to e mRNA. The core-polymerase (C/P) mRNA codes for both the core 
and polymerase proteins and is the largest of the mRNA transcripts at 3.5kb in length. 
The C/P mRNA also serves another function as a reverse transcriptase for the entire DNA 
negative strand and so is also referred to as pregenomic RNA, which is crucial for viral 
replication to occur. In addition to the reverse transcriptase, the polymerase protein also 
consists of an RNase H enzyme which serves to destroy the RNA template so that 
synthesis of the DNA positive strand can occur. This feature, Hepadnaviridae share with 
retroviruses but they differ in other respects such as there is no integrase activity; the 
HBV DNA is episomal and independent of the host DNA. 
 
1.5 Viral Replication 
The life cycle of HBV is intricate and unusual. It is not fully understood, but from animal 
studies especially with duck hepatitis B virus (DHBV), it is thought to involve a number of 




Figure 1-4 Viral Replication (taken from Ganem D, Schneider RJ. Hepadnaviridae: The 
Viruses and Their Replication. In: Knipe DM, Howley PM, editors. Fundamental Virology. 
4 ed. Philadelphia: Lippincott Williams & Wilkins; 2001. 1285-1332)13 
 
1.5.1 Viral binding and entry 
The first step in viral infection is attachment of the virus to the host cell. The preS1 
domain, which ultimately produces large hepatitis B surface proteins, has been strongly 
implicated in attaching the virus to the host cell because sub-viral particles, rich in preS1 
peptides, have been shown to bind to cells whilst particles only containing S domain 
don’t. If the preS1 sequence was subsequently added to the S domain then binding 
ability was restored. Further animal studies have shown that for infection to occur, with 
both HBV and HDV particles, there needs to be post-translational N-terminal 
myristylation of the large protein and that this can be blocked if a N-terminal 
myristoylated peptide corresponding to amino acids 2–48 of this pre-S1 domain is used. 
19-21 However only recently have Yan et al have confirmed that the viral preS1 receptor 
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binding region interacts with a multiple transmembrane transporter called sodium 
taurocholate cotransporting polypeptide (NTCP). NTCP is predominantly found in the 
sinusoidal/baso-lateral membrane of hepatocytes and partakes in the enterohepatic 
circulation of bile salts. They showed that blocking NTCP could prevent HBV and HDV 
infection and that non-susceptible hepatocellular carcinoma cells could be made 
susceptible if they were transfected with human and tree shrew NTCP.  Similarly if part of 
the amino acid sequence of non-functional monkey NTCP was replaced with human 
NTCP then this bestowed the ability to be infected with human HBV and HDV.22 
Following attachment to the hepatocyte, there are at least two methods by which the 
virus can enter the cell. The first is by direct membrane fusion using a fusion peptide in a 
similar fashion to alphaviruses.23 The other method is via receptor-mediated 
endocytosis.24 
 
1.5.2 Transport of viral genome within hepatocyte 
In order for replication to occur, the viral genome needs to be delivered to the cell 
nucleus. How this happens has not been conclusively determined. There may be passive 
diffusion or microtubule-dependent mechanisms. Having reached the nucleus, there is 
uncertainty as to how the virus traverses the nuclear pores as the nucleocapsid appears 
too large. One theory is that there is uncoating of the genome in the cytosol and the DNA 
travels into the nucleus. Once inside the relaxed circular genomic DNA (rcDNA) is then 
converted, via a number of complex steps, into plasmid-like covalently closed, circular 
DNA (cccDNA). Whilst the exact details of how this occurs are unknown, what has been 
determined is that there is repair of the single-stranded gap in the positive DNA strand, 
removal of the 5’-terminal structures (RNA and P protein), and covalent ligation of the 




1.5.3 Transcription and translation of viral mRNA 
There are two main types of mRNA. One of which is shorter than genomic length and is 
referred to as subgenomic RNAs. They code for the large, medium and small surface 
proteins and the X protein. The other type is greater than genomic length: one of them 
codes for HBeAg and the other one codes for the core and pol proteins. This latter mRNA 
is referred to as pregenomic or pgRNA.  All transcription occurs in the nucleus and is 
regulated by a number of promoters and enhancers.  
Transcription is carried out by host RNA polymerase II using cccDNA as a template. It 
results in the synthesis of a full-length positive RNA strand as well as multiple 
overlapping mRNAs. From this they are transported to the cytoplasm to be translated 
into the four main viral proteins. The pol protein produces the DNA polymerase 
necessary for the formation of the complimentary negative DNA strand. 
 
1.5.4 Encapsidation of pgRNA and polymerase into nucleocapsids 
Viral packaging or encapsidation occurs in the cytoplasm and is initiated by the binding of 
viral polymerase to a unique stem-loop structure at the 5’ end of the pgRNA. This 
encapsidation signal (ε) is relatively small (about 100 nucleotides in size) and consists of a 
number of repeats that are folded to give a distinct hairpin loop shape that has a bulge 
on one side and conserved loop at the top with the stem structure being maintained by 
base pairing (see Figure 1-5). All viral RNAs have ε at their 3’ ends but only pgRNA has it 
at its 5’ end, and for some unknown reason, only the 5’ copy of ε is functional; this could 




Figure 1-5 Structure of the encapsidation signal (taken from Jilbert AR, Mason WS, Kann 
M. Hepatitis B Virus Replication. In: Lai CL, Locarnini S, editors. Hepatitis B Virus. 2 ed. 
London: International Medical Press; 2008. 4.1-4.1325 
 
Polymerase (pol) and ε form a complex that begins upstream of a region on the pgRNA 
called DR1 and continues beyond DR2, another downstream DR1 (called DR*1) and ends 
at the 3’ end polyadenylation site. In a process that is not fully determined, the complex 
interacts with core protein to manufacture core protein dimers. These dimers then 
become assembled to form an immature nucleocapsid. 
 
1.5.5 Reverse transcription and synthesis of DNA 
DNA synthesis occurs in the cytoplasm and is thought to occur either just prior to or just 
after encapsidation. It is initiated by reverse transcriptase from the pol protein and starts 
with pgRNA acting as a template for negative DNA strand synthesis. It begins with the 
pol-oligonucleotide complex from ε translocating to the DR*1 sequence (at the 3’ end) of 
pgRNA.  The negative strand is elongated by travelling towards the 5’ end of the pgRNA. 
As it does so, the pgRNA template is degraded by another enzyme from pol called RNase 
H; this is necessary so that the negative DNA strand can act as a template for the positive 
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strand. All that remains of the pgRNA template after RNase H activity is a small sequence 
of nucleotides which includes the DR1 sequence. This is important because this RNA 
sequence is translocated to DR2 and used as a primer for positive DNA strand synthesis. 
Elongation of the positive DNA strand begins from the 3’ end of the negative DNA strand. 
Ultimately circular DNA is produced of which the positive DNA strand will have a variable 






Figure 1-6 Replication of HBV (taken from Jilbert AR, Mason WS, Kann M. Hepatitis B 
Virus Replication. In: Lai CL, Locarnini S, editors. Hepatitis B Virus. 2 ed. London: 





After viral replication has been completed, the nucleocapsid can follow one of two final 
pathways. The first is to be transported back to the nucleus to establish and maintain a 
reservoir of cccDNA. This is most likely to occur with early infection when there are 
relatively small quantities of cccDNA and other viral proteins. The cccDNA will act as a 
template for positive strand DNA which will remain in place even when the infected 
hepatocyte divides through mitosis. cccDNA is very stable and is immune to antiviral 
drugs that target reverse transcriptase and clear viral DNA from the cytoplasm.  
The other pathway is export of the virion from the hepatocyte. In order for this to 
happen, it needs to be enclosed with an envelope developed from the S gene proteins: 
surface, M and L. Assembly occurs in the endoplasmic reticulum and Golgi apparatus 
where a lipid layer and the transmembrane proteins are added. This final stage of the 
viral life cycle, where there is release of new virions and subviral particles (that do not 
contain a nucleocapsid), is completely dependent on the S gene and in particular the 
surface and pre-S1 proteins. 
 
1.6 Pathogenesis 
Hepatitis B infection can result in either acute or chronic disease states, both of which 
are associated with a spectrum of clinical manifestations. Acute infection can present as: 
asymptomatic infection, anicteric hepatitis, icteric hepatitis or fulminant hepatitis. 
Chronic infection can vary from an asymptomatic carrier state to chronic, active 
hepatitis, compensated cirrhosis, decompensated liver disease or hepatocellular 
carcinoma. 5-10% of infections acquired in adulthood develop chronic infection 
compared to 30-90% of children infected before the age of 5.26;27 
HBV per se is not directly cytopathic to cells. The damage that occurs is thought to be due 
to the interplay between viral replication and the immune response. Age has a role to 
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play as demonstrated by experiments with neonatal ducks28 and woodchucks29 which 
demonstrated that whilst only tiny amounts of viral inoculum were required to cause 
infection, there were threshold values whereby either transient or chronic infection 
occurred. Similarly with older animals it required larger viral loads to induce chronic 
infection. It is unclear why the immune response of children and young animals to HBV is 
so weak when they mount adequate response to other viral infections.  
Following viral infection, each hepatocyte contains 5-50 copies of cccDNA that acts as a 
reservoir for new virion production and these continue to infect the rest of the liver. 
Animal studies have propounded that infection usually occurs via cell-to-cell contact and 
increases exponentially such that almost the entire liver of 1012 hepatocytes could be 
infected in about 7 weeks.30 There is more uncertainty regarding the question of how the 
immune system clears the liver of cccDNA to prevent re-infection, and why some 
patients do not clear the virus and subsequently become chronically infected.   
HBV infection has an incubation period of 2-3 months (but can be up to 6 months) before 
the onset of symptoms, which coincides with detection of HBV antigens in the liver and 
serum, and with the initiation of immune clearance of the infection.31 What actually 
triggers the immune response is not fully known but it is thought that there is a multi-
specific polyclonal cytotoxic T lymphocyte (CTL) response to several HBV antigens. This 
could explain why patients who experience fulminant hepatitis B suffer massive immune-
mediated destruction of hepatocytes despite there being a very low viral load. Similarly 
those individuals who clear HBeAg either spontaneously or with interferon treatment 
often experience an exacerbation in their liver disease with a rise in the liver 
transaminases (ALT).32 The initial response of the immune system appears to be critical in 
determining whether the infection is transient or remains chronic.  
The proportion of CTLs to infected hepatocytes is so small that other parts of the 
immune system must be involved. Natural Killer cells have been implicated in resolution 
of HBV-infected hepatocytes.31;33 They have the effect of killing infected cells by direct 
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cell-cell contact and by releasing inflammatory cytokines such as interferon gamma 
(IFNγ) and tissue necrosis factor alpha (TNFα).  
Resolution of transient infection is thought to occur through turnover of previously 
infected hepatocytes in a piecemeal fashion as there is no significant decrease in 
hepatocyte mass during this time. Elimination of cccDNA is not fully understood. It may 
be that there is dilution of the cccDNA to progeny hepatocytes when the infected 
hepatocytes die, or that cytokines directly destroy cccDNA or even that cccDNA is 
unstable and its synthesis is inhibited during resolution which ultimately leads to its 
disappearance.26 That said it is very rare to get complete eradication of cccDNA even 
after recovery of acute hepatitis as the disease can reactivate many years later during 
periods of immunosuppression or with liver transplantation.34 
 
1.7 Histopathology of HBV Infection 
Analysis of the liver histology gives an indication of how effectively the liver deals with 
viral replication and the immune response against the virus. In the normal liver, 
hepatocytes are arranged in plates to form a network that extends between the portal 
tracts and terminal hepatic veinules. These plates are separated by sinusoids, which are 
lined with endothelial cells and phagocytic Kupffer cells. The hepatocytes are arranged in 
anastomosing plates that are 1 cell thick with the layer of hepatocytes that is closest to 
the portal area called the limiting plate, which is an important anatomical landmark with 
progressive chronic inflammation.  
In acute HBV, there are non-specific changes with the immune system effectively 
destroying the cells that harbour viral antigens to produce a spotty necrosis that is 
pancinar in distribution. Apoptosis is the major underlying mechanism causing acidophilic 
and ballooning degeneration of hepatocytes that results in swelling and destruction with 
phagocytosis of the cellular remnants. In severe cases there may also be simultaneous 
loss of adjacent hepatocytes which is referred to as bridging necrosis. Most cases of 
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acute infection resolve 1-3 months after the onset of symptoms resulting in no remaining 
hepatocellular injury. 
Some patients experiencing transient infection present with acute (fulminant) hepatic 
failure. In these cases there is sub-massive hepatic necrosis with extensive loss of 
hepatocytes and collapse of the supporting connective tissue stroma. There may be 
bridging necrosis with portal-portal or portal-central linkage, with the bridges being 
composed of collapsed reticulin, newly laid down collagen fibres, hypertrophied Kupffer 
cells and other inflammatory cells. The hepatocyte damage is zonal and usually 
centrilobular. If the patient survives the acute injury there is usually regeneration of the 
liver but there may be some residual nodules.  
A characteristic feature of chronic HBV infection is the presence of ground glass 
hepatocytes.35 These are liver cells which have an eosinophilic, granular, glassy 
cytoplasm when stained with different immunohistochemical techniques using light 
microscopy. Such cells contain large amounts of cytoplasmic HBsAg and are found in 
patients who are in the non-replicative phases where there is more HBV DNA integrated 
into the hepatocyte genome and less HBcAg being produced. 
With chronic infection, inflammation tends to spread out from the portal tracts. 
Expansion beyond this area to involve the limiting plate is referred to as interface 
hepatitis or piecemeal necrosis. As the necro-inflammatory process progresses and 
engages more hepatocytes, collagen fibres are laid down which can condense and 
eventually contract to leave scars. It is the contraction of these fibrous septa, the 
formation of regenerative nodules and the development of fibrous bridges (either portal-
portal, central-central or central-portal), which leads to parenchymal architectural 
distortion that ultimately destroys the acinar structure and leads to cirrhosis. 
Often patients will suffer episodes of exacerbation with an increase in severity of the 
inflammation and associated fibrosis, followed by periods of quiescence in which the 
injury and inflammation decrease and the fibrosis activity may even appear to have 
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lessened.  Even if cirrhosis develops then this should not be seen as a condition that does 
not change. If the underlying cause persists the hepatic parenchyma will continue to be 
transformed into increasing amounts of scar tissue and eventually clinical 
decompensation can ensue. The opposite is also true and if the instigating disease 
subsides or is treated, then fibrosis may regress to a degree. During seroconversion there 
may be a flare of the disease and histology may demonstrate increased severity of injury, 
but once this is concluded, inflammation and activity will diminish.  
The stage of HBV infection refers to the modification of structure or loss of function as 
the disease progresses. As the disease advances, the patient goes from a normal liver to 
a stage of fibrous portal expansion that extends between vascular structures, develops 
bridging fibrosis and then results in the appearance of parenchymal nodules surrounded 
by fibrous tissue. When there is complete loss of architecture and composition consists 
entirely of nodules and fibrosis, then cirrhosis has developed.  
The grade or activity corresponds to the severity of one or more clinical, functional or 
histological features. It gives an indication of how rapidly the disease will progress 
through the stages, with a low-grade disease being slowly progressive while a high grade 
disease is rapidly progressive. Histological grading of HBV involves assessing the severity 
of the hepatocellular injury and inflammation and deciding whether the activity is mild, 
moderate or severe.  There are four major scoring systems for grading and staging 
chronic inflammation which were initially developed for use in patients with chronic HCV 
infection36-39 (see Table 1-1 and Table 1-2).  
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Minimal hepatitis A1 Grade 1 0-3 0-3 
Mild hepatitis A1 Grade 2 3-5 3-6 
Moderate hepatitis  A2 Grade 3 6-9 7-9 
Severe hepatitis A3 Grade 4 10-12 10-15 
Severe hepatitis with bridging 
necrosis 
A3 Grade 4 14-18 16-18 
Table 1-1 Various scoring systems for grading liver inflammation 
 
Histological Stage Metavir36 Batts-
Ludwig37 
Knodell     
(I-III)38 
Ishak39 
No fibrosis F0 Stage 0  0 0 
Portal fibrosis (minor) F1 Stage 1 1 1 
Portal fibrosis (major) F1 Stage 1 2 2 
Bridging fibrosis (minor) F2 Stage 2 3 3 
Bridging fibrosis (major) F3 Stage 3 3 4 
Incomplete cirrhosis F4 Stage 4 4 5 
Cirrhosis F4 Stage 4 4 6 
Table 1-2 Various scoring systems for grading liver fibrosis 
 
1.8 Natural History of Chronic Hepatitis B 
The clinical course of chronic HBV infection is long and complicated (see Figure 1-7). 
Although it is determined by the interaction of viral replication and the host immune 
response, it is affected by other factors such as patient's age, alcohol consumption 
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and co-infection with other viruses, such as hepatitis C. Men have an greater risk of 
HCC and disease progression than women especially after the age 45.40 By 
understanding the natural history, informed decisions can be made about disease 
monitoring, and when to initiate (or even terminate) treatment. Whilst there is some 
debate as to the actual number (and naming) of phases that HBV infection undergoes, 
it is accepted that there is a period whereby viral replication and liver damage is more 
prominent followed by a period where there is a degree of remission.41;42 Similarly 
there is a difference between patients acquiring the disease perinatally and in early 
childhood than those that acquire it at a later time in their lives.  
 
Figure 1-7 Natural history of the phases of chronic HBV infection (taken from Yuen 
MF, Lai CL. The Natural History of Chronic Hepatitis B. In: Lai CL, Locarnini S, editors. 
Hepatitis B Virus. 2 ed. London: International Medical Press; 2008. 12.1-12.1143 
 
The first phase is called the immune tolerance phase and occurs in individuals 
infected in early childhood, especially perinatally. Patients typically are HBeAg 
positive and have very high amounts of HBV DNA (usually 108-1011 copies/ml) but 
little in the way of active disease as evidenced by normal ALT and liver histology.44 
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The lack of liver damage in the face of active viral replication would suggest that the 
immune system does not recognise the virus as a threat. HBeAg has been implicated 
with inducing tolerance as it has been shown to traverse the placenta whilst not 
stimulating the production of anti-HBe.45 This phase can last up to three decades in 
some individuals. Liver biopsy at this stage typically shows minimal liver damage and 
treatment is not usually indicated.  
Individuals infected beyond early childhood tend to enter the immune active or 
immune clearance phase shortly after infection rather than the 20-30 year wait 
experienced with perinatal infection patients. This phase is characterised by the host 
recognising the virus as foreign and mounting a concentrated immune-mediated 
attack. The trigger for this phase developing is not known. Whilst this response is 
usually not strong enough to eliminate the virus it does cause hepatocyte damage, 
release of ALT, and reduction in DNA levels with suppression of the virus. There is also 
10-20% chance of spontaneous seroconversion of HBeAg to anti-HBe.46 Depending on 
the strength and duration of the response, there may be significant fibrosis, cirrhosis 
or even liver decompensation. For this reason, anti-viral treatment should be 
considered. Interferon can be used, even if compensated cirrhosis has developed 
(Childs-Pugh A), but should be avoided in decompensated cirrhosis (Childs-Pugh B & 
C) because it can cause a flare in ALT levels that may lead to further decompensation, 
sepsis and death.47 Factors associated with an increased prospect of HBeAg 
seroconversion include genotype B, older age, and elevated ALT as this suggests a 
heightened immune response.43;47 
However, recently there have been questions about whether teenagers and young 
adults are still in a "true" immunotolerant phase because their viral loads tend to be 
slightly lower (106-108 copies/ml) than younger children but the ALT levels tend to 
slowly increase. It may be that there is some immune pressure and some disease 
progression.48;49 The longitudinal REVEAL-HBV study from Taiwan, showed that 
persistence of high viral loads (>104 copies) over a long length time and admittedly in 
older adults, even in the absence of elevated ALT and being HBeAg positive, was 
associated with increased risk of HCC.50  
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The loss of HBeAg and the occurrence of anti-HBe usually signifies entry into the third 
phase. This phase has been given a number of different names: residual phase,43 
immunosurveillance phase51 and inactive phase.52;53 In the vast majority of patients 
there is an corresponding reduction in viral load (from undetectable to 103 - 105 
copies/ml), near normalisation of ALT and improvement of histological grade. All this 
would suggest that the patient is of low infectivity and low risk of transmitting the 
virus to others. In a long term follow up of patients who had HBeAg seroconversion 
over 65% remained in remission. However, the remainder either returned to being 
HBeAg positive or remained HBeAg negative but with elevated ALT.  
Some patients develop HBeAg negative chronic hepatitis whereby there is active 
replication and increased viral load, elevated ALT and deterioration of histology but 
with undetectable HBeAg. These patients may be thought of as entering a fourth 
phase where there is immune escape due to a mutation that fails to produce HBeAg. 
In these cases there appear to be mutations in the precore or core promoter 
regions.54-57  
In addition to HBeAg seroconversion happening, there can also be HBsAg 
seroconversion. This has an annual incidence of 0.4-2% rate for Caucasians and 0.1-
0.8% for Asians.58;59 Predictors of spontaneous loss of HBsAg include older age and 
persistent inactive hepatitis.60 In younger individuals (aged less than 50) this is 
associated with a reduced risk of developing complications like hepatocellular 
carcinoma. Unfortunately, undetectable levels in serum does not mean complete 
eradication of the virus, as 10 year follow up studies have found that 100% have 
intrahepatic HBV DNA and 73% have intrahepatic cccDNA.61 
 
1.9 Laboratory Diagnosis of Hepatitis B 
Identification of HBsAg is the characteristic marker of HBV infection. Typically it is 
detected in the serum 6-10 weeks after exposure to the virus and predates clinical 
symptoms or biochemical changes. In addition to HBsAg, other markers of acute HBV 
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infection also detected include HBeAg and HBV DNA (see Figure 1-8). Hepatitis B core 
antigen is not readily detected in the serum. 
 
Figure 1-8 Changes in viral markers and ALT over time with acute HBV infection (taken 
from Bowden S. Laboratory Diagnosis of Hepatitis B. In: Lai CL, Locarnini S, editors. 
Hepatitis B Virus. 2 ed. London: International Medical Press; 2008. 11.1-11.1662 
 
The development of symptoms signifies the host immune response and the 
production of antibodies to these viral antigens. The first of these to appear is 
antibody to core antigen, anti-HBc. Initially anti-HBc immunoglobulin M (IgM) is 
detected and this peaks during early recovery before waning after 3-12 months; this 
coincides with the appearance of anti-HBc immunoglobulin G (IgG). Whilst IgM is a 
marker of acute hepatitis, it can occur with flares of chronic hepatitis and may persist 
for around 2 years; total anti-HBc will persist indefinitely and be an indicator of 
previous HBV infection. Next to appear is antibody to e antigen, anti-HBe, and this is 
coupled with a dramatic decrease in HBeAg and HBV DNA. There may also be an 
increase in ALT at the time of HBeAg seroconversion as the immune system 
eliminates infected hepatocytes.  Last to transpire is the production of the 
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neutralising antibody to surface antigen, anti-HBs, whose occurrence implies 
immunity to HBV. 
Perseverance of HBsAg for greater than 6 months denotes chronic HBV infection. 
Whereas greater than 95% of immunocompetent adults with genuine acute HBV clear 
HBsAg spontaneously,63 those patients who develop chronic HBV infection have a less 
than 1% rate of clearance per year.59 With persistence of infection, there is an 
improvement of ALT levels although not usually to normal, and there may be a flare 
up if seroconversion, especially with HBeAg, happens (see Figure 1-9). 
 
Figure 1-9 Changes in viral markers and ALT over time with chronic HBV infection 
(taken from Bowden S. Laboratory Diagnosis of Hepatitis B. In: Lai CL, Locarnini S, 
editors. Hepatitis B Virus. 2 ed. London: International Medical Press; 2008. 11.1-
11.1662 
 
The natural history of chronic HBV infection is incompletely understood (see earlier). 
HBeAg existence is allied with high HBV DNA levels and has been thought of as 
signifying high infectivity. With the production of anti-HBe there is a decline in HBV 
DNA. However, in a proportion of patients that are now HBeAg negative, there may 
still be high amounts of HBV DNA (typically greater than 104 copies/ml) that leads to 
severe liver disease, even if anti-HBe is present. In these cases some form of mutation 
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has occurred: 1) G to A substitution at nucleotide 1896 in the precore region leading 
to a stop codon be created to prevent translation of HBeAg64 2) nucleotide 
substitutions at position 1762 and 1764 in the basal core promoter region that may 
reduce transcription of mRNA that encodes HBeAg. 
It is important to evaluate HBV DNA as this can serve a number of functions: acting as 
a marker of disease activity and so assessing those individuals who should be treated 
- persistent HBV DNA >105 copies/ml is an independent risk factor for cirrhosis and 
hepatocellular carcinoma50;65; identifying those patients who are unlikely to respond 
to treatment66; determining those patients who have a suboptimal response to 
treatment (< 2 log10 drop in HBV DNA and continues to stay above 10
4 copies/ml after 
6 months of treatment); and identifying the emergence of viral resistance41 (> 1 log10 
increase in HBV DNA from baseline after starting treatment). 
In most cases, presence of anti-HBs signifies immunity to HBV, but there are some 
individuals who are HBsAg positive as well as being anti-HBs positive.67 HBV DNA is 
still present and so they must be regarded as patients with chronic HBV infection but 
in whom anti-HBs fails to act as a neutralising antibody to HBsAg. Another scenario 
involves babies born of HBV positive mothers, who are given hepatitis B immune 
globulin (HBIG) at birth and in spite of supposedly adequate amounts of antibody, go 
on to develop hepatitis B infection and chronic liver disease. These cases of "vaccine 
escape" occur because of mutations in the S and other genes during viral replication 
due to a variety of causes. For instance, HBV reverse transcriptase does not have a 
proof reading ability and it has been estimated that there are 1.4-3.2 x10-5 nucleotide 
substitutions per site per year, which is more than ten times the error rate of other 
DNA viruses. Because of the compact structure of HBV, the S ORF is completely 
overlapped by the Pol ORF and this gene codes for reverse transcriptase. A mutation 
in this domain can be transmitted to the other domains including the S domain. 
Resistance to the reverse transcriptase (nucleoside) antagonist lamivudine (3TC) can 
result from a number of mutations in the Pol gene. One of these, rtV173L, is 
associated with the sE164D mutation in the "a" determinant region of the S gene.68 
The "a" determinant is a highly conserved region that is about 99-170 amino acids 
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long and is common to all hepatitis B genotypes. It is the anti-HBs antibody domain 
and used in all vaccinations against HBV. The most common alteration occurs at 
amino acid 145 where glycine is replaced by arginine. Other changes can occur from 
deletions, substitutions or insertions of various amino acids in this a determinant 
region, all of which can alter the conformational structure and prevent the 
production of functional HBsAb. These transformations may occur either 
spontaneously or through selection of various quasi-species by using oral anti-viral 
agents or HBIg as treatments.69-71 
 
1.10 Point of Care Testing for HBV 
Currently serological confirmation of HBV infection is through using solid phase 
immunoassays. The principle involves anti-HBS antibody being immobilized to a 
physical support such as micro well, plastic tube or bead. The test sample, supposedly 
containing HBsAg is added and this antigen-antibody complex is identified by another 
antibody attached to a radioisotope (radioimmunoassay, RIA) or enzyme (enzyme 
immunoassay, EIA). This technique has high specificity and sensitivity which allows for 
the screening of multiple blood samples in a relatively short time but expense and the 
ability to access reference laboratories can preclude use in rural, resource-deprived 
areas where often there is a high prevalence of the disease. 
Since the late 1970s there have been attempts to use rapid "point of care" tests that 
can identify cases with much smaller quantities of blood and within a matter of 
minutes but with variable degrees of accuracy.72 There are various types: 
microfiltration methods, that allow easy separation of blood73; chromatogenic tests, 
where a colour change on a nitrocellulose test strip can confirm infection and give a 
result in about 15 minutes74-76; and dried blood spot testing (DBS), which involves 
using a lancet to draw a single drop of capillary blood that is collected on a piece of 
filter paper and is then allowed to dry.77;78 DBS has many obvious advantages 
including easier sampling, minimal problems with transportation (such as not having 
to struggle with breaking tubes or requiring cold storage), and more straightforward 
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sample processing without the need for centrifuging and separating sera. More 
recent studies have shown it to be an accurate test for HBsAg with sensitivities and 
specificities > 95%.79;80 When used in substance misuse clinics in Wales, albeit testing 
users for HCV IgG, researchers found that clients much preferred DBS than venous 
blood sampling.81 This would suggest the potential use of DBS in large scale 
population screening for blood borne viruses. Despite over time improving the 
sensitivity and specificity, even with the different genotypes and possible mutations 
to HBsAg, currently none of these testing kits have been approved either by the US 
Food and Drug Administration (FDA) or European Union.82 
Although more acceptable, DBS involves a degree of pain when the skin is pricked and 
the risk of needle stick injury still exists. HBV exists in other body tissues and fluids. A 
completely different method that involves testing oral fluid obviates both these 
problems. HBV can be detected in saliva, the gingival cervical fluids and oral mucosal 
transudate (OMT), albeit in much lower quantities, and these together collectively 
make up oral fluid.83;84 As OMT represents an ultra-filtrate of blood, it can be used to 
screen for blood borne viruses. Currently there are FDA approved, over-the-counter, 
OMT kits for diagnosing HIV (OraQuick® Orasure Technologies Inc., Bethlehem, 
Pennsylvania, USA). but no FDA approved or CE marked tests for HBV. There have 
been a few studies that have shown good sensitivity and specificity (>95%) in 
identifying HBV and HCV using OMT but none of these kits are FDA approved or CE 
marked.85-87  
 
1.11 Clinical Manifestations of HBV Infection 
Of the patients who contract acute HBV, only about 30% will develop clinical 
symptoms. When symptoms occur they progress in a sequential manner. Typically 
there is an incubation of about 2-6 months before there is the development of the 
prodromal phase. This consists of non-specific symptoms such as lethargy, malaise, 
nausea and anorexia. Next to arise is the icteric phase, which can last 1-3 months and 
is characterised by jaundice, dark urine and right upper quadrant pain.  After this 
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phase has taken place there is usually complete resolution of symptoms, especially in 
those who do not progress onto chronic HBV. In less than 1% of patients acute, or 
even hyper-acute, liver failure can transpire and this is exemplified by the presence of 
hepatic encephalopathy between 8 and 28 days from the onset of jaundice (hyper-
acute is when encephalopathy occurs within 7 days).88 Here the prognosis is poor and 
may require liver transplantation as a treatment option.  
Chronic HBV does not display any specific clinical syndromes. Patients may present 
with decompensated cirrhosis as embodied by portal hypertension (ascites, variceal 
haemorrhage and hepatorenal syndrome) and encephalopathy, or with 
hepatocellular carcinoma (HCC). In a proportion of patients, HBV infection can also be 
associated with other extrahepatic manifestations. These are thought to be related to 
circulating immune complexes and can result in the non-specific serum sickness-like 
prodrome that occurs with acute hepatitis as well as with arthralgia, arthritis and skin 
rashes. There are 2 other specific linked complications that have been linked to HBV 
infection: a) polyarteritis nodosa, which can result in neuropathy, vasculitis, renal 
disease, arthritis and Raynaud's phenomenon89;90 and b) membranoproliferative 
glomerulonephritis.91;92 
 
1.12 Epidemiology of HBV Infection 
In the past it has been difficult to ascertain accurate numbers of HBV infected 
individuals. Diagnosis relied on detecting anti-HBc for evidence of previous infection 
and HBsAg for current infection. It has been estimated that almost 2 billion people 
have been previously infected with HBV and that approximately 350 million are 
currently chronic carriers of the disease.93 Approximately 600,000 to 1.2 million 
individuals die each year from HBV due to acute or chronic HBV or HCC.94 HCC is the 
5th commonest cancer worldwide and its incidence is increasing with approximately 
300,000 to 500,000 new cases each year.95  
Prevalence of HBV varies across the world, with some areas having low endemicity 
(0.1 - 2% of the population such as USA, Canada, Western Europe, and Australasia), to 
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areas of intermediate endemicity (2 - 7% such as the Mediterranean, Central and 
Latin America, the Middle East, Central Asia and the Indian Subcontinent), to areas of 
high endemicity (8-20% such as China, Far East, Pacific Islands, and Sub-Saharan 
Africa)(see Figure 1-10).96 In countries where the prevalence rate is low, the infection 
is typically acquired during adulthood, infection is usually transmitted horizontally 
and is more likely to present with a symptomatic acute illness. This is in contrast to 
high prevalence regions where the infection is transmitted vertically and is obtained 
during the perinatal period or early childhood.   
 
 
Figure 1-10 Map showing worldwide prevalence of chronic HBV infection (taken from 
Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res 
Clin Gastroenterol 2008; 22(6):991-100896 
 
HBV can be carried in a number of body fluids: blood, saliva, semen, vaginal 
secretions and menstrual blood. It has also been detected, albeit to a lesser extent, in 
sweat, tears, breast milk and urine. It is resistant to breakdown and can survive 
outside the human body. The commonest horizontal routes of transmission include 
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via blood transfusion, sexually, percutaneously (especially with intravenous drug 
users (IVDU) or through an accidental needle stick injury) and via infected devices 
such as with patients undergoing haemodialysis. Even though it is theoretically 
possible, there is no evidence of HBV being spread to humans by HBV infected 
"blood-sucking" insects such as mosquitoes or bedbugs.97  
A characteristic feature of low endemic areas is that there is a low perinatal HBV 
infection rate. Typically this can be as low as 10% when compared to high endemic 
areas such as the Far East where transmission rates via this route can be as high as 
90%.27;98 One reason for this may be the increased proportion of pregnant women 
who are HBeAg positive and so also have high viral loads. It is thought that most 
infection occurs when the baby is exposed to maternal blood during passage through 
the birth canal or in the time period soon afterwards. However it can also occur with 
preterm labour and spontaneous abortion. In spite of this, there is no convincing 
evidence that elective caesarean section prevents the maternal transmission of 
HBV.99 In Africa there is evidence to suggest that transmission occurs in very early 
childhood via child-to-child contamination.100;101 Newborn immunoprophylaxis with 
HBIG and HBV vaccine has been shown to be very effective, which goes against the 
idea of intrauterine infection. Even though HBsAg has been detected in colostrum, 
breast feeding is not contraindicated in infected mothers and has not been shown to 
spread the disease to the newborn.102;103 
There are 3 types of HBV vaccine which differ only from where they are derived from: 
plasma, yeast or mammalian cells (recombinant). All of these vaccines consist of the S 
envelope protein but not the M or L proteins. Enclosed within the S protein is a region 
known as the "a determinant" which is common to all HBV genotypes; this region is 
the reason why the vaccine is highly immunogenic and provides protection against all 
HBV genotypes. The vaccine is given in 3 doses over a 6 month period and the 
"amount" of neutralising anti-HBs can be measured in the blood.  In 1992, the WHO 
endorsed the plan that all countries with high endemicity (>8%) should incorporate 
HBV vaccination into their national immunization programs by 1995, and that all 
other countries should do this by 1997. By 2011, 179 countries had adopted a 
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universal vaccination program, whilst 14 countries operated a "selective" vaccination 
program. The UK is one of the countries that does not operate a universal HBV 
vaccination program (see Figure 1-11). Although not all countries that have adopted a 
universal vaccination program start vaccination at birth there has been a significant 
improvement in the prevalence of HBV. Taiwan introduced a vaccination program in 
1984 and although there is 80-90% coverage there has been a major improvement. 
After 20 years the chronic HBV carrier rate of children under 15 years had dropped 
from 9.8% to 1.2% and the incidence of HCC had dropped from 1.02 per 100,000 to 
0.3 per 100,000.104;105 In low endemicity countries, the beneficial effects of universal 
vaccination are unlikely to be seen for 20-30 years as infection tends to occur in 





Figure 1-11 Map showing countries that have adopted universal HBV vaccination 
programs (taken from World Health Organization 
(www.who.int/immunization_monitoring/diseases/hepatitis/en/index.html)) 
 
1.13 HBV Genotypes 
HBV can be organized into at least 10 genotypes, A-J, based on there being >8% inter 
group diversity throughout the complete genome. Traditionally there were 4 
serotypes (adr, adw, ayr, and ayw) which were based on the unifying "a" determinant 
of the surface gene and 2 mutually exclusive sub-determinants "d/y" and "r/w".106 
However, the trend has been to shift from serotypes and classify HBV according to 
genotype. The first genotypes to be identified were A-D107 and they also happen to be 
the most prevalent genotypes. They were then followed by the discovery of 
genotypes E and F,108 G109, H110, I111 and J.112 In a similar manner to hepatitis C 
genotypes, the HBV genotypes are distributed geographically in a characteristic 
fashion that correlates with ethnicity and mode of transmission. This distinctive 
allocation can be seen in Figure 1-12 (Fung et al 2004).113 Genotype A is more 
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prevalent in North America, Northern Europe, Australasia, Africa and the Indian 
Subcontinent. Genotypes B and C are predominantly found in the Far East. Genotype 
D is found in Southern Europe, the Middle East, Africa and the Indian Subcontinent. 
Countries, such as the USA, have been shown to contain genotypes A-G which reflects 
the underlying ethnic spectrum: genotype A is more prevalent amongst Caucasian 
and black patients, whilst B and C are characteristic of individuals of Far Eastern 
extraction.114  
 
Figure 1-12 Map showing geographical distribution of the various HBV genotypes 
(taken from Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the 
outcome of HBV infection? Hepatology 2004; 40(4):790-792)113 
 
The genotypes may occur in combination (for instance genotype A and G)115 or even 
as recombination or mixture of 2 genotypes such as C and D. 116Genotypes can be 
further subdivided into sub-genotypes if there is >4% divergence in the entire 




Table 1-3 Geographic distribution of HBV genotypes and subtypes (adapted from 
Tanwar S, Dusheiko G. Is there any value to hepatitis B virus genotype analysis? 
Curr Gastroenterol Rep 2012; 14(1):37-46.)117 
 
There are both clinical and virological differences between genotype as well as within 
genotype. Genotype A has at least 3 sub-genotypes of which A1 is predominantly 
found in Sub-Saharan Africa and A2 is found more in Europe. A1 is associated with 
HBeAg seroconversion earlier but a greater risk of developing HCC in Black Africans at 
an earlier age.118-120 As mentioned earlier, a substitution at position 1896 between 
guanosine to adenosine can lead to the prevention of HBeAg being expressed. In 
genotype A the nucleotide cytosine, rather than uracil, is carried at position 1858 and 
this restricts the base pairing with adenosine at 1896. Instead genotype A is 
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associated with core promoter mutations such as substitutions at 1762 (A-to-T) and 
1764 (G-to-A), which has been linked with suppressing HBeAg expression. 
 
Table 1-4 Comparison of clinical and virological features of HBV genotypes (adapted 
from Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis 
B: role of hepatitis B virus genotypes A to J. Semin Liver Dis 2013; 33(2):97-
102.).121 
 
Genotypic variations may have an effect on disease progression. Most studies have 
not compared all the genotypes against each other but mainly A versus D and B 
versus C (see Table 1-4 ). Genotype A has a greater risk of developing CHB after acute 
infection but less risk of cirrhosis and HCC than genotype D. Genotype B can exist as 
two subtypes: Ba, comprising B2-B5 and Bj, comprising B1 and B6. B1 has been 
implicated with developing fulminant hepatic failure, whilst individuals with Bj have a 
higher chance of developing HCC and cirrhosis earlier. Genotype C is associated with 
longer time for HBeAg seroconversion and more mutations, especially PreS deletions, 
than genotype B. This may mean progressive liver damage that does not correlate 
with viral replication activity and greater risk of HCC with a worse outcome.117;121;122 
However, other factors known to affect disease progression, such as age of 
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acquisition, mode of transmission, mutations, HBV DNA level, and environmental 
factors like alcohol intake and exposure to aflatoxin need to be taken into 
consideration as well.123;124  
A meta analysis of  IFNa and PEG-IFNa treatment for CHB showed that the best 
responses in terms of HBeAg seroconversion and HBsAg loss have been with 
genotype A and also in HBeAg positive genotype B patients compared to genotypes D 
and C respectively.125 However, the same meta analysis could not find any significant 
differences in terms of treatment response between genotypes regarding nucleoside 
(lamivudine, telbivudine and entecavir) or nucleotide (adefovir) anti-viral agents but 
did not examine tenofovir. A recent study by Marcellin et al reported that 10% of 
HBeAg positive CHB patients treated with tenofovir for 5 years had HBsAg loss. This 
occurred in significantly more in Caucasian patients with genotype A and (to a lesser 
degree D). However this did not happen in Asian patients, most of whom are 
genotype B and C.126 Currently genotype status is not routinely utilised to determine 
decisions to initiate treatment.  
 
1.14 Disease Progression of HBV  
There are a number of independent factors associated with severe disease (cirrhosis, 
decompensated liver disease and HCC). These can be broadly subdivided into 3 





Figure 1-13 Risk factors associated with progression of disease in patients with 
chronic HBV infection (taken from Liaw YF, Sollano JD. Factors influencing liver 
disease progression in chronic hepatitis B. Liver Int 2006; 26(Supplement 2):23-29127 
A number of studies have shown that active viral replication, as evidenced by HBeAg 
positivity and high viral load, lead to cirrhosis and as HCC is a complication of 
cirrhosis, they are also implicated in the development of HCC. One retrospective 
study found that the incidence of cirrhosis in patients who remained HBeAg positive 
was 3.5% per year and that these patients had significantly higher incidence of 
cirrhosis and HCC compared to those who underwent HBeAg seroconversion.128  
Another study was performed by Yang and colleagues following up 11893 men for the 
development of HCC.129 Compared to men who were HBsAg and HBeAg negative, the 
relative risk of developing HCC in those who were HBsAg positive was 9.6 and 60.2 in 
those who were both HBsAg and HBeAg positive. A criticism of this study is that 
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HBeAg status was only checked on entry into the study. Hsu et al found that in 283 
patients who underwent HBeAg spontaneous seroconversion, the greatest risk to 
developing cirrhosis occurred in those who subsequently returned to being HBeAg 
positive; similarly those who remained in remission had a very low risk of developing 
cirrhosis. However, they also noticed that up to a third of patients developed HBeAg 
negative hepatitis with elevated ALT and HBV DNA, and that a significant proportion 
of these patients developed cirrhosis and HCC. This would suggest that whilst 
seroconversion may confer a more favourable prognosis, there is still a risk of 
developing HCC in patients with active disease.130;131 
The bearing of viral load on cirrhosis risk was demonstrated by a Taiwanese study 
involving 3582 HBV individuals. 85% were HBeAg-negative and were followed up for a 
mean duration of 11 years. The incidence of cirrhosis rose in a dose-dependent 
manner with entry level HBV DNA level and was independent of HBeAg status or ALT 
level. The adjusted relative risk of cirrhosis for HBV DNA level of 104 copies/ml was 
2.5 but this increased to 6.5 for patients with entry HBV DNA levels of >106 
copies/ml.65 Using the same population, another study found that this dose-
dependent relationship also existed for predicting which patients developed HCC; this 
was especially the case in those individuals who were HBeAg negative, had normal 
ALT levels and not cirrhotic at study entry. They determined the adjusted hazard ratio 
to be 2.3, 6.6 and 6.1 for individuals with entry HBV DNA levels of 104-5, <105-6, and 
>106 respectively. Similarly a reduction in HBV DNA was associated with a reduction in 
the development of HCC.50 Similar findings have been reported by other studies.132;133  
In addition to viral load and HBeAg status, other viral factors such as genotype and 
the presence of mutations have been linked to progressive disease. As previously 
mentioned, a number of investigators have found that compared to genotype B 
infection, genotype C is associated with a more aggressive disease that has less 
chance of spontaneous seroconversion.134-137  There is less data on other genotypes 
but one study from the Indian Subcontinent has suggested that genotype D is more 
associated with worse liver disease and HCC than genotype A138;  although this 
suggestion has subsequently been challenged.139 A number of mutations have been 
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discovered to be associated with advanced disease: precore (PC) G1896A mutation
140; 
basal core promoter (BCP) A1762T, G1764A mutations
141; pre-S deletion mutations.142 A 
recent study has suggested that rather than occur as single mutations, they may co-
exist in a complex pattern to induce progressive disease.143 
As most chronic HBV infections are acquired vertically or in early childhood, the age 
of the patient roughly corresponds to duration of the disease. Since the immune 
clearance phase tends to occur after 20-30 years, it is likely that the complications of 
cirrhosis and HCC will happen after this time period. A number of studies, using both 
Far Eastern subjects50;133;144 and Europeans,145;146 have shown that age is an 
independent risk factor for cirrhosis and HCC. Another host factor that has been 
implicated with advanced disease is male sex. Cross-sectional studies147;148 and 
follow-up studies50;65;129 have consistently shown that males are more associated with 
severe disease.  
The immune response to the virus plays an important role in persistence, as well as 
clearance of the disease. During the immune clearance phase, there is inflammation 
and necrosis of the liver but these may be temporary.  Raised ALT is a marker of 
active inflammation. Various studies have shown that elevated enzymes (greater than 
0.5-1.0 x upper limit of normal, ULN) are significantly associated with liver-related 
mortality - not only with viral hepatitis but also in patients with no known liver 
disease.43;149 However, a large study by Yuen et al, following up 3233 chronic HBV 
Chinese patients, found that patients with the highest risk of developing advanced 
liver disease had "mildly elevated" ALT (1-2 x ULN); whilst patients with ALT >6 x ULN 
had significantly lower risk of complications. They postulated that very high ALT rises 
resemble the situation of acute HBV and so do not usually lead to chronic damage. 
The mildly elevated ALT, on the other hand, suggests a more insidious attack on the 
liver leading to persistence of the infection.150 
Other "environmental" factors have been implicated with HBV disease progression. 
Cross-sectional studies in Far Eastern individuals have suggested there is a role for 
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aflatoxin,151 persistent alcohol intake,152;153 cigarette smoking129;153 and co-infection 
with other  viruses such as hepatitis C,154 hepatitis D155 and HIV.156  
 
1.15 Treatment of HBV 
Complete elimination of HBV is not possible because cccDNA cannot be eradicated 
from infected hepatocytes.  Therefore the ultimate goal of treatment is to improve 
quality of life and prevent the development of cirrhosis, decompensated disease and 
HCC. To do this there needs to be sustained suppression of the virus to undetectable 
levels. Achievement of this can lead to normalisation of ALT; loss of HBeAg, and 
possible loss of HBsAg; improvement of liver fibrosis; and the prevention of 
complications from occurring. The rationale for reducing the viral load to 
imperceptible amounts is so that there is much less chance of resistance 
developing.157 Having said this, there is as yet no conclusive, randomised controlled 
trial evidence that any therapeutic option prevents the development of HCC.158 There 
are studies which have shown reversal of fibrosis and potentially cirrhosis with oral 
anti-virals but there is no conclusive evidence that they can avert HCC.159-161 This is 
because the development of advanced disease occurs many years after the diagnosis 
of HBV and none of the studies have looked at long term benefits of treatment.   
Not all patients with chronic HBV infection need antiviral treatment. Patients who 
would benefit from treatment include: patients with decompensated liver disease 
and those with compensated cirrhosis; those with HBV receiving immunosuppressive 
or chemotherapy as they are at risk of experiencing an exacerbation of their hepatitis; 
and babies born of mothers with HBV, especially those who are HBeAg positive, with 
HBIG. Other individuals who may benefit from treatment include patients in the 
immune active or immune clearance phase with elevated DNA levels (>2000 IU/ml or 
104 copies/ml), raised ALT (> 2x ULN) and marked fibrosis on liver biopsy (Metavir F2). 
These patients also should be older than 30 as younger individuals have a higher 
chance of spontaneous seroconversion. Those who do not routinely require antiviral 
treatment include: patients in the immune tolerant phase, who are characterised by 
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high DNA levels, but normal ALT and minimal inflammation and fibrosis on liver 
biopsy; and patients in the immunosurveillance or inactive phase, who are 
characterised by having low DNA and ALT levels with minimal inflammation and 
fibrosis on liver biopsy. These patients do, however, require continued follow 
up.47;157;158;162 
There are 3 main types of treatment: interferons (conventional Interferon alpha 
(IFNα) and pegylated Interferon, (PEG IFN2α)), nucleosides (lamivudine, telbivudine, 
emtricitabine and entecavir) and nucleotides (adefovir and tenofovir). Interferons are 
given as subcutaneous injections and have the advantages of being of finite duration 
(approximately 12 months) and not inducing resistant mutants. Unfortunately they 
are not well tolerated due to being associated with numerous side effects and should 
not be used in patients with decompensated disease. They are most effective in 
younger patients, with genotypes A and B,163 who have high ALT levels, low DNA 
levels (<107) and high inflammation on liver biopsy.157;164 NAs are oral drugs that are 
better tolerated but are usually given for long term therapy and can lead to the 
development of resistant strains. Lamivudine and telbivudine are safe, rapid and 
potent suppressors of HBV DNA but have high rates of drug resistance (low genetic 
barrier). Adefovir has the advantage of being useful in patients with lamivudine 
resistance but is not as potent. The newer drugs, tenofovir and entecavir, have high 
potency and are much less prone to the development of resistance, especially with 
wild-type viruses, and can be used as first line monotherapy (see Figure 1-14). 
Emtricitabine is not used alone in the treatment of HBV, but instead is combined with 


















ADV = adefovir; TDF = tenofovir
ETV= entecavir; FTC = emtricitabine; IFN = interferon; LAM=lamivudine; LdT= telbivudine
 
Figure 1-14 Antiviral activity and genetic barrier for resistance of current anti-HBV 
agents (slide courtesy of Dr Ines Ushiro-Lumb) 
 
1.16 Monitoring Treatment 
Recent EASL guidelines for the management of CHB recommend that patients being 
treated with PEG-IFN have monitoring of their full blood count (anaemia, 
leucopaenia, and thrombocytopaenia), liver function tests (hepatic flares) and thyroid 
function tests (thyroiditis) every three months in addition to safety whilst they on 
their twelve month course of treatment.165 HBV DNA should be checked at 6 and 12 
months during treatment and 6 and 12 months post treatment (and also HBeAg and 
HBeAb status for those with HBeAg positive disease). Successful treatment is 
characterised by sustained off-treatment normal ALT and HBV DNA <2000 IU/ml, and 
HBeAg seroconversion with HBeAg positive disease. If HBV DNA becomes 
undetectable then there is a better chance of HBsAg loss and HBsAg should be 
checked yearly. There is still the potential that HBeAg reversion can still occur so this 
needs to be regularly checked. Lately a "futility" rule has been suggested whereby 
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PEG-IFN treatment could be stopped if there has been no decline in HBsAg levels by 
three months because there is very little chance that therapy will be successful.166;167 
NAs should be monitored every three months for HBV DNA and LFTs to assess for 
treatment response as well as for the development of resistance in the form of 
virological or biochemical breakthrough. Virological response occurs when there is no 
detectable HBV DNA during continuous treatment, whilst partial virological response 
exists when there is still detectable HBV DNA during treatment. The first indication of 
viral resistance is the appearance of virological breakthrough, which is defined as a 1 
log10 increase in the HBV DNA from nadir in a patient that had an initial virological 
response. The rate of developing resistance depends on a number of factors: pre-
treatment DNA levels, the time taken to achieve viral suppression, the duration of 
treatment and whether the patient had been exposed to antiviral treatment.168 30% 
of cases of virological breakthrough are due to treatment non-compliance.47 
Following on from this comes biological breakthrough, characterised by an increase in 
ALT, and then genotypic and phenotypic resistance. With lamivudine resistance, the 
commonest mutation results in substituting methionine in the YMDD (tyrosine-
methionine-aspartate-aspartate) motif of the reverse transcriptase region of the 
polymerase for valine or isoleucine; the resulting mutation is known as rtM204V/I. 
This mutation is also effective against other nucleosides and has the ability to be 
archived so that should the patient be started on lamivudine at a later date the 
resistance to effect will be maintained. If resistance should develop then either 
switching or adding a different class of drug should be tried. For instance with 
lamivudine or telbivudine resistance the strategy should be to switch to a nucleotide 
like tenofovir. If there is entecavir resistance then switch to or add in tenofovir. So far 
there is no evidence of tenofovir resistance in treatment naive patients but if it 
should happen, EASL guidelines recommend adding or switching to entecavir.165 
As NAs have the potential for causing renal impairment, more so with nucleotides, 
serum creatinine and creatinine clearance should be monitored every three months. 
Renal dysfunction is more likely to occur in patients with pre-existing intrinsic renal 
disease, poorly controlled diabetes and/or hypertension, contemporaneous use of 
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nephrotoxic drugs or solid organ transplant (because of the potential nephrotoxic 







2 Materials & Methods 
 
2.1 General Introduction 
All the work carried out by myself was performed either at the Royal London Hospital 
(RLH) or at Newham University Hospital (NUH) as this is where the patients attending 
the outpatient clinics were. This occurred between October 2006 and September 
2009.  
2.2 Validation of oral mucosal transudate in chronic hepatitis B 
2.2.1 Introduction 
Blood-borne viruses such as HIV, HBV and HCV are under-diagnosed in the 
population. A major reason for this is that diagnosis relies on plasma or serum 
samples confirming the presence of an antibody (HIV antibody or HCV IgG) or antigen 
(HBsAg). There are a number of problems associated with relying on blood tests. 
Many individuals, especially children, object to having blood tests because of the pain 
caused in penetrating the skin; there is also the difficulty in accessing veins, especially 
in patients who are current or previous IVDUs; and there is the potential for a "needle 
stick" injury because of accidental puncture with an infected (blood) needle. 
 
In the present study we wanted to adopt a completely different method that involves 
testing oral fluid which did not require taking blood samples and was completely 
painless. Saliva predominantly contains salivary immunoglobulin A (sIgA), whereas 
OMT contains a mixture of sIgA, IgG and IgM and more concentrated amounts of 
antigens derived from various pathogens like HBV.169 Those studies that have 
managed to identify HBV and HCV with satisfactory sensitivity and specificity (> 95%) 
used the Orasure® collection device (Orasure Technologies Inc., Bethlehem, 






To validate immunoassays to identify hepatitis B surface antigen (HBsAg) and 
antibody to hepatitis B core antigen (anti−HBc) using the OraSure® oral fluid 




One hundred patients, known to have chronic hepatitis B and who were attending the 
hepatology clinics at Barts and the London Hospital, were invited to take part in the 
study. The patients were of all ethnicities and all were aged over 18. They were 
selected by their attendance of the hepatology clinic on the day of testing and asked 
if they would be willing to take part in a study to diagnose HBV. All patients gave full, 
informed consent to taking part in the study and having the results analysed in 
another laboratory. They were given a patient information sheet and the study was 
explained to them in English or in whatever language they understood with the use of 
interpreters if necessary. Local research and ethics committee approval for testing 
patients with hepatitis B using OMT had been sought and given (see appendix 1). 
 
The only inclusion criterion was that patients had to be chronic HBV carriers by being 
HBsAg positive on two or more occasions six months apart prior to testing (i.e. to 
differentiate them from patients with acute HBV infection that had now cleared the 
virus). Sixty eight patients were male of which 47 were HBeAg negative. Thirty two 
patients where female of which 21 were HBeAg negative. The other demographics of 





Demographic Mean Range 
Age 40 18-78 
ALT/IU 55 11-240 
HBV DNA/ log IU/ml 4.00 0-9.72 




Each OMT testing kit consisted of two components: two Orasure® (Orasure 
Technologies Inc., Bethlehem, Pennsylvania, USA) mouth swabs and a storage vial as 
shown in Figure 2-1 below.  The costs of providing the testing kits, transporting the 
samples, and the analysis was provided by Altrix Healthcare Limited, Warrington, UK. 
 
The swab is a nylon stick that has a cotton pad attached to one end of it. The pad 
contains an electrolyte solution of 3.5% sodium chloride, 0.1% gelatine, 0.1% sodium 
benzoate, and 0.1% potassium sorbate buffered to pH 7.2. When placed in the lower 
mouth areas of the buccal mucosa, the hypertonic milieu of the pad allows passive 
transport of the interstitial fluid to this adsorbent area. Upon attaining the OMT, the 
swab is removed from the mouth, snapped off midway along its length at a specific 
point and then inserted into the storage vial.  
 
The storage vial is made of plastic, is about 8cm in length, has a top that can be 
screwed off and contains preservative in the bottom of it. The preservative is made of 
0.01% chlorohexidine digluconate and 0.5% Tween-20. To increase the volume of 
sample taken, two swabs are inserted into the mouth on either side and then put into 










Testing involved inserting 2 Orasure® swabs into either side of the mouth between 
the buccal mucosa and the lower, lateral gingival surface. All of the tests were 
administered by myself or another research fellow who had been trained in how to 
use the testing kit. Each swab was left in-situ for two minutes and not longer than five 
minutes before removing the swab from the patient's mouth. The stick was then 
snapped at the correct point and inserted into the vial. Each patient was assigned a 
unique test number and each test kit had a unique barcode number. Each vial had a 
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barcode sticker on it and this matched the barcode sticker on a paper request form. 
The request form was labelled with the unique test number, barcode sticker, patient's 
date of birth and the date of collection. There were no other identifying markers put 
on the request form to the analysing laboratory. Samples were put in a sealed 
envelope and were sent by courier to the central reference laboratory at the West of 
Scotland Specialist Virology Centre, Gartnavel Hospital, Glasgow.  
 
Analysis of the samples and interpretation of the results were performed by Dr Sheila 
Cameron and Professor William Carman. The method of processing the samples was 
done according to the standard operating procedure described in a previous paper.170 
The current ELISA assays to detect HBV in plasma or serum are the Murex HBsAg (v3) 
and the Murex anti-HBc (total) (Abbot diagnostics Europe, Wiesbaden, Germany). 
Using plasma/serum samples, the procedure that they followed is summarised in  
Table 2-2. For the present study these assays were "adapted" within Professor 
Carman’s laboratory to detect HBsAg and anti-HBc using OMT samples.  
 
Plasma/Serum HBsAg Anti-HBc 
Sample amount/μl 75 50 
Incubation period 60 min at 37°C 30 min at 37°C 
Washes - x5 
Conjugate + 50 µl conjugate for 30 min 
at 37°C 
+ 50 µl conjugate for 30 min at 
37°C 
Washes  x5 x5 
 
Table 2-2 Summary of procedure for identifying HBsAg and anti-HBc in plasma/serum   
 
There were three experiments. The first was to adapt the current Murex HBsAg and 
anti-HBc assays to detect HBsAg and anti-HBc in OMT. This was done by altering the 
various parameters of sample amount, incubation period and conjugate until the 
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highest sensitivity was achieved. The OMT was taken from three samples of patients 
known to be positive for HBsAg and anti-HBc. 
 
There are a number of other commercially available assays for detecting HBsAg and 
anti-HBc using plasma/serum samples. Three of these other ELISA based kits are: 
 
1) BioMérieux Hepanostika HBsAg Ultra & anti-HBc Uni-Form (BioMérieux, Craponne, 
France) 
2) Bio-Rad Monolisa HBsAg ULTRA & anti-HBc PLUS (Bio-Rad, Marnes-la-Coquette, 
France) 
3) Dade Behring Enzygnost HBsAg 5.0 & Anti-HBc monoclonal (Dade Behring, 
Deerfield, Illinois, USA) 
  
Experiment two involved comparing the "adapted" Murex assay with these three 
testing kits for the amount of false negative HBsAg and anti-HBc. As all the 100 
samples were from patients known to be positive or reactive to HBsAg and anti-HBc, 
there should ideally be 0 false negatives in the adapted Murex assay.  
 
Experiment three involved adapting the three commercial kits from BioMérieux, Bio-
Rad and Dade Behring in a similar fashion to that done with the Murex assay i.e. by 
altering sample amount, incubation period and conjugate. Then the proportion of 






Table 2-3 shows the adaptations done to improve the sensitivity of detecting HBsAg 
and anti-HBc in the Murex assays using OMT. Over the three samples, the only 
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modification to the procedure with HBsAg was increasing the number of washes from 
5 to 6. The sample volume was the same at 75 μl. 
 
There were significant differences when adapting the assay for anti-HBc. The optimal 
sample volume was 100 μl. In order for the sensitivity to improve the samples 
required overnight incubation at room temperature. In addition the number of 
washes was also increased.  
 






60 min at 37°C Overnight at room temperature 
Washes - x12 
Conjugate + 50 µl conjugate for 30 min 
at 37°C 
+ 50 µl conjugate for 60 min at 
room temperature 
Washes  x6 x6 
Table 2-3 Summary of procedures to "adapt" Murex HBsAg and Anti-HBc assays for 




Using the "adapted" procedure for the Murex assay, the numbers of false negatives 
for HBsAg and anti-HBc were 6 and 2 respectively. From Table 2-4 it can be seen that 
apart from the BioMérieux HBsAg assay, all of the other assays had many more false 









BioMérieux Bio-Rad Dade Behring 
Assay type HBsAg Anti-HBc HBsAg Anti-HBc HBsAg Anti-HBc 
False 
negatives 
6 32 13 18 8 49 
Table 2-4 Number of false negatives for HBsAg and anti-HBc using OMT samples using 
plasma/serum (unadapted) commercial assays 
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 Experiment 3 
 
Table 2-5 and Table 2-6 encapsulate the process by which all the commercial assays 
for HBsAg and anti-HBc were adapted for use with OMT.  
 
Adapted HBsAg assay Murex BioMérieux Bio-Rad Dade Behring 
Sample volume (µl) 100 100 100 100 + 25 conjugate 1 
Incubation period 1 60 minutes at 37°C 
Conjugate volume (µl) 50 50 50 100 conjugate 2 
Incubation period 2 60 minutes at 37°C 
Substrate volume (µl) 100 100 100 75 
Incubation period 3 In the dark at room temperature for 30 minutes 
Stopping solution 
volume (µl)  
50 100 100 75 
Table 2-5 Summary of procedures for adapting HBsAg assays for detecting HBsAg in 
OMT 
 
Adapted anti-HBc assay Murex BioMérieux Bio-Rad Dade Behring 
Sample volume (µl) 100 
Incubation period 1 Overnight at room temperature 
Conjugate volume (µl) 50 50 200 100 
Incubation period 2 60 minutes at room temperature 
Substrate volume (µl) 100 
Incubation period 3 In the dark at room temperature for 30 minutes 
Stopping solution volume 
(µl)  
50 100 100 100 
Table 2-6 Summary of procedures for adapting anti-HBc assays for detecting anti-HBc 
in OMT 
 
Table 2-7 and Table 2-8 show the number of false negatives and sensitivities for the 
four assays before and after adaptation for OMT to detect HBsAg and anti-HBc 
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respectively. With HBsAg, the BioMérieux adapted assay had no change in sensitivity 
compared with the un-adapted assay and this may have been because the procedure 
for adaptation is very similar to how the original BioMérieux assay is produced. That 
said there was a significant improvement in sensitivity with adapting the BioMérieux 
anti-HBc assay. The most sensitive adapted HBsAg assay was the Dade-Behring, with 
the Murex having a sensitivity of 94.3%. The Murex was the most sensitive anti-HBc 
assay.  
 
An interesting finding from the results is that the identified false negatives were not 
the same samples in all the assays. Of the six false negative HBsAg in the Murex assay, 
only 3 of them matched the six false negatives of the BioMérieux assay. The one false 
negative of the Dade Behring HBsAg assay was positive in all the other assays. In 
contrast, the two false negatives of the Murex anti-HBc assay were all negative in the 
other three assays. 
 
HBsAg assay Murex BioMérieux Bio-Rad Dade Behring 
Un-adapted false 
negatives (sensitivity) 
- 6 (94.3) 13 (88.5) 8 (92.6) 
Adapted false negatives 
(sensitivity) 
6 (94.3) 6 (94.3) 8 (92.6) 1 (99) 
Table 2-7 Number of false negatives and sensitivities (%) for un-adapted and adapted 
assays testing for HBsAg in OMT 
 
 
Anti-HBc assay Murex BioMérieux Bio-Rad Dade Behring 
Un-adapted false 
negatives (sensitivity) 
- 32 (75.7) 18 (84.8) 49 (67.1) 
Adapted false negatives 
(sensitivity) 
2 (98) 14 (87.7) 5 (95.2) 6 (94.3) 
Table 2-8 Number of false negatives and sensitivities (%) for un-adapted and adapted 




The aim of the study was to validate an adapted immunoassay to identify HBsAg and 
anti-HBc in OMT samples and in this respect, it was successful. The adapted Murex 
assay had sensitivities of 94.3% and 98% for identifying HBsAg and anti-HBc 
respectively. The Murex assays had similar sensitivities to the other 3 immunoassays 
for recognizing HBsAg and was the best at finding anti-HBc.  
 
Ideally the sensitivity of both immunoassays would be approaching 100% as all the 
samples came from patients known to have HBV. As mentioned in the results there 
was some disparity between the false negative samples detected by the various 
assays. With future studies, using samples with different volumes, incubation times, 
or altering the number of washes may improve this.  
 
There have been other studies looking at detecting HBV using different oral fluid 
collection devices. A study by Hutse et al collected the saliva from 43 patients who 
were HBsAg positive and 73 who were HBsAg negative using the Oracol collection 
device (Malvern Medical Developments, Worcester, UK) and analysed by a modified 
ETI-MAK-4 ELISA. They found sensitivity of 90.7% and specificity of 100%.171  
 
The study by Thieme et al used the Orasure® collection device to test oral fluid in 29 
patients who were HBsAg positive and 29 patients who were HBsAg negative. They 
used a Murex ELISA but the sample volumes were either 200μl or 400μl. They had 
100% sensitivity and specificity.85 Compared to the present study, their study has 
much smaller numbers and uses different sample volumes and procedures.  
 
A criticism of the present study is that because there is no negative control arm, that 
is we did not screen patients who are known not to have HBV, we cannot comment 
on false positives and hence specificity. At the time of the ethics application, there 
was another on-going study that was looking at this issue. That study involved 
screening GP practices for HBV and HCV by conventional blood tests (for HBsAg, anti-
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HBc and HCV IgG) as well as using the Orasure® collection device. We anticipate that 
with a hepatitis B prevalence of around 2% in this GP population  490 subjects who 
are proven to be HBsAg negative by blood testing will be screened with the Orasure 
testing system. Thereby we will obtain a clear assessment of the rate of false positives 
using the Orasure testing system. However this on-going study will not provide 
information regarding the false negative rates as too few patients with hepatitis B will 
be screened. The current study is therefore designed to complement our on-going 
studies by assessing the false negative rate with this testing system. 
 
We felt that sensitivity of 94.3% for HBsAg using the adapted Murex assay that had a 
98% sensitivity for detecting anti-HBc was acceptable for screening an asymptomatic 
population for HBsAg. This level of sensitivity would not be sufficient if the task was 
screening blood samples for transfusion or trying to confirm a diagnosis in patients 
referred for hepatitis B testing. However in our view the slight loss of sensitivity with 
the assay was more than offset by the advantage in high throughput community 
screening.  
 
In our sample of 100 patients, 2 had HBV DNA 0 and 10 had viral loads <1.30 log 
IU/ml. Unfortunately it was not possible to ascertain from the analysing laboratory 
which patients had the false negatives and see if this correlated with HBV DNA. At the 
time of the study HBsAg quantication of serum samples was not being carried out. It 
would have been useful to have values of HBsAg determined in serum and OMT at 
the same time, giving the opportunity to do limiting dilution analysis in a subset of 
samples. This would give the added information about the sensitivity level when using 
OMT compared to serum. Future studies could have compared using OMT with 
paired blood samples and DBS samples, as a control point of care test, to see which 




2.3 Statistical Analysis 
All the data collected was categorical and so non-parametric tests such as Chi square, 
Fisher's exact test and logistic regression were performed. Statistics were calculated 
using computer software (SPSS version 16, SPSS Inc., Chicago, IL, USA and GraphPad 
Prism version 5, GraphPad Software Inc., La Jolla, CA, USA). 
Before starting the research I went on courses at Cambridge University about 
statistics methods & testing and on how to use SPSS. I approached Dr Janice Thomas, 
statistician at QMUL for statistical advice on a number occasions regarding test 
choice. Following analysis, I discussed the results with her and she was satisfied with 




3 Preliminary Studies 
 
3.1 General introduction 
This thesis examines chronic hepatitis B infection in the immigrant communities of 
East London. The focus of the study is looking at the epidemiology of the disease, and 
specifically the prevalence and disease burden. In order to accomplish this, a number 
of preliminary studies had to be carried out. These were done by other individuals 
and organisations but I played an important role in their design, collection of samples, 
and execution. 
 
The first of these studies is collection of demographic data from the Office of National 
Statistics (ONS). This involved using the 2001 UK census data to determine the 
number of immigrants of various nationalities, including Bangladeshi and Pakistani, 
who were residing in East London. 
   
The second study is the ‘Mosque Screening Study’. This involved targeted screening 
of Bangladeshi and Pakistani individuals who attended local mosques in East London. 
Screening was done using validated OMT test kits. Based on these results, the 
prevalence of hepatitis B in people attending mosques was calculated.  
 
Although not a separate study, the next section concerns the demographics of the 
Bangladeshi and Pakistani population. These were derived from utilising the Mosque 





3.2  Office for National Statistics data 
The Office for National Statistics (ONS) is part of the UK Statistics Authority, which is 
an independent government department that answers directly to Parliament.  It 
collects and publishes data on the population, economy and society of England and 
Wales at national, regional and local levels over time. Every 10 years there is a 
national census which all households in the UK have to respond to by law as 
accurately as possible. At the time of this study, statistics were retrieved from the 
2001 UK national census.  
 
The census contains a vast amount of socio-demographic information about the UK 
population including details about age, sex, ethnicity, and country of birth. Country of 
origin was not a category in the 2001 census and so country of birth was used as a 
surrogate marker for this. All this information is in the public domain and can be 
readily accessed on the internet (http://www.nomisweb.co.uk/). However, the data 
that is publicly available is not specific enough to calculate the prevalence of HBV in 
the Bangladeshi and Pakistani populations. The data can be manipulated to give at 
most 3 variables in a particular region such as local authority: age versus sex versus 
ethnicity. Even then, this age data is arranged in large groups: 0-15, 16-64, and 65 and 
over.  
 
There are tables which have been commissioned by other researchers and these are 
available on request to the ONS. These include table CO182: country of birth by sex 
and age, and table CO954: country of birth and age by ethnic group by sex. The 
problems with these tables are that they give very gross figures which lack the ability 
to give much detail. In table CO182, the age ranges were 0-15, 16-39, 40-64, 65-74 
and 75 and older for males and females according to each London authority. In table 
CO954, the age ranges were every 5 years (i.e. 1-4, 5-9, 10-14, etc.) for males and 
females depending on the country of birth (i.e. Bangladesh) but could only classify 
individuals as Asian/Asian British versus other ethnic group and this was at national 
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level. There was no currently commissioned table that had the 4 variables: age, sex, 
country of birth and ethnicity.  
 
I negotiated with the ONS census commissioning team, explaining that we needed a 
single table with those 4 variables and to a highly specific degree (5 year age bands) in 
order to work out prevalence of HBV in particular populations (Bangladeshis, Indians 
and Pakistanis) of East London. The only way to achieve this would be to commission 
and pay for our own bespoke table that would have all this information. Their 
disclosure team scrutinised our request and agreed to give us the data to the level of 
detail we required. Table C1056 consists of age (5 year age bands) and country of 
birth by sex and by ethnic groups at a local authority level. The layout of table C1056 





Table 3-1 Part of commissioned ONS table C1056 showing age and country of birth by sex by ethnic groups (Source: 2001 Census Commissioned 
Table. Crown copyright 2009. Crown copyright material is reproduced with the permission of the Controller of HMSO) 
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Table C1056 shows the number of Bangladeshi, Indian and Pakistani individuals of 
both sexes born in Bangladesh, India, Pakistan, UK and the rest of the world. The 
mosque study mentioned above did look at viral hepatitis in Indians and that was why 
the ethnic Indians and those born in India are included. This data also improves the 
accuracy of identifying the number of Bangladeshis and Pakistanis born outside the 
UK as some were born in India.  
 
Data from the migration department of ONS suggest that there has been less than 2% 
migration of Bangladeshis and Pakistanis to the London Boroughs of Newham and 
Tower Hamlets (which are the two East London local authorities involved in the 
research study) between 2001 and 2006 (unpublished data kindly provided by ONS 
and based on official immigration statistics). Given the low rates of migration we 
assumed that the impact of inward and outward migration would be minimal and 
therefore this factor was ignored. To evaluate population density at the time of our 
study we completed a simple numerical calculation i.e. those individuals who would 
have been in the 16-20 age group in 2001 would now be in the 21-25 age group in 
2006. The corrected population numbers for Bangladeshis and Pakistanis born abroad 
(first generation immigrants) and those born in the UK (second generation 





 Male Bangladeshi Female Bangladeshi 
Age range Born abroad Born in UK Born abroad Born in UK 
16-20 1221 4044 1154 4032 
21-30 4898 3714 6204 4054 
31-40 6893 705 6689 820 
41-50 4342 146 3169 103 
51-60 1200 33 2594 52 
61-70 1890 43 1586 24 
71-80 1427 25 635 19 
81 and over 197 28 132 32 
Total 20847 8738 21009 9136 
Table 3-2 Population of Bangladeshis living in the two boroughs of Newham and 
Tower Hamlets according to age, sex and whether they were born in the UK or abroad 
 
 Male Pakistani Female Pakistani 
Age range Born abroad Born in UK Born abroad Born in UK 
16-20 232 936 205 837 
21-30 904 1540 808 1453 
31-40 1668 690 1128 780 
41-50 1153 58 1165 67 
51-60 734 28 696 22 
61-70 327 11 361 9 
71-80 228 15 158 9 
81 and over 48 13 37 15 
Total 5062 3291 4353 3192 
Table 3-3 Population of Pakistanis living in the two boroughs of Newham and Tower 




As individuals aged under 16 were not included in the study, their numbers are not 
included in the above tables. The results show that the youngest age groups of both 
sexes and ethnicities were born in the UK. Similarly with the 31-40 age group and 
older age groups more immigrants were born abroad. As expected with an immigrant 
population, as people get older their age groups have fewer numbers but that those 
born abroad still outnumber their UK born counterparts. These findings are typical of 
mass immigration trends into the UK from Commonwealth countries and made easier 
by the popularity of air travel. In these 2 boroughs, Bangladeshis outnumber 
Pakistanis. The borough of Tower Hamlets in particular has a very large Bangladeshi 
population. Bangladeshis and Pakistanis, amongst other ethnic groups, tend to 
congregate in particular towns and districts, and this could explain the large number 




3.3 Mosque study 
3.3.1 Aims 
The aims of the mosque study were to estimate the prevalence of HBV and HCV in 





The study took place between January 2006 and December 2008, and involved 
screening healthy individuals for viral hepatitis in mosques, temples, community 
centres and some GP surgeries. This initially started in East London but was later 
extended to 4 other English regions: West London, Sandwell and Walsall in the West 
Midlands, and Bradford in West Yorkshire. These areas were picked because of their 
high concentration of immigrants from Bangladesh, India, and Pakistan. In total, 52 
centres were used to screen for viral hepatitis. Ethical approval and permission from 
the mosque, temple, and community leaders was sought and granted before 
screening proceeded. Adverts were placed locally in the screening centres on the day 
of testing offering free viral hepatitis testing. Screening was performed by the 
research team along with various medical students and volunteers who had been 
trained in how to use the screening devices. I played a minor role in screening 
individuals in two East London mosques. All patients were given a patient information 
sheet in their primary language and asked to sign a consent form. They gave informed 
consent that should they test positive for HBV or HCV by oral fluid then they would 
have a confirmatory blood test and if they tested positive for HBsAg or HCV IgG they 
would be referred to a local treating physician and be managed according to local 
treatment guidelines. If patients were unwilling to have a confirmatory blood test 




Free HBV and HCV testing with oral fluid (OMT) was available to all persons attending 
the screening centre aged 16 or over. However, only those with Bangladeshi, Indian, 
or Pakistani ethnic origin were included in the final analysis. Persons from other 
countries such as Somalia or Afghanistan, who opted to be tested, underwent exactly 
the same procedure and were informed of a positive result in exactly the same way. 
Apart from contact information, which was known only to the screeners and principal 
investigator, various demographic data was also collected. These included age, 
gender, city and country of birth, country of birth of parents (if person was born in 
the UK), length of stay in the UK (if person was born abroad), and other medical 
conditions, specifically diabetes mellitus. 
 
A total of 5162 people attending all of the sites underwent screening, with 4833 
coming from the study countries and being included in the analysis. The number of 
males was 2970 (61%) and the age range was 16 to 103 with a median of 48. The 
number of first generation immigrants was 4381, of which 726 were from 
Bangladesh, 1197 were from India and 2458 were from Pakistan. In East London 1975 
people were screened, 1387 in Bradford, 644 in Walsall, 448 in Sandwell and 379 in 
West London. 
 
3.3.2.2 Materials & Procedure 
OMT Screening was done using the Orasure® collection device (Orasure Technologies 
Inc., Bethlehem, Pennsylvania, USA) using exactly the same procedure as was 
described above in the methods section of the validation study. Testing involved two 
mouth swabs that were left in-situ in either side of the mouth for two minutes before 
inserting into the storage vial. As with the previous study, the samples were coded 
anonymously with a unique identification number and a unique barcode sticker was 
applied to the storage vial and sample request form. The completed samples were 
sealed in an envelope and were couriered to the West of Scotland Specialist Virology 
Centre, Gartnavel Hospital, Glasgow, which acted as the central reference laboratory. 
Analysis of the OMT was again carried out by Dr Sheila Cameron and Professor 
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William Carman using the same operating procedure with the adapted Murex ELISA 
assay described above. As with the validation study, all the financial costs associated 
with provision of kits, transportation to the central laboratory and virological analysis 
were borne by Altrix Healthcare Limited, Warrington, UK. 
 
3.3.2.3 Virological analysis 
OMT samples were tested for HBsAg and HCV IgG. The study investigators noticed 
that with the initial 1000 cases, there were a number of HBsAg OMT false positives 
whose corresponding serum samples were negative (for HBsAg). To counteract this, 
the HBsAg positive OMT samples were also tested for anti-HBc. Only those OMT 
samples which tested positive for both HBsAg and anti-HBc were assumed to be from 
HBV positive persons. These people were then contacted to have confirmatory blood 
tests to see if they had HBV. Those who declined to have confirmatory blood tests 
were assumed to be HBV positive if they had positive/reactive HBsAg and anti-HBc 
OMT samples. It took about one week for the results of the OMT analysis to be 
relayed to the study investigators. Upon receiving the information the study team 
contacted the individuals concerned and requested that they attend for confirmatory 
blood tests. All participants were informed that if they were not contacted within 20 
days of being tested then they should assume that the tests for HBV and HCV were 
negative.  
 
The subjects that did screen positive had their blood tests for HBsAg and HCV IgG 
analysed by the virology laboratory at the Royal London Hospital.  
 
3.3.3 Results 
A total of 57 individuals were diagnosed with HBV and 75 with HCV. The vast majority 
of cases were first generation immigrants as shown in Table 3-4. In 2nd generation 
immigrants there was 1 case of HBV and 2 cases of HCV. With HBV infection there 
were much higher odds of contracting the infection if born in Bangladesh or Pakistan. 
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The results for HCV are different in that the odds of infection are higher if born in 
Pakistan.  
 
Ethnicity Bangladeshi Indian Pakistani 
HBV 11(1.5) 1 (0.1) 44 (1.8) 
HCV 4 (0.6) 2 (0.2) 67 (2.7) 
Table 3-4 Overall number of cases and prevalence (%) of HBV and HCV in first 
generation immigrants attending screening centres.172  
 
Figure 3-1demonstrates the distribution of individuals screened in the mosque study. 
3558 Bangladeshi and Pakistani individuals were screened, of which 3184 were first 
generation immigrants born abroad in Bangladesh and Pakistan and 374 were second 


















Figure 3-1 Ethnicity, immigration and gender status of volunteers seen in mosque 
study 
 
Figure 3-2 and Figure 3-3 show the age distribution of the first generation immigrant 
Bangladeshi and Pakistani population that was screened during the Mosque Study. 
The mean age of Bangladeshi males was 48.0 years (range 16-103 years) and females 
was 44.5 years (17-89 years); and Pakistani males was 47.7 (16-103 years) and 
females was 46.7 (16-103 years). Very few individuals of either sex who were 
screened were under 20 years old or over 80 years old. This may be due to these 
5162 screened volunteers 
in mosque study 
 
1604 not Bangladeshi or 
Pakistani 
3558 Bangladeshi and 
Pakistanis  
3184 first generation  
immigrants 
237 Female 1662 Male 796 Female 489 Male 
726 Bangladeshis  2458 Pakistanis  
374 born in UK 
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individuals either not attending the mosques for health or social reasons or that they 















































Figure 3-2 Age and sex distribution of first generation Bangladeshi volunteers 
















































Figure 3-3 Age and sex distribution of first generation Pakistani volunteers screened 
in mosque study 
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Figure 3-4 and Figure 3-5 shows the age and sex distribution for second generation 
Bangladeshis and Pakistanis attending the mosques who agreed to be screened. The 
most notable difference between these figures and Figure 3-2 and Figure 3-3 is that 
there were far fewer UK-born individuals attending (and being screened at) the 
mosques. Those that did attend were much younger, with very few (less than 10%) 
being over 40 years old. The mean age of these Bangladeshi males was 29.3 years 
(range 16-65 years) and females was 30.2 years (20-42 years); and Pakistani males 
















































Figure 3-4 Age and sex distribution of second generation Bangladeshi volunteers 

















































Figure 3-5 Age and sex distribution of second generation Pakistani volunteers 
screened in mosque study 
 
Figure 3-6 shows the age distribution of the 55 first generation Bangladeshi and 
Pakistani individuals who screened positive for HBV. 11 Bangladeshis tested positive 
for HBV, of which 10 were male, and 44 Pakistanis tested positive, of which 31 were 
male. 
Only two of the second generation immigrants tested positive for HBV: one Pakistani 
and one Bangladeshi.  Apart from Bangladeshi females, the peak prevalence for HBV 
was in the 40-49 age group for Pakistani males and females and Bangladeshi males. 
The prevalence of HBV was four times higher in the first generation Pakistani 


















































Figure 3-6 Age distribution of HBV in screened first generation Bangladeshi & 
Pakistani volunteers of both sexes 
 
Figure 3-7and Figure 3-8 show the prevalence of HBV in the first generation screened 
Bangladeshi and Pakistani population for each of the different age groups for both 
sexes. The overall prevalence of HBV in both sexes is also shown; the prevalence of 































































































3.4 Demographics of HBV in Bangladeshis and Pakistanis living in East 
London 
3.4.1 Introduction 
At the time of this study only the Mosque study above had estimated the prevalence 
of HBV in Bangladeshi and Pakistani immigrants.172 Recently  there has since been 
another study conducted in the North-East of England which screened the Chinese 
and South-Asian communities using dried blood spot testing. In this study the 
prevalence of HBV was estimated to be 3.1% in Pakistanis and 0.5% in 
Bangladeshis.173 
Tower Hamlets and Newham are boroughs in North East London with large immigrant 
communities (see Figure 3-9). In Newham, there are approximately equal numbers of 
Bangladeshis and Pakistanis and together they make up 17% of the population. In 
Tower Hamlets, there is a very large Bangladeshi community which comprises a third 
of the population; this is in contrast to Pakistanis who comprise 1% of the population.  
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The two populations are served by two hospitals, Barts and the London (BLT) and 
Newham University Hospital (NUH), which provide free NHS care to all residents. The 
proximity of the hospitals to the local population and the referral patterns of local 
primary care physicians (who refer patients to local physicians) ensure that the vast 
majority of patients with liver disease are referred locally to either of these hospitals.  
 
Figure 3-9 Map showing the London Boroughs of Newham and Tower Hamlets 
 
3.4.2 Aims 
To determine the prevalence of chronic HBV in hospital based patients from 






Data from the 2001 ONS census was used to provide information on the population 
living in Tower Hamlets and Newham who were born in Pakistan or Bangladesh. 
Migration data from ONS indicates that there has been less than a 2% change in the 
Pakistani/Bangladeshi population in the UK between 2001 and 2006 and the 2001 
census data was therefore deemed to be accurate. The Mosque Study showed that, 
by multivariable analysis there was no difference in the prevalence of HBV between 
people originating from Pakistan or Bangladesh and there was no difference in 
prevalence in the different regions in the UK. There was, however, a difference in 
prevalence between men and women and a difference in prevalence between the 
different ages. To allow for aging of the population all ages were expressed as 2006 
ages (i.e. 5 years was added to the age of the individuals identified in the 2001 
census). The proportion of people of different ages with chronic HBV was derived by 
simple calculation. The analysis of the prevalence of HBV in this dataset was 
performed solely by myself. 
Over a 30 month period from January 2006 to June 2008 I sought to identify every 
patient with HBV that presented to the 2 hospitals either as an outpatient clinic 
attendee or who was admitted as inpatient. I achieved this by contacting the coding 
departments of both hospitals and identifying all patients admitted with a diagnosis 
of hepatitis, decompensated liver disease or liver cancer and corroborating the details 
with the patient notes, which were searched by hand. Outpatients were identified 
from clinic waiting lists and checking the electronic patient record systems of both 
hospitals. Confirmation of HBV status was done by checking the virology records on 
the hospital pathology system. Of the 1243 patients (of all ethnicities) attending the 
out-patient clinics with a diagnosis of chronic HBV, 268 patients were of Bangladeshi 
and Pakistani ethnicity. Patients with co-infections such as delta, HCV and HIV were 




3.4.3.2 Statistical Analysis 
All the data collected was categorical and so non-parametric tests such as Chi square, 
Fisher's exact test and logistic regression were performed. Statistics were calculated 
using computer software (SPSS version 16, SPSS Inc., Chicago, IL, USA and GraphPad 
Prism version 5, GraphPad Software Inc., La Jolla, CA, USA). 
 
3.4.3.3 Ethical Approval 
Ethical approval for this study was granted by Oxfordshire REC A as an amendment to 
the study: Case finding and prevalence of chronic viral hepatitis in South Asians living 
in the UK – Number 06/Q1604/185.   
 
3.4.4 Results 
3.4.4.1 Prevalence of HBV in Bangladeshi and Pakistani immigrants 
living in East London  
Table 3-5 through Table 3-8 show the estimated predicted prevalence of HBV, for the 
different age groups, in the first generation immigrant Bangladeshi and Pakistani 
populations of East London for males and females respectively. As only two second 
generation immigrant volunteers tested positive for HBV (1 Pakistani and 1 
Bangladeshi), we cannot determine the prevalence in the second generation 
populations. Similarly there was only one female first generation Bangladeshi who 
tested positive and this explains why there are only estimated prevalence numbers in 
the 30-39 age group. This is almost certainly not the case but it was not possible to 
estimate prevalence of HBV in this sector of the population based on the small 
numbers of individuals who agreed to be screened. The estimated numbers were 
calculated by multiplying the prevalence for each age group with the population 
numbers for each age group derived from the 2001 census data. Because there are 
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large confidence intervals for the prevalence of HBV in the different age groups, this 
translates into much wider estimates for the true numbers of infected individuals in 




Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Prevalence of HBV (%) (and 95% confidence interval) 1.7 (± 3.3) 1.6  (± 2.2) 2.7 (± 3.0) 3.5 (± 4.8) 0 2.8 (± 4.8) 
Population in East London 6119 6893 4342 1200 1890 1624 
Estimated number of people who are HBsAg  positive 104 (0-306) 110 (0-262) 117 (0-247) 42 (0-100) NA 45 (0-123) 
 
Table 3-5 Estimated HBV burden in male Bangladeshi first generation immigrants in East London  
 
 
Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Prevalence of HBV (%) (and 95% confidence interval) 0 1.6 (± 3.1) 0 0 0 0 
Population in East London 7358 6689 3169 2594 1586 767 
Estimated number of people who are HBsAg  positive NA 118 (0-314) NA NA NA NA 
 





Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Prevalence of HBV (%) (and 95% confidence interval) 0.8 (± 1.1) 2.3 (± 1.6) 2.7 (± 1.7) 1.9 (± 1.4) 1.6 (± 1.8) 1.4 (± 1.6) 
Population in East London 1136 1668 1153 734 327 276 
Estimated number of people who are HBsAg  positive 9 (0-22) 38 (0-65) 31 (11-52) 14 (4-25) 5 (0-12) 4 (0-8) 
 
Table 3-7 Estimated HBV burden in male Pakistani first generation immigrants in East London 
 
 
Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Prevalence of HBV (%) (and 95% confidence interval) 0 1.4 (± 1.9) 2.9 (± 2.3) 1.7 (± 1.9) 2.1 (± 2.8) 0 
Population in East London 1013 1128 1165 696 361 195 
Estimated number of people who are HBsAg  positive NA 16 (0-37) 34 (7-61) 12 (0-25) 8 (0-18) NA 
 
Table 3-8 Estimated HBV burden in female Pakistani first generation immigrants in East London 
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3.4.5 Acute hepatitis B 
During the study time period, 268 patients with hepatitis B were seen in both of the 2 
hospitals, of which 7 were deemed to have had acute hepatitis B (see Table 3-9). 
These patients presented with the clinical syndrome of an acute hepatitis: jaundice, 
elevated ALT and were HBsAg positive. In addition virological testing showed that all 
these patients were HBcAb (hepatitis B core antibody) IgM positive. In 5 patients, 
there was HBsAg seroconversion on outpatient follow up. 2 patients were lost to 
follow up so it is conceivable that they may have had an acute flare of pre-existing 
hepatitis B. Many patients with acute hepatitis B do not get referred by their GPs or 
present to the emergency department and so the true numbers of patients with 
acute hepatitis B may be higher, especially as the majority were born abroad. 
Although acute hepatitis B is a notifiable disease many patients from immigrant 
communities may be reluctant to present to health practitioners, particularly if their 
immigration status is unclear. None of these patients smoke or drank alcohol, or was 
diabetic. Of these 7 patients, 1 patient tested positive for HCV but none of them were 
tested for HIV or delta co-infection at the time of presentation. Acute HBV can have 
severe complications but these did not occur in our cohort, and as our focus was on 





Age Sex Ethnicity Immigration status 
32 F Bangladesh First generation 
31 F Bangladesh First generation 
45 M Bangladesh First generation 
24 M Pakistan First generation 
54 M Bangladesh First generation 
52 F Bangladesh First generation 
32 M Bangladesh Second generation 
 
Table 3-9 Demographics of Bangladeshi and Pakistani patients with acute hepatitis B 
admitted to hospital 
 
3.4.6 Chronic hepatitis B 
Figure 3-10 shows the distribution of all patients diagnosed with HBV of Bangladeshi 
and Pakistani ethnicity attending the two London hospitals, either as out-patients or 
who were admitted as inpatients between 1 January 2006 and 30 June 2008. Of the 
remaining 261 patients with chronic HBV, 10 patients had HCV co-infection and 1 had 
HDV co-infection. One of the HCV co-infected patients also had cirrhosis. None of 
these patients had HIV co-infection. As both HCV and HDV co-infections can cause 
cirrhosis or decompensated disease, these patients were also excluded from the 
remainder of the study as it would have been impossible to determine the 
contribution played by their co-infection. All further analysis of severe disease will 





7 acute HBV 
10 HCV co-infection 
261 chronic HBV  
250 mono-HBV chronic 
infection 
217 mono-HBV first 
generation immigrants 
33 born in UK  
61 Female 39 Male 20 Female 97 Male 
Figure 3-10 Distribution of HBsAg+ patients attending hospital 
158 Bangladeshis 59 Pakistanis 
1 HDV co-infection 
268 Bangladeshi & 





250 patients had chronic HBV but of this, more than 85% were first generation (born 
abroad) immigrants. Of the 33 second generation (born in the UK) immigrants, 12 
were males (6 Bangladeshi) with a mean age of 26 (range 17-34); and 21 were 
females (15 Bangladeshi) with a mean age of 29 (range 18-45). The combined male 
and female age distribution is displayed in Figure 3-11. Compare this with Figure 3-12 
which shows the age distribution of first generation immigrants. Because only two of 
the second generation volunteers who attended screening in the mosques tested 
positive for HBV, it was not possible to calculate the prevalence in this group and 
therefore it was not possible to estimate the numbers of HBV infected second 
generation immigrant patients who should be attending hospital. Hence it is 
impossible to say with any certainty whether the 33 patients, who were being 
investigated in hospital, are an under- or overestimate of the true population 


































Figure 3-11 First generation immigrant Bangladeshi and Pakistani chronic HBsAg+ 































Figure 3-12 Second generation immigrant Bangladeshi and Pakistani chronic HBsAg+ 
males & females living in East London and attending hospital 
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4 Hepatitis B in Bangladeshi and Pakistani population of East London 
 
4.1 Introduction 
There are approximately 350 million people chronically infected with hepatitis B virus 
(HBV) around the world. In a landmark longitudinal study by Beasley et al, they 
showed that the incidence of HCC and cirrhosis in Taiwanese men, was intimately 
linked with chronic HBV infection.174 After tobacco, HBV is thought to be the second 
commonest carcinogen.175 There are varying estimates as to how many deaths per 
year are attributable to HBV but the recent Global Disease Burden Study 2010 
proposed approximately 785,000 deaths worldwide, including half of all liver cancers 
deaths and a third of all cirrhosis deaths.176 
 Further studies, primarily using patients from the Far East, have demonstrated that 
viral factors such as HBeAg seropositivity,128;129;131 elevated viral load (HBV DNA),50;65 
and genotype C133;136 are associated with advanced disease states of cirrhosis and 
HCC. In addition to these, other authors have established that host factors are also 
significantly associated with cirrhosis and HCC: increasing age and male sex50;177;178; 
elevated ALT150; alcohol152;153 and smoking.129;153;179 In hepatitis C (HCV) infection 
there is also an association with disease progression and diabetes,180;181 however, 
there is a lack of evidence for a similar relationship with HBV.182  
The World Health Organization (WHO) has documented the prevalence of HBV in 
various countries to assess endemicity.101 Far more difficult a task is to calculate the 
prevalence and disease burden in immigrant populations in low endemic countries 
such as the UK. Some have attempted to predict HCC incidence due to HBV by 
assuming that the HBV prevalence in the immigrant group was equivalent to the 
prevalence of HBV in the country of origin and then utilising incidence rates based on 
longitudinal studies.183;184 Other studies have attempted to delineate prevalence in 
immigrant groups by looking at prevalence of serum HBsAg in refugees.185;186 Another 
option has been to target screening at specific "high risk" groups (individuals from 
high endemic areas, specifically those from Eastern Asian countries like China) 
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through invitation to health fairs.187-191 Fattovich et al192 carried out a systematic 
review of incidence rates and prognostic factors associated with progressive disease 
(cirrhosis, decompensation and HCC). They concluded that the only adequate, 
longitudinal studies to be included in their review were from Western countries 
(North America, West and Southern Europe) and the Far East. They did not focus on 
immigrants, let alone those from the Indian Subcontinent. 
The prevalence of HBV in Bangladesh has been estimated to be 5.5-5.8%.193;194 
Another review has purported the prevalence of HBV in Pakistan to be 3.3% (in 
healthcare workers) to 7.4% (in surgical patients).195 The same study states that the 
predominant genotype in Pakistan is genotype D with 63%, followed by genotype A 
with 10%, genotype C with 7.5% and genotype B with 5%. In Bangladesh, genotype D 
is still the most predominant type with 50% prevalence, but genotype C is common 
with 37.5%, and genotypes A and B with 2.5%.196 
 
4.2 Aims 
There is little information on the outcome of chronic HBV in people from Bangladesh 
and Pakistan and there is no data on the outcome in Bangladeshi and Pakistani 
immigrants who have settled in the UK. The aim of this study was to: 
1. To identify the risk factors associated with the development of cirrhosis and 
decompensated liver disease in first generation immigrants (i.e. those born 
abroad) infected with chronic HBV. 
2. To determine the disease burden of chronic HBV in immigrants from 
Bangladesh and Pakistan living in East London. 
4.3 Methods 
4.3.1 Patients 
Patients with CHB attending NUH and RLH were identified from the electronic patient 
records and hospital notes as described in Chapter 3.  
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To determine the burden of end stage liver disease we assumed that all patients with 
cirrhosis and decompensated liver disease (due to hepatic encephalopathy, ascites or 
variceal haemorrhage, and HCC) would present to one of the two regional hospitals 
and a database of such patients was created by myself. Over a 30 month period from 
January 2006 to June 2008 hospital and virology records for every patient admitted 
with end stage liver disease were evaluated and patients with decompensated liver 
disease due to chronic HBV infection in the absence of delta, HCV, and HIV co-
infection were noted.  
For patients with uncomplicated disease the age at final attendance was recorded. 
For patients with complications the age at which these developed was used and for 
patients requiring therapy the age at which therapy was introduced was recorded. 
As with previous studies, risk factors for progression of disease were identified and 
assessed for statistical significance. These included host factors such as age, sex, 
ethnicity, smoking and drinking history, and the presence of diabetes; HBV factors 
such as eAg status, HBV DNA, genotype and whether anti-HBV treatment had been 
given; and other factors such as ALT. Most of the risk factors utilise nominal values 
and so the data collected were assigned to different categories such as: current or ex-
smoker versus non-smoker; alcohol drinker versus no alcohol (teetotal); diabetic 
versus non-diabetic; cirrhotic versus non-cirrhotic. Parameters with continuous data 
such as age, HBV DNA viral load and ALT at diagnosis were also assigned to 
categories: under 40 years (16-39) versus over 40 years (≥40); low DNA (≤ 4.0 log 
IU/L) versus high DNA (> 4.0 log IU/L); and low ALT (≤ 40 IU/L) versus high ALT (> 40 
IU/L). Cirrhosis was diagnosed by liver biopsy (either percutaneous or transjugular) or 
by confirmatory findings on triphasic CT liver or MRI liver with the patient having 
clinical and endoscopic features of portal hypertension (low albumin, low platelets, 




4.3.2 Virological Analysis 
A single, central laboratory provides virological support to both hospitals and patients 
with HBV are routinely evaluated for HBsAg, HBeAg, anti-HBe antibody and delta virus 
superinfection. HBV DNA levels are measured using standard, commercial assays. In 
this chapter I shall refer to patients who are HBsAg positive as infected with HBV. 
Analysis of genotypes was performed by Dr Samreen Ijaz, clinical scientist at Health 
Protection Agency (HPA), Colindale, London. She carried out PCR amplification and 
sequence analysis across the entire HBsAg region, the overlapping polymerase region, 
part of the X region (last 60 amino acids which cover the basal core promoter), the 
entire precore and core regions. Patients with cirrhosis and advanced disease were 
identified and their frozen stored plasma or serum samples were retrieved. The 
samples were allowed to defrost at room temperature for 2 hours, centrifuged and 
then had 0.5 ml aliquoted from them. The new samples were then put into new 
sample tubes, sealed, packed in dry ice and sent to the HPA by courier. To act as a 
control group, samples from patients who were age and sex matched immigrant 
Bangladeshis and Pakistanis but without cirrhosis or advanced disease, were also sent 
in exactly the same way as the patients with cirrhosis and advanced disease. The ratio 
of controls to disease patients was 2:1. 
 
4.3.3 Statistical Analysis 
All the data collected was categorical and so non-parametric tests such as Chi square, 
Fisher's exact test and logistic regression were performed. Statistics were calculated 
using computer software (SPSS version 16, SPSS Inc., Chicago, IL, USA and GraphPad 




4.3.4 Ethical Approval 
Ethical approval for this study was granted by Oxfordshire REC A as an amendment to 
the study: Case finding and prevalence of chronic viral hepatitis in South Asians living 
in the UK – Number 06/Q1604/185.  
 
4.4 Results 
4.4.1 Characteristics of Bangladeshi and Pakistani chronic HBV patients 
attending hospital 
The social and viral demographics for male and female HBV infected patients who 
attended hospital, either as out-patients or were admitted as inpatients, according to 
the various age groups are shown in Table 4-1, Table 4-2, Table 4-3, and Table 4-4. 
They show that all of the infected men aged over 40 and virtually all the infected 
women over 40 were born in their home countries of Bangladesh and Pakistan. Of 
note is the lack of alcohol intake in both sexes, but especially in women, which is 
probably related to the prevalent Islamic beliefs practised in both countries and in 














No Yes No Yes 
16-29 22 12 25 9 27 5 30 2 34 0 
30-39 34 12 43 3 27 14 39 2 44 2 
40-49 20 8 28 0 21 7 26 2 22 6 
50-59 16 9 25 0 17 7 23 1 13 12 
60-69 4 1 5 0 3 2 4 1 2 3 
≥70 7 3 10 0 6 4 10 0 4 6 
 
Table 4-1 Social demographics of chronic mono-infected male HBsAg+ Bangladeshi and Pakistani first and second generation immigrants 






ALT at diagnosis 
eAg status at 
diagnosis 











No Yes No Yes 
16-29 14 20 27 6 20 14 28 6 32 2 
30-39 18 28 36 10 28 18 20 16 41 5 
40-49 12 16 18 7 13 13 18 10 24 4 
50-59 6 19 20 5 12 11 19 6 14 11 
60-69 3 2 4 1 4 1 3 2 2 3 
≥70 4 6 8 2 4 4 5 5 5 5 
 
Table 4-2 Viral demographics of chronic mono-infected male HBsAg+ Bangladeshi and Pakistani first and second generation immigrants 
















No Yes No Yes 
16-29 26 9 24 11 34 1 35 0 34 1 
30-39 23 9 24 8 30 2 32 0 30 2 
40-49 13 2 13 2 15 0 15 0 12 3 
50-59 10 4 14 0 12 2 14 0 9 5 
60-69 3 2 5 0 5 0 5 0 0 5 
≥70 1 0 1 0 1 0 1 0 1 0 
 
Table 4-3 Social demographics of chronic mono-infected female HBsAg+ Bangladeshi and Pakistani first and second generation 









eAg status at 
diagnosis 











No Yes No Yes 
16-29 26 8 29 5 16 8 32 3 35 0 
30-39 26 5 30 2 17 10 27 5 31 1 
40-49 12 3 14 1 8 4 14 1 15 0 
50-59 10 4 13 1 6 4 14 0 14 0 
60-69 4 1 5 0 3 2 5 0 5 0 
≥70 1 0 1 0 0 1 1 0 1 0 
 
Table 4-4 Viral demographics of chronic mono-infected female HBsAg+ Bangladeshi and Pakistani first and second generation 
immigrants presenting to secondary services in East London 
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4.4.2 Demographics of chronic HBV in 1st generation immigrant population 
Figure 4-1 to Figure 4-4 show the distribution of chronic HBV infection in the first 
generation immigrant Bangladeshis and Pakistanis who attended the two East London 
hospitals. There are twice as many chronic HBV infections in Bangladeshi males and 
three times as many in Bangladeshi females as there are in Pakistanis, 97:39 (Figure 
4-1 and Figure 4-3) and 61:20 respectively (Figure 4-2 and Figure 4-4). All of the 
graphs show a skew in disease prevalence towards younger age although this is more 
prominent with Bangladeshis compared to Pakistanis. The differences in patient 
numbers between Bangladeshis and Pakistanis probably relates to the difference in 


































Figure 4-1 First generation immigrant Bangladeshi chronic HBsAg+ males living in East 



































Figure 4-2 First generation immigrant Bangladeshi chronic HBsAg+ females living in 

































Figure 4-3 First generation immigrant Pakistani chronic HBsAg+ males living in East 



































Figure 4-4 First generation immigrant Pakistani chronic HBsAg+ females living in East 
London and attending hospital 
 
The number of first generation Bangladeshi and Pakistani patients who are estimated 
to have chronic HBV (along with confidence intervals) are shown in Table 3-5 through 
to Table 3-8 for males and female. These numbers were determined from the 
calculated prevalence. The actual numbers of males and females who are infected 
with chronic HBV and being seen in hospital are shown in Table 4-5 through to Table 
4-8. Also displayed in these tables are the estimated proportions of chronic HBV 
patients being seen in hospital. In most age groups, less than half of the expected 
number of patients are attending hospital. If the estimated numbers are assumed to 
be accurate then the overall proportion of Bangladeshis seen is 23% for males and 
57% for females. Compared to Bangladeshis, the overall Pakistani proportions differ 




Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Estimated number of 
people who are 
HBsAg+   
104 110 117 42 NA 45 
Actual number of 
HBsAg+  people 
attending hospital 
18 32 20 16 4 7 
Proportion attending 
hospital (%) 36 45 26 62 NA 18 
 
Table 4-5 Proportion of chronic HBsAg+ first generation immigrant Bangladeshi males 
attending hospital 
 
Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Estimated number of 
people who are 
HBsAg+   
NA 107 NA NA NA NA 
Actual number of 
HBsAg+  people 
attending hospital 
19 17 11 10 3 1 
Proportion attending 
hospital (%) NA 16 NA NA NA NA 
 
Table 4-6 Proportion of chronic HBsAg+ first generation immigrant Bangladeshi 




Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Estimated number of 
people who are 
HBsAg+   
9 38 31 14 5 4 
Actual number of 
HBsAg+  people 
attending hospital 
7 11 8 9 1 3 
Proportion attending 
hospital (%) 
78 29 26 64 20 75 
 
Table 4-7 Proportion of chronic HBsAg+ first generation immigrant Pakistani males 
attending hospital 
 
Age  16-29 30-39 40-49 50-59 60-69 ≥70 
Estimated number of 
people who are 
HBsAg+   
NA 16 34 12 8 NA 
Actual number of 
HBsAg+  people 
attending hospital 
5 7 2 4 2 0 
Proportion attending 
hospital (%) 
NA 44 6 33 25 NA 
 
Table 4-8 Proportion of chronic HBsAg+ first generation immigrant Pakistani females 
attending hospital 
 
4.4.3 Differences between first generation immigrant Bangladeshis and 
Pakistanis in East London 
Before identifying risk factors associated with cirrhosis and advanced disease, the two 
first generation immigrant populations were compared to see if there were any 
significant differences in a variety of independent variables. Frequencies were 
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determined and then non-parametric descriptive statistics were performed 
comparing Bangladeshis and Pakistanis.  
Table 4-9 shows these comparisons with the 2x2 contingency tables, p values, odds 
ratio and 95% confidence intervals. Initially Chi-square tests were employed with 
each of the 2x2 contingency tables, but some of these did not meet all the conditions 
required for using this test - in each cell, all the expected values must be greater than 
5 and in this study some of the sample sizes were too small to meet the test criteria. 
To ensure that there was congruity with all the risk factors, Fisher's exact test was 
utilised for all of the contingency tables to generate an exact p value.  
Age 40 was used as an arbitrary figure for distinguishing between older and younger 
individuals. An ALT of 40 was selected to separate ‘high ALT’ from ‘low ALT’. A value 
of 40 is regarded as the upper limit of normal in many biochemistry laboratories for 
patients without underlying liver disease, though it has been suggested that this value 
is too high (especially for women), and that many patients with significant liver 
inflammation have a ‘normal ALT’ i.e. below 4047;197. All the other risk factors were 
divided into distinct groups.  
HBe antigen status at diagnosis was statistically different between Bangladeshis and 
Pakistanis with more Bangladeshi patients being HBeAg positive at the time of 
diagnosis. Another difference between the two communities was having patients on 
anti-HBV treatment, those currently having treatment and those who have had it in 
the past: more Bangladeshis than Pakistanis were having or had treatment. These 
may be true differences but more likely they are a reflection of the local population. 
The majority of HBV patients seen in RLH are from the local Tower Hamlets 
population, which has a very large Bangladeshi population and a very small Pakistani 
population. In Newham, the Bangladeshi and Pakistani populations are similar in size 
(about 8% each) so proportionally more Pakistanis would be seen in NUH. At the time 
of the study, all treatment for HBV was initiated at RLH. In order to get treatment, 
patients originally seen in NUH would have had to have been referred to RLH. Delays 
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in diagnosis, referral or because of patient non-attendance at RLH for treatment with 
Pakistani patients may account for this disparity in treatment. 
At the time this study was carried out routine testing of HBV genotype was not 
available. Genotype has been implicated in the development of cirrhosis and HCC. 
There is a possibility there may have been a difference between the 2 ethnicities but 






Risk Factor Category Bangladesh Pakistan 






≤40 89/217 31/217 
0.647 1.17 0.64 - 2.12 
>40 69/217 28/217 
Sex 
Female 61/217 20/217 
0.637 1.19 0.64 - 2.24 
Male 97/217 39/217 
ALT at diagnosis 
Low (≤40) 81/215 32/215 
0.648 0.87 0.47 - 1.59 
High (>40) 76/215 26/215 
eAg at diagnosis 
Negative 124/212 55/212 
0.002 0.15 0.03 - 0.63 
Positive 31/212 2/212 
HBV DNA at diagnosis 
Low (≤4 log) 84/194 33/194 
0.40 0.72 0.37 - 1.41 
High (>4 log) 60/194 17/194 
Cirrhosis 
No cirrhosis 134/217 53/217 
0.386 0.63 0.24 - 1.63 




Stable Disease 149/217 55/217 
0.75 1.20 0.36 to 4.07 
Decompensated/HCC 9/217 4/217 
On anti-HBV treatment (Rx) 
now 
Not on Rx now 124/217 54/217 
0.029 0.34 0.13 to 0.91 
Currently on Rx 34/217 5/217 
On anti-HBV Rx ever 
Never had Rx 113/217 51/217 
0.022 0.39 0.17 to 0.90 
Have had Rx 45/217 8/217 
Smoking 
Never smoked 123/213 49/213 
0.700 0.81 0.37 to 1.78 
Smoker 31/213 10/213 
Alcohol drinker 
No alcohol 148/213 57/213 
1.000 0.87 0.17 to 4.42 
Alcohol 6/213 2/213 
Diabetes 
Non-diabetic 126/217 46/217 
0.851 1.11 0.54 to 2.30 
Diabetic 32/217 13/217 
 




4.4.4 Cirrhosis in first generation immigrant Bangladeshis and Pakistanis 
This section examines various risk factors associated with cirrhosis in the immigrant 
Bangladeshi and Pakistani population of East London. Risk factors such as age (Figure 
4-5 and Table 4-10); sex (Figure 4-6 and Table 4-11); ALT at diagnosis (Figure 4-7 and 
Table 4-12); being on anti-HBV treatment at the present time (Figure 4-8 and Table 
4-13); ever being on anti-HBV treatment (Figure 4-9 and Table 4-14); smoking (Figure 
4-10 and Table 4-15); and diabetes (Figure 4-11 and Table 4-16) were significant using 
univariate analysis. Alcohol (Figure 4-12 and  
Table 4-17) was not statistically significant as a risk factor for cirrhosis, but is 
represented graphically for comparison with the other risk factors. Other 
independent risk factors such as HBeAg status at diagnosis and HBV DNA viral load at 
diagnosis were not statistically significant.  
 






































<40 113/217 7/217 
0.001 5.02 2.05 - 12.29 
>40 74/217 23/217 
 
Table 4-10 Univariate statistics for age vs cirrhosis in first generation immigrant 







































Female 80/217 1/217 
< 0.001 21.68 2.89 - 162.60 
Male 107/217 29/217 
 
Table 4-11 Univariate statistics for sex vs cirrhosis in first generation immigrant 























Figure 4-7 ALT vs cirrhosis in first generation immigrant Bangladeshis and Pakistanis 
 














Low (<40) 105/215 8/215 




Table 4-12 Univariate statistics for ALT vs cirrhosis in first generation immigrant 
Bangladeshis and Pakistanis 
 
Figure 4-8 and Figure 4-9 suggest that treatments both now and in the past are 
significantly associated with cirrhosis. The clinical significance of these results is 
difficult to explain but it is probable that those patients who have developed cirrhosis 
are much more likely to be commenced on antiviral therapy than those who have not 
developed severe fibrosis.  
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Figure 4-8 Treatment now vs cirrhosis in first generation immigrant Bangladeshis and 
Pakistanis 
 















Not on Rx 
now 
167/217 11/217 





Table 4-13 Univariate statistics for treatment now vs cirrhosis in first generation 




















































Table 4-14 Univariate statistics for treatment ever vs cirrhosis in first generation 












































0.002 4.03 1.73 - 9.41 
Smoker 29/213 12/213 
 
Table 4-15 Univariate statistics for smoking vs cirrhosis in first generation immigrant 























Figure 4-11 Diabetes vs cirrhosis in first generation immigrant Bangladeshis and 
Pakistanis 
 
















0.029 2.61 1.14 - 5.98 
Diabetic 34/217 11/217 
 
Table 4-16 Univariate statistics for diabetes vs cirrhosis in first generation immigrant 












































0.073 4.32 0.97 - 19.20 
Alcohol 5/213 3/213 
 
Table 4-17 Univariate statistics for alcohol vs cirrhosis in first generation immigrant 
Bangladeshis and Pakistanis 
 
As age group, sex, ALT group, smoking and diabetes were significant predictors of 
cirrhosis by univariate analyses, they were also tested using multivariate analysis. As 
mentioned before, treatment, either currently or in the past, was not utilised because 
of its uncertain clinical significance. Because of the binary nature of the outcome (i.e. 
presence of cirrhosis or not) binary logistic regression was employed using the forced 
enter method.  
Table 4-18 shows that only age and sex show statistically significant associations with 
cirrhosis when the variables are controlled for. The odds ratio of age >40 was 4.57 
and of male sex was 11.74 but both are associated with wide 95% confidence 
intervals suggesting that neither is very good at giving an accurate estimate of the 







95% Confidence Interval 
for EXP(B) 
Lower Upper 
Age group <.01 4.57 1.56 13.43 
Sex <.02 11.74 1.48 93.43 
ALT .16 2.21 .83 5.92 
Smoking .08 2.35 .92 6.00 
Diabetes .81 1.14 .40 3.22 
 
Table 4-18 Logistic regression showing significant variables for predicting cirrhosis with odds ratio and confidence intervals in 




4.4.5 Decompensated disease in first generation immigrant Bangladeshis 
and Pakistanis 
Decompensated disease refers to patients with HCC or decompensated cirrhosis. 
Below are the 2x2 contingency tables, p values, odds ratio and 95% confidence 
intervals of various risk factors associated with decompensated disease in the 
immigrant Bangladeshi and Pakistani population of East London. Risk factors such as 
age (Figure 4-13 and Table 4-19); sex (Figure 4-14 and Table 4-20); ALT at diagnosis 
(Figure 4-15 and Table 4-21); being on anti-HBV treatment at the present time (Figure 
4-16 and Table 4-22); smoking (Figure 4-17 and Table 4-23); alcohol (Figure 4-18 and 
Table 4-24); and diabetes (Figure 4-19 and Table 4-25) were significant using 
univariate analysis. Other independent risk factors such as e-antigen status at 
diagnosis and HBV DNA viral load at diagnosis, or ever being on anti-HBV treatment 










































<40 120/217 0/217 
<.001 38.50 2.26 - 657.1 
>40 84/217 13/217 
 
Table 4-19 Univariate statistics for age vs decompensated disease in first generation 









































Female 81/217 0/217 
0.002 17.80 1.04 - 304 
Male 123/217 13/217 
 
Table 4-20 Univariate statistics for sex vs decompensated disease in first generation 
immigrant Bangladeshis and Pakistanis 
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Low (<40) 110/215 3/215 




Table 4-21 Univariate statistics for ALT vs decompensated disease in first generation 
immigrant Bangladeshis and Pakistanis 
 
Figure 4-16 shows that a significant proportion of patients with HCC or 
decompensated cirrhosis are receiving antiviral therapy. It is not clear why some 
patients with advanced disease were not receiving therapy and it is probable that 
such patients may have left the area and be undergoing therapy elsewhere.  
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Figure 4-16 Treatment now vs decompensated disease in first generation immigrant 





















Not on Rx 
now 
171/217 7/217 





Table 4-22 Univariate statistics for treatment now vs decompensated disease in first 

























Figure 4-17 Smoking vs decompensated disease in first generation immigrant 





















< 0.001 18.17 4.73 - 69.83 
Smoker 31/213 10/213 
 
Table 4-23 Univariate statistics for smoking vs decompensated disease in first 

























Figure 4-18 Alcohol vs decompensated disease in first generation immigrant 






















0.008 11.70 2.44 - 56.04 
Alcohol 5/213 3/213 
 
Table 4-24 Univariate statistics for alcohol vs decompensated disease in first 
























Figure 4-19 Diabetes vs decompensated disease in first generation immigrant 





















0.007 5.10 1.62 - 16.04 
Diabetic 38/217 7/217 
 
Table 4-25 Univariate statistics for diabetes vs decompensated disease in first 
generation immigrant Bangladeshis and Pakistanis 
 
The significant univariate predictors of decompensated disease: age group, sex, ALT 
group, smoking, alcohol and diabetes, were analysed using multivariate analysis (see 
Table 4-26). Again this was done using binary logistic regression as the outcome 
measure was either presence of decompensated liver disease or not, and this was 
with the forced enter method. In this case, only smoking was a statistically significant 







95% Confidence Interval 
for EXP(B) 
Lower Upper 
Age group 1.00 30298832.0 .00  
Sex 1.00 43376323.0 00  
ALT .40 2.08 .39 11.26 
Smoking <.002 12.05 2.56 57.00 
Diabetes .76 1.27 .28 5.76 
Alcohol .99 .00   
 
Table 4-26 Logistic regression showing significant variables for predicting 
decompensated disease with odds ratio and confidence intervals in Bangladeshis and 
Pakistanis.  
 
4.4.6 HBV genotypes 
To examine the impact of HBV genotype we studied 31 patients with cirrhosis and 13 
patients with decompensated disease. However analysis was only possible in 20 
patients with cirrhosis and 7 with decompensated disease. In 8 patients no samples 
were available and in 9 patients the low levels of HBV DNA precluded successful 
amplification. Control samples were matched in age and sex to the samples from 
decompensated disease and cirrhosis patients. There were 50 cirrhosis controls and 
37 decompensated disease controls.  
The distribution of genotypes A-D for cirrhosis and decompensated disease are 
shown in Figure 4-20 and Figure 4-22. The predominant genotypes in the Indian 
Subcontinent had been thought to be A and D but C appears to be fairly common as 
well. Two of the patients with liver cancer did not have underlying cirrhosis and in 
both cases they had genotype D. Regarding cirrhosis patients, there was a statistically 
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significant difference between non-genotype D and genotype D infected individuals 
(see Figure 4-21 and Table 4-27). It may be that genotype D is protective against the 
development of cirrhosis. However, as the odds ratio and the lower limit of the 
confidence interval are below 1 it is uncertain whether this could be indicative of the 
true HBV population in Bangladeshis and Pakistanis.  
Table 4-27 shows that none of the other genotypes were significantly associated with 
cirrhosis. Table 4-28 shows that none of the genotypes were significantly associated 






















































































Genotype  A 
30/57 12/57 
0.117 2.86 0.85 - 9.64 




Genotype  C 
32/57 14/57 
0.307 2.29 0.63 to 8.34 




Genotype  D 
13/57 14/57 
0.015 0.23 0.07 - 0.75 
Genotype D 24/57 6/57 
 
Table 4-27 Genotypes in patients with cirrhosis and their clinical significance in first generation immigrant Bangladeshis and Pakistanis 













































Figure 4-22 Genotype vs decompensated Disease in first generation Bangladeshi and 














































Table 4-28 Genotypes in patients with Decompensated disease and their clinical 





4.4.7 Disease burden of HBV in first generation immigrant Bangladeshi and 
Pakistani population 
Table 4-29 and Table 4-30 show the disease burden of HBV based on estimated 
prevalence calculations for Bangladeshis and Pakistanis. For the purposes of the 
analysis, patients with decompensated disease were divided according to their age 
being above or below age 40 - all of these patients were male (see Table 4-19). As 
mentioned previously, screening of mosque volunteers in the various centres 
revealed 41 males that had HBV. This gives an overall screened point prevalence of 
1.7% for under 40 years and 2.0% for over 40 years. This point prevalence was then 
multiplied by the estimated population prevalence (see Table 3-5 and Table 3-7) to 
give the expected population prevalence. The annual admission rates for 
Bangladeshis and Pakistanis with decompensated disease (based on our calculations 
of how many people are estimated to be HBV positive) are shown in Table 4-29 and 
Table 4-30. From our data, we estimated that 208 first generation immigrant 
Bangladeshi males under 40 would be infected with HBV and there would be 208 over 
40. The corresponding male Pakistani numbers are 48 aged under 40 and 50 aged 
over 40.  No HBV individuals, from either ethnicity, aged under 40 were admitted to 
hospital with decompensated liver disease or HCC. However, in the 30 month time 
period, 2006 to 2008, 13 individuals (9 Bangladeshi and 4 Pakistani) aged over 40 
were admitted to hospital with advanced liver disease. Of those with decompensated 
disease, the majority were e antigen negative, but as already mentioned e antigen 
status was not statistically significantly associated with progressive disease. The 
calculations suggest that approximately 1.4% of male first generation Bangladeshi 
patients with chronic HBV aged over 40 will be admitted to hospital with advanced 
liver disease per year. The corresponding rate for male first generation immigrant 




Age < 40 > 40 
Population census 13012 9056 
Screened population 185 305 
Screened population point 
prevalence 
3 (1.6%) 7 (2.3%) 
Expected population prevalence 208 (1.6% x 13012) 208 (2.3% x 9056) 
Admissions to hospital 2006-8 0 9 
Annual admission rate % 0 1.4 
Table 4-29 Disease burden in male Bangladeshi 1st degree immigrants chronically infected with HBV 
 
Age < 40 > 40 
Population census 2804 2490 
Screened population 601 1061 
Screened population point 
prevalence 
10 (1.7%) 21 (2.0%) 
Expected population prevalence 48 (1.7% x 2804) 50 (2.0% x 2490) 
Admissions to hospital 2006-8 0 4 
Annual admission rate % 0 2.7 




4.5.1 Prevalence, disease burden and predictive factors 
This study examined the prevalence of chronic HBV in the immigrant populations 
from Bangladesh and Pakistan living in East London based on those attending 
hospital. The prevalence of HBV in 1st generation Bangladeshi and Pakistani males 
and females according to age is shown in Table 3-5 through Table 3-8. Also shown in 
these tables are the estimated numbers of patients who are thought to have HBV 
based on the calculated prevalence. Cirrhosis and decompensated liver disease 
(decompensated cirrhosis and HCC) only affected males and so the disease burdens 
for male Bangladeshis and Pakistanis are shown in Table 4-29 and Table 4-30.  
The study examined the risk factors associated with cirrhosis and decompensated 
disease. Age group, sex, ALT group, smoking and diabetes were significantly 
associated with the development of cirrhosis through univariate analyses. This 
suggests that they are all important independent factors in predicting cirrhosis. Using 
binary logistic regression multivariate statistics there was a significant association 
with older age and male sex. For decompensated disease, univariate analysis 
demonstrates that age group, sex, ALT group, smoking, alcohol and diabetes are all 
statistically significant independent factors. Multivariate analysis showed that only 
smoking was significant albeit with a very large 95% confidence interval.  
The role of gender and age in the progression of HBV is a complex and unresolved 
issue. Many studies from all around the world have shown that the prevalence of HBV 
is greater in males.198 Since transmission in high and medium endemic countries (like 
Bangladesh and Pakistan) is vertical and equal number of boys to girls are born that 
would suggest females are better at eliminating the virus. Longitudinal follow up 
studies of CHB patients have shown that cirrhosis and HCC occur more frequently and 
at an earlier age in males.50;145 Females have increased numbers of CD4+ lymphocytes 
and a greater proportion of CD4+:CD8+ than males and this may have some influence 
on why autoimmune liver diseases (autoimmune hepatitis and primary biliary 
cirrhosis) are more common in females.199;200 Studies looking at HCV infection, have 
 163 
 
shown that females have higher rates of spontaneous viral clearance, lower 
biochemical values and lower rates of fibrosis. This may be due to gender differences 
in the immune response and/or the defensive anti-fibrotic properties of 
oestrogens.198;200;201 There is a lack of evidence as to whether these phenomena apply 
to HBV.  
In spite of not knowing the mechanism by which disease progression in males occurs 
it does have potential public health implications. African and Asian (Far East) men are 
at higher risk of developing HCC and it has been proposed that they are screened at 
age 40.120 Various "HCC risk calculators" have also recently been created, all of which 
have age and gender incorporated as independent risk variables, to predict the 
cumulative risk of developing HCC in CHB patients.202-204 The problem with these are 
that they have only been validated in Taiwan, Korea, China and Hong Kong and not 
tested in other populations. However, based on our results it would suggest that 
screening this particular immigrant population for HBV would be clinically justified. 
In our study, there are many more individuals of both sexes who are HBeAg negative 
than HBeAg positive in all the age groups (see Table 4-2 and Table 4-4). In the 
immune tolerance phase of CHB infection patients are typically HBeAg positive with 
high viral loads and normal ALT values. The immune surveillance phase follows the 
immune tolerant and immune active phases and is when patients are typically HBeAg 
negative, HBeAb positive, have lower viral loads and normal ALT values. In our study 
only 2 patients were young (28 and 30), had normal ALT, were HBeAg positive and 
had high viral loads: 8.4 and 5.3 log IU/ml respectively. Usually the immune tolerant 
phase is associated with viral loads >8 log IU/ml. All of the individuals aged under 20 
(6) and 41 (out of 51) aged 21-30 were HBeAg negative and HBeAb positive and the 
majority had normal ALT (<40 IU/L) and low viral loads (<4.0 log IU/ml) at diagnosis. 
This finding raises questions about which phase of the disease patients are actually in 
or whether these phases are accurate but blood tests at one point in time are not 
diagnostic. The roles of genotype and HBsAg levels are not known. Our finding of 
predominant HBeAg negative disease has also been replicated in a recent study from 




4.5.2 Bias and confounding 
The prevalence and disease burden results of this study are heavily dependent on the 
screening study undertaken by Uddin et al172. In that study, mosques and community 
centres were targeted for screening. It was assumed that as most Bangladeshis and 
Pakistanis were Muslim and that they would attend these places. It was also assumed 
that they would attend a mosque that was located in the borough of London that 
they lived in. i.e. that a Pakistani male who lived in Newham would attend a mosque 
in Newham or in the adjoining borough of Tower Hamlets rather than travel further 
afield. Similarly it was assumed, that they would attend their local hospital for follow 
up and admission if they developed decompensated disease. These assumptions are 
based on the fact that these two London boroughs have an abundance of mosques 
and that NHS healthcare in the UK is free. As we relied on volunteers attending 
mosques, this could possibly account for the low numbers of Bangladeshi women 
who were screened and tested positive for HBV. There are also a number of 
Bangladeshi and Pakistani individuals who are Muslim but do not attend mosques. 
Despite both Bangladesh and Pakistan being Islamic states (where Islam is the official 
religion), there will be a number of individuals who belong to other religious faiths 
and so will not attend mosques; these individuals would not have been targeted 
during the screening process.   
A recent unpublished study206 has evaluated different methods of screening for viral 
hepatitis in the Pakistani population of East London. They compared three 
approaches: distribution of testing cards in mosques, opportunistically screening 
Pakistani patients attending GP surgeries, and specifically writing to and telephoning 
patients of Pakistani origin to offer screening for HBV and HCV unless they explicitly 
expressed that they did not want to be contacted by telephone. There was very poor 
uptake of the 5000 patients offered screening when visiting the mosque with none 
subsequently visiting their GPs for testing. 17 out of 1163 (1.5%) in the opportunistic 
arm were screened but none were found to be positive. Of the 1134 patients in the 
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other arm, only 600 patients could be contacted and were eligible for testing. So far 
232 have been screened and 1% are HBsAg positive. This study highlights the 
difficulty in case finding infected individuals. It may be that screening of primary care 
may be the most cost-effective method. Further large scale studies need to be carried 
out to see if this increases the confidence of the observed prevalence numbers.  
We calculated the prevalence of first and second generation immigrants based on the 
2001 census data that we got from the Office of National Statistics which is publicly 
available on request. Whilst it is mandatory to fill in the census form back in 2001 it 
was not a criminal offence and so it may well be that there was a degree of under 
reporting of actual numbers. However, under reporting is probably a pan-UK 
phenomenon and not specific to these two London boroughs even though they do 
have more ethnic minority populations than the national average.  
The introduction of universal screening for hepatitis B during pregnancy in the UK was 
proposed in 1998 but was not fully implemented until April 2000207.  Figure 3-10 
shows that 33 second generation immigrants were HBsAg positive. All of these 
individuals would have been born before antenatal screening of hepatitis B occurred. 
The parents of these individuals may have been first generation immigrants and may 
have contracted HBV abroad. If this were the case, then to all intents and purposes, 
the transmission of the disease in these patients would be the same as if they were 
first generation immigrants. Some hospitals did vaccinate babies of HBV infected 
pregnant women prior to 1998 but there was no routine screening policy in the two 
NHS hospitals involved in this study. Therefore it is not possible to say whether there 
was vaccine failure unless the baby was specifically given HBV vaccination. 
Because this was a retrospective study, the results are heavily dependent on the 
accuracy of patient notes and electronic records. This has an impact on determining 
the significance played by the various independent factors. ALT, HBV DNA and HBeAg 
status were all taken from the earliest recorded visit that the patient made to the 
hospital. In some cases, the patients may have been seen on a number of occasions 
before these tests were requested. Smoking was found to be significantly associated 
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with both cirrhosis and decompensated disease but the notes mostly did not 
elaborate on how much or for how long the patient smoked. Included in the smoker 
group were patients who were ex-smokers but it was not possible to work out from 
the notes how long they had abstained. A similar story goes for alcohol: how much 
alcohol is deemed harmful for progression of HBV-related liver disease. One of the 
unusual features about studying this particular population was that alcohol was less 
of an issue because of religious beliefs (alcohol is banned by the Muslim faith).  
We do not know the role of anti-viral medications or their combinations on the 
progression of disease in our cohort. It may have been that medication was started 
because patients had more advanced (fibrosis) disease and was used as a 
preventative measure against developing decompensated disease or that some 
individuals were started on it to try and halt the progression of the disease.  
 
4.5.3 Comparison with other studies 
The most famous study looking at factors associated with cirrhosis and HCC due to 
HBV is the REVEAL-HBV study (Risk Evaluation of Viral Load Elevation and Associated 
Liver Disease/Cancer-Hepatitis B Virus) carried out by Chen and colleagues in 
Taiwan50. They followed up 3653 individuals aged 30-65 from 7 townships with HBV 
mono-infection and detectable HBV DNA over an 11-13 year period to see who 
developed HCC. They found that 15% of individuals who had HBV DNA >6 log 
copies/mL at study entry had developed HCC by the 13th year of the study. There 
appeared to be an increasing risk of HCC with higher levels of DNA and this was still 
significant using multivariate statistics when factors such as ALT, e-antigen status and 
presence of cirrhosis were controlled for. The authors purport that increased age, 
male sex, smoking, and alcohol drinking were also significantly associated with HCC 
but do not elaborate on the strength of this relationship. Regarding HBV DNA in our 
study, we used international units per millilitre (IU/mL) where 1 IU/mL ≈ 5.8 
copies/mL. Due to financial and time constraints, this study could not follow up 
patients for the same duration to see whether similar results would be produced. 
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Also individuals in the REVEAL study were not offered treatment and referral to a 
treatment centre only occurred if cirrhosis or HCC was diagnosed. Our study showed 
similar significant findings with age, sex, smoking, alcohol and ALT. Their study looked 
at individuals in a region of high endemicity where the predominant genotypes were 
B (1520/2405) and C (801/2405).208 This is in contrast to our study which looked at 
immigrants from an area of intermediate endemicity where genotype B is rare and 
genotypes A, C and D are more common.  
To date, only the recent study by McPherson et al has also screened South Asian 
immigrants for HBV (and HCV) in mosques in North East England. In their study they 
used volunteers attending the mosques and used DBS rather than OMT. Those 
patients that tested positive for HBsAg on DBS were then invited for specialist 
outpatient review, however none accepted this offer.173 
Studies that do not rely on volunteers run the risk of selection bias. Studies on 
pregnant mothers or blood donors may not give representative figures because these 
groups may be self-selecting to seek medical help. Because of misconceptions of how 
HBV has been contracted, there is a lot of stigma attached to being diagnosed with 
the disease and individuals often do not want to know or have their families know.209 
Another source of bias with studies using immigrants concerns socio-economic status. 
First generation immigrants may be more affluent than the indigenous population 
back home and so may have the means to leave the country. Refugees, on the other 
hand, may have suffered more hardships and so may be at greater risk of contracting 




The results of this study show that various factors are associated with progression to 
decompensated disease. Future studies are needed to determine the strength of this 
relationship. Follow up of 3 years is too short to fully understand what will happen to 
these patients. There needs to be accurate recording of baseline values and regular 
follow up to see the effects of time and also treatment on disease evolution. Better 
education of the immigrant population to eliminate feelings of stigmatisation will 





5 Hepatitis B in non-Indian Subcontinent immigrants in East London 
5.1 Introduction 
Hepatitis B is a global pathogen with almost 2 billion people having been infected 
with the virus in the past. The world can be subdivided based upon the distribution of 
cases into areas of high, intermediate and low endemicity (see chapter 1).96;210 The 
regions of HCC high incidence are Eastern and South-Eastern Asia, Middle and 
Western Africa and the Pacific islands, which are also the high HBV endemic areas. In 
Asia, HBV kills more people through HCC and cirrhosis than Tuberculosis, malaria and 
HIV/AIDS.176;211 Most of the infections in these regions would have been transmitted 
vertically, peri-natally or in early childhood (especially in African children) rather than 
horizontally (via blood or sexually). There are environmental factors associated with 
HCC such as alcohol, tobacco and aflatoxin and these pose a greater risk in individuals 
infected with HBV. Aflatoxin is produced by Aspergillus sp and is found in foodstuffs 
like corn and peanuts that are harvested and allowed to mature in hot, humid 
conditions. The risk of HCC can go up 60-fold in those HBV patients who show urinary 
metabolites of aflatoxin.212;213 
Social, economic and political (including wars and conflicts) reasons, coupled with the 
convenience of air travel have made migration easier and more common. Western 
Europe (including the UK) and North America are popular destinations with most 
migrants coming from the intermediate and high HBV prevalence areas of Asia and 
Africa. In Europe there is also increased migration from Eastern Europe due to 
relaxation of border controls. Studies have shown that in low endemic countries areas 
the majority of infected individuals are immigrants who contracted the disease in 
their country of origin.214-216 This finding has led to the argument for the screening of 
the immigrant population for hepatitis B as they pose a potentially significant health 
burden.217;218 A Dutch study proposed that this might be a cost-effective strategy. The 
authors suggested that a single one-off screen could potentially reduce liver-related 
mortality by 10% by detecting and treating infected patients earlier.219  
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There have been a number of attempts both in the UK and in other countries to 
estimate the prevalence of CHB in the immigrant population. Most of these have 
come from blood transfusion audits and antenatal screening.220-222 Some studies have 
looked at particular ethnicities (Chinese, South Asian and Somalian) attending clinics, 
health fairs or places of worship.172;173;223;224 A report by the Hepatitis B Foundation 
UK has given various estimates of the prevalence of CHB in the UK within various 
ethnic groups based on country of birth.225 In this study most of these estimates are 
based on numbers from CDC, Department of Health and from other studies 
estimating the prevalence of HBV in the original country of origin (for example Custer 
et al101).  Using 0.25% prevalence in UK born individuals and estimating that 6500 
cases enter the UK every year, they calculated that in 2007 there were 326,388 cases 
of CHB, of which 193,888 came from foreign born immigrants.  
Since the REVEAL study was carried out examining the natural history of CHB in 
affected individuals in Taiwan, there have been very few longitudinal studies and 
none in immigrant populations.208 It is by no means clear that the natural history of 
HBV in immigrants will follow that seen in their country of origin. Recently, two fairly 
large, multi-centre, cross-sectional studies have looked at the viral and demographic 
characteristics of CHB in immigrant groups. An Italian study (SIMIT) looking at CHB 
infected patients compared 900 immigrants with 2800 native Italians from 74 centres. 
They found the proportions of HBV in the immigrant groups were younger, had a 
greater proportion of females, but had less advanced disease (cirrhosis and HCC) and 
were also less likely to be on treatment.226 A UK study (CUSHI-B) identified 698 
patients being followed up in 15 centres of which 80% were born abroad. Their 
results were different in that 20% of patients had cirrhosis and third were on 
treatment, although not always on the correct first line treatment and a number of 
these had antiviral resistance.227 The burden of HBV in the UK is unknown. In the UK 
between 2006-2010, 3406 liver transplants were performed, of which 16% were 
carried out on patients with viral hepatitis and 3% were due to HBV cirrhosis.228 Given 
their greater prevalence of HBV, it is more likely that immigrant groups rather than 
Caucasians will present with end-stage liver disease. 
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London is the largest city in the UK. The East London boroughs of Newham and Tower 
Hamlets are the most ethnically diverse regions. There are many individuals from 
areas of high and moderate HBV endemicity such as Sub-Saharan Africa, the Far East, 
the Indian Sub-Continent, and Eastern Europe. The impact of this diversity on the 
prevalence and outcome of viral hepatitis is unknown.  
 
5.2 Aims 
The aim of this study was to compare and contrast the severity of disease due to viral 
hepatitis in immigrant and British populations in the multi-ethnic boroughs of 




Every individual diagnosed with HBV who presented as an outpatient to the 
hepatology clinics or as an inpatient to Barts and the London (BLT) and Newham 
University Hospitals (NUH) was traced by accessing the out-patient letters and 
virology database. Over a 30 month period from 1 January 2006 to 30 June 2008, all 
the hospital and virology records for these patients were reviewed. BLT and NUH are 
the two local hospitals providing services to the boroughs of Tower Hamlets and 
Newham and there are no alternative health care providers. NHS care is provided free 
of charge to the patient and we therefore, assumed that patients with liver disease 
would attend their local hospital and that those attending would be representative of 
the infected population.  
For patients with uncomplicated disease the age at final attendance was recorded. 
For patients with complications, such as the development of decompensated cirrhosis 
or hepatocellular carcinoma (HCC), data was censored at the age at which these 
developed and for patients requiring therapy the age at which therapy was 
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introduced was recorded and the disease process was assumed to stabilise at that 
time. 
The diagnosis of cirrhosis was made on histological or radiological criteria. 
Decompensated disease referred to the presence of complications of cirrhosis such as 
variceal haemorrhage, ascites, spontaneous bacterial peritonitis, hepatic 
encephalopathy or HCC. Cases were confirmed by review of the hospital notes and 
clinic letters available on the hospital electronic patient record; reports from 
endoscopy and radiology; analysis of histology reports and laboratory values; and 
evaluation of multidisciplinary outcome letters.   
As with previous studies, risk factors for progression of disease were identified and 
assessed for statistical significance. These included host factors such as age, sex, 
ethnicity and ALT; HBV factors such as eAg status, HBV DNA, genotype and whether 
anti-HBV treatment had been given; and other factors such as alcohol, smoking and 
the presence of diabetes. Most of the risk factors utilise nominal values and so the 
data collected were assigned to different categories such as: current or ex-smoker 
versus non-smoker; alcohol drinker versus no alcohol (teetotal); diabetic versus non-
diabetic; cirrhotic versus non-cirrhotic. Parameters with continuous data such as age, 
HBV DNA viral load and ALT at diagnosis were also assigned to categories: under 40 
years (i.e. 16-39) versus over 40 years (i.e. ≥40); low DNA (≤ 4.0 log IU/L) versus high 
DNA (> 4.0 log IU/L); and low ALT (≤ 40 IU/L) versus high ALT (> 40 IU/L). 
 
5.3.2 Virological Analysis 
A single, central laboratory provides virological support to both hospitals and patients 
with HBV are routinely evaluated for HBsAg, HBeAg, anti-HBe antibody and delta virus 
superinfection. HBV DNA levels are measured using standard, commercial assays. In 




5.3.3 Statistical Analysis 
All the data collected was categorical and so non-parametric tests such as Chi square, 
Fisher's exact test and logistic regression were performed. Statistics were calculated 
using computer software (SPSS version 16, SPSS Inc., Chicago, IL, USA and GraphPad 
Prism version 5, GraphPad Software Inc., La Jolla, CA, USA). 
 
5.3.4 Ethical Approval 
Ethical approval for this study was granted by Oxfordshire REC A as an amendment to 
the study: Case finding and prevalence of chronic viral hepatitis in South Asians living 
in the UK – Number 06/Q1604/185. 
 
5.4 Results 
5.4.1 Chronic HBV in patients of all ethnicities 
5.4.1.1 Demographics 
The boroughs of Newham and Tower Hamlets are in East London. Both of these areas 
are densely populated. From the 2001 census, the total population of Newham is 
243,884 and that of Tower Hamlets is 196,100. Compared to the rest of London (and 
England), these two boroughs have a younger and more ethnically diverse 
population. The under 16 population in Newham is 63,841 and in Tower Hamlets it is 
44,890. In both boroughs, white British form a minority of the population but in 
Tower Hamlets, Bangladeshis form more than 50% of under sixteen year olds.  
Figure 5-1 and Figure 5-2 show the corresponding distribution of ethnicities in those 
aged over 16 years for the boroughs of Newham and Tower Hamlets, respectively. 
The population of Newham is 180,430 and Tower Hamlets is 151,210. In Newham the 
proportion of adult white British compared to children under 16 has decreased from 
38% to 24%, whilst in Tower Hamlets the adult white British population is almost 
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twice that of the younger population, 47% to 24%. In Newham no one ethnic minority 
predominates, with there being large Afro-Caribbean and Indian Subcontinent 
populations. The Black African and Caribbean population account for around a 
quarter of the adult population in Newham, but less than 10% in Tower Hamlets. The 
Bangladeshi population is the predominant ethnic minority in Tower Hamlets and 
comprises over a third of the total adult population.  
Immigrants from the Far East, especially China, form 2-3% of the population in the 
young and adult population of both boroughs. It was not possible to further 
characterise the Black African, Black Caribbean, Western European, Eastern European 
or “Other” populations as these groups are not separated in the output data from the 
national census. Data on country of birth for these populations is not collected but 
data on ‘born in the UK’ or “Not born in the UK’ is available. Data on country of birth 
was therefore inferred from the census data and we assumed that people born 
abroad who listed their ethnicity as “Non-English” were born in the country relating 
to their ethnic origin. For the Indian sub-continent more information is available and 
an in-depth analysis of these populations is provided in earlier chapters.  
In line with our ethical approval this study focussed on adults with HBV (defined as 
greater than 16 years old).  
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Figure 5-2 Ethnic distribution of individuals aged over 16 years in Tower Hamlets 
 
5.4.1.2 HBV in patients attending hospital 
Over the period, 1st January 2006 to 30 June 2008, 1243 patients with HBV were seen 
in the hepatology and gastroenterology clinics at the 2 local hospitals, NUH and BLT.   
Figure 5-3 and Figure 5-4 show the age and sex distribution of patients with both 
forms of HBV (acute and chronic) according to their ethnicity, including people born 
in the UK and abroad. For ease of comparison the arbitrary distinction between older 























































































Figure 5-3 Age distribution of acute and chronic HBV amongst patients of all 






















































































Figure 5-4 Sex distribution of acute and chronic HBV amongst patients of all 
ethnicities attending hepatology clinics 
 
Acute  
Forty-three patients were deemed to have had acute HBV, based upon the clinical 
symptoms of acute infection (see Chapter 4). The distribution of these patients is 
shown graphically in Figure 5-5. Twelve of the patients with acute HBV were British. 
Thirty-one patients had HBsAg seroconversion on follow up. Twelve patients were 
lost to follow up. Approximately two-thirds of these patients were non-British. As 
alluded to in chapter 4, the identification of patients with acute HBV relies upon 
presentation to hospital and the numbers identified may be a significant 
underestimate of the total disease burden. Although non-attendance may have been 
influenced by language, cultural or legal/immigration issues we assume that the 
proportions attending are representative of the proportions who are infected.   
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All but one of the 43 patients was tested for HCV, 11 were tested for HIV and 8 for 
HDV. 2 patients were co-infected with HIV and both were African. One Bangladeshi 
patient, already described in chapter 3, had HCV co-infection and there were no HDV 
co-infections. 
The prevalence of acute HBV in White British is 8.7 per 100,000 compared to 23.4 per 
100,000 for Non-British using the estimated population numbers from Table 5-1. This 
would suggest that White British patients are less likely to get acute HBV that is 





















Figure 5-6 shows the distribution of the 1200 patients with chronic HBV infection. Of 
these, there were 42 patients with co-infections: 16 HIV, 21 HCV and 5 HDV co-
infections. 8 of these patients had cirrhosis and 1 had decompensated cirrhosis, 
possibly due to HBV but conceivably also due to HCV or HDV.  None of these co-
infected patients were subsequently used in the analysis of chronic HBV disease in 
various ethnic groups. 
Results from chapter 4 showed that the bulk of chronic liver disease from HBV is 
carried in first generation immigrants, who bring the disease (and its complications) 
with them from their home country. We will apply this same assumption to other first 




 1243 patients with HBV 
seen in outpatient clinic 
43 acute HBV 
16 HIV co-infection 
1200 chronic HBV  
21 HCV co-infection 
5 HDV co-infection 
1161 mono-HBV 
chronic infection 
1026 mono-HBV 1st 
degree immigrants 





















Figure 5-6 Distribution of HBV patients in the study 
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Figure 5-7 shows the percentage proportions by ethnicity attending the hepatology 
outpatient and inpatient services of both hospitals. Also included are British patients 

























Figure 5-7 Proportion of British and first generation immigrant chronic HBsAg+ 
patients attending hospital 
 
Figure 5-8 shows that the majority of patients are young and the distribution is similar 
to Figures 4-13 to 4-16 in Chapter 4 which looked at infected first generation patients 
from Bangladesh and Pakistan. Unfortunately there are no available statistics for 






































Figure 5-8 First generation immigrant chronic HBsAg+ patients of all ethnicities 
attending hospital by sex and age 
 
Table 5-1 shows the distribution of CHB by regional ethnicity. The second column 
shows the estimated adult population (aged over sixteen) of first generation 
immigrants living in the two London boroughs from the ONS 2001 census. As Indians, 
Bangladeshis and Pakistanis are the predominant ethnic minorities there is more 
accurate data on their country of birth and ethnicity. With the other ethnicities, the 
numbers are based on country of birth and include all individuals of both sexes aged 
over 16.  
The calculated prevalence of CHB in the local population (column 4) is based on the 
number of patients from each ethnicity diagnosed with CHB who attend hospital 
divided by their estimated population in the boroughs of Newham and Tower 
Hamlets. The prevalence of diagnosed HBV in the non-immigrant British population is 
very low, along with individuals from Western Europe and the Other White ethnic 
groups and this may reflect the different routes of transmission of the disease in 
these countries (via sex and infected blood transmission) compared to individuals 
from developing countries (more vertical and perinatal transmission). The Indian 
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Subcontinent prevalence is slightly lower than that in Chapter 4 and that is because it 
takes into account Indians who have a large population but fewer patients with HBV.  
The regional HBV prevalence values are taken from Kowdley et al's study.229 These 
numbers are from pooled data which is also subject to wide variations within each 
country let alone within the region. Other caveats include who the samples are from: 
antenatal screening, prisoners, refugees, children and whether or not they include 
patients with acute hepatitis.230 The penultimate column estimates the total number 
of patients of each regional ethnicity who have CHB. The value is calculated by 
multiplying the prevalence in the original region with their respective local population 
numbers. The final column is the estimated amount of undiagnosed CHB in the local 
population because they have not been seen in hospital and formally diagnosed with 
HBV. The percentages refer to the proportion of CHB patients not attending hospital. 
Only a small fraction of the total CHB population of all ethnicities is being followed up 
in secondary care. This also appears to be the case for Caucasian British where less 
than 10% of the true CHB population is being seen. The Central Asian values showing 
apparent good pick up of HBV cases are probably more of a reflection of the low 
numbers in the area and the low numbers that have presented to clinic rather than us 













CHB in local 







numbers of CHB in 
local population 
Estimated numbers of 
HBV infections not 
attending hospital (%) 
African 28713 417 1.5 ± 0.1% 10.3 2957 2540 (86%) 
Caribbean 6330 16 0.3 ± 0.1% 4.5 285 269 (94%) 
Central Asian 1098 37 3.4 ± 1.1% 3.4 37 0 
Indian 
Subcontinent 
63553 249 0.4 ± 0.1% 3.6 2288 2039 (89%) 
Far Eastern 8611 183 2.1 ± 0.3% 9.0 775 592 (76%) 
Eastern 
European 
4455 87 2.0 ± 0.4% 3.3 147 60 (41%) 
Western 
European 
11377 8 0.1 ± 0.1% 0.6 68 60 (88%) 
British1 137407 47 0.0 ± 0.0% 0.5 687 640 (93%) 
Other White 6899 5 0.1 ± 0.1% 0.6 41 36 (88%) 
Unknown 1555 24 1.6 ± 0.6%    
 
Table 5-1 Estimated prevalence of people diagnosed with chronic HBV amongst first generation immigrants living in the boroughs of 
Newham and Tower Hamlets based on hospital attendance along with estimated numbers of undiagnosed HBV infections based on 
prevalence rates in original region and estimated numbers not attending hospital. 1British patients included here are Caucasian (as 
opposed to Black or Asian British) and are not immigrants.  
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5.4.1.3 Risk factors for cirrhosis 
Figure 5-9 shows the distribution of cirrhosis amongst the first generation immigrants 
of the various ethnic groups. Table 5-2 demonstrates that three ethnic groups in 
particular appear to have an increased risk of developing cirrhosis: African, Indian 
Subcontinent and Far Eastern. The Indian Subcontinent patients have already been 
discussed in detail in Chapter 4. As the prevalence of chronic HBV in Indian first 
generation immigrants is low, as determined by our community prevalence study172, 
no further analysis of this ethnic group will be performed. The proportion of 
Caribbean patients developing cirrhosis is high but due to the overall small numbers 
of this population further analysis of this group is unlikely to be meaningful. The 
converse is true for Eastern European patients; whilst there are only 3 out of 87 cases 
developing cirrhosis, this group forms about 8% of patients attending hospital. 
Possible risk factors for developing cirrhosis will be examined in the African, Far 
Eastern and Eastern European ethnic groups.  
The risk factors for developing cirrhosis in those ten British (non-immigrant) patients 























































































Figure 5-9 Distribution of cirrhosis amongst first generation immigrant patients with 
chronic HBV of all ethnicities attending hepatology clinics 
 
Ethnicity Group Non-Cirrhosis Cirrhosis Proportion with Cirrhosis (%) 
African 390/417 27/417 6.5 
Caribbean 14/16 2/16 12.5 
Central Asian 35/37 2/37 5.4 
Indian Subcontinent 218/249 31/249 12.4 
Far Eastern 162/183 21/183 11.5 
Eastern European 84/87 3/87 3.4 
Western European 8/8 0/8 0 
British1 37/47 10/47 21.3 
Other White 5/5 0/5 0 
Unknown 22/24 2/24 8.3 
Table 5-2 Distribution of cirrhosis amongst first generation immigrant patients with 
chronic HBV of all ethnicities attending hepatology clinics. 1British patients included 
here are not immigrants.  
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This section shows the 2x2 contingency tables, p values, odds ratio and 95% 
confidence intervals of various risk factors associated with cirrhosis in the first 
generation immigrant HBV patients of all ethnicities seen in the hepatology clinics. 
Risk factors such as age (Figure 5-10 and Table 5-3); sex (Figure 5-11 and Table 5-4); 
ALT at diagnosis (Figure 5-12 and Table 5-5); being on anti-HBV treatment at the 
present time (Figure 5-13 and Table 5-6); ever being on anti-HBV treatment (Figure 
5-14 and Table 5-7); smoking (Figure 5-15 and Table 5-8); and diabetes (Figure 5-17 
and Table 5-10) were significant using univariate analysis. Alcohol (Figure 5-16 and 
Table 5-9) was not statistically significant as a risk factor for cirrhosis, but it is 
represented graphically for comparison with the other risk factors. Other 
independent risk factors such as e-antigen status at diagnosis and HBV DNA viral load 
at diagnosis were not statistically significant. Seven patients with liver cancer did not 










































<40 612/1026 19/1026 
<0.0001 6.82 4.03 to 11.53 
≥40 326/1026 69/1026 
 
Table 5-3 Univariate statistics for age vs cirrhosis in first generation immigrant HBV 








































Female 512/1026 14/1026 
<0.0001 6.35 3.54 to 11.41 
Male 426/1026 74/1026 
 
Table 5-4 Univariate statistics for sex vs cirrhosis in first generation immigrant HBV 

























Figure 5-12 ALT vs cirrhosis in first generation immigrant HBV patients of all 
ethnicities 
 






















Table 5-5 Univariate statistics for ALT vs cirrhosis in first generation immigrant HBV 
patients of all ethnicities 
 
As discussed in chapter 4 with Bangladeshi and Pakistani cirrhotic patients, Table 5-6 
and Table 5-7 show a similar phenomenon in that treatments both now and in the 
past are significantly associated with cirrhosis. As previously discussed this is most 
probably related to an increased tendency to treat patients with cirrhosis rather than 

























Figure 5-13 Treatment now vs cirrhosis in first generation immigrant HBV patients of 
all ethnicities 
 

























Table 5-6 Univariate statistics for treatment now vs cirrhosis in first generation 



























Figure 5-14 Treatment ever vs cirrhosis in first generation immigrant HBV patients of 
all ethnicities 
 

























Table 5-7 Univariate statistics for treatment ever vs cirrhosis in first generation 















































<0.001 2.76 1.68 to 4.55 
Smoker 125/993 26/993 
 
Table 5-8 Univariate statistics for smoking vs cirrhosis in first generation immigrant 















































0.09 1.78 0.96 to 3.28 
Alcohol 88/993 14/993 
 
Table 5-9 Univariate statistics for alcohol vs cirrhosis in first generation immigrant 













































<0.0001 3.63 2.04 to 6.48 
Diabetic 62/1026 18/1026 
 
Table 5-10 Univariate statistics for diabetes vs cirrhosis in first generation immigrant 
HBV patients of all ethnicities 
 
In addition, multivariate analysis using logistic regression with relevant factors was 
performed to see if a model for developing cirrhosis could be developed. As age 
group, sex, ALT group, smoking and diabetes, were significant from univariate 
analyses, they were used for multivariate analysis. As mentioned before, treatment, 
either currently or in the past, was not utilised because of its uncertain clinical 
significance. Because of the binary nature of the cirrhosis outcome, binary logistic 




Table 5-11 shows that age over 40, being male and having an elevated ALT at 
diagnosis are significant predictors for developing cirrhosis in chronic HBV in first 
generation immigrants even when the other significant univariate variables are taken 
into account. With age >40, male sex and elevated ALT, the lower limits of the 
confidence intervals are greater than 1 which gives us confidence that the direction of 






Interval for EXP(B) 
Lower Upper 
Age group <.0001 5.27 2.97 9.34 
Sex <.0001 3.53 1.82 6.84 
ALT <.05 1.68 1.01 2.82 
Smoking .45 1.25 .70 2.23 
Diabetes .99 .99 .49 2.00 
 
Table 5-11 Logistic regression showing significant variables for predicting cirrhosis 
with odds ratio and  confidence intervals in first generation immigrant HBV patients 
of all ethnicities.  
 
5.4.1.4 Risk factors for decompensated disease 
The decision to be referred for specialist follow up depends on a number of factors: 
patient's knowledge and understanding of the condition and its consequences; 
financial constraints; cultural and social beliefs; and ease of access to healthcare. 
Most patients with compensated disease, including cirrhosis without complications, 
are asymptomatic and may not seek medical help. Even though healthcare is free to 
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patients there may be referral bias by primary care physicians who may not 
appreciate the severity or investigate patients with asymptomatic HBV infection. As a 
result there is probably under-representation of HBV in outpatient clinics. However, 
once patients develop decompensated disease such as variceal haemorrhage, ascites, 
or HCC, they are likely to be physically unwell and be more amenable to seek medical 
help from the nearest hospital. These numbers are probably a better reflection of 
decompensated disease in our cohort.   
Figure 5-18 shows the distribution of decompensated disease amongst the first 
generation immigrants of the various ethnic groups. Table 5-12 demonstrates that 
the same 3 ethnic groups that have increased risk of developing cirrhosis, are also the 
ones associated with an increased risk of developing decompensated disease: African, 
Indian Subcontinent and Far Eastern. The Indian Subcontinent patients have already 
been discussed in detail in Chapter 4 and so no further analysis of this ethnic group 
will be performed. There is only one Eastern European patient who developed 
decompensated disease and so no further analysis of this ethnic group was 
undertaken. Possible risk factors for developing decompensated disease will be 
examined in the African and Far Eastern ethnic groups.  
The risk factors for developing decompensated disease in those 6 British (non-

























































































Figure 5-18 Distribution of decompensated disease (decompensated cirrhosis or HCC) 










African 408/417 9/417 2.2 
Caribbean 15/16 1/16 6.3 
Central Asian 37/37 0/37 0 
Indian Subcontinent 235/249 14/249 5.6 
Far Eastern 174/183 9/183 4.9 
Eastern European 86/87 1/87 1.1 
Western European 8/8 0/8 0 
British1 41/47 6/47 12.5 
Other White 5/5 0/5 0 
Unknown 24/24 0/24 0 
Table 5-12 Distribution of decompensated disease amongst patients with chronic HBV 
of all ethnicities attending hepatology clinics. 1British patients included here are 
Caucasian (as opposed to Black or Asian British) and are not immigrants 
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Below are the 2x2 contingency tables, p values, odds ratio and 95% confidence 
intervals of various risk factors associated with decompensated disease in the first 
generation immigrant HBV patients of all ethnicities. Risk factors such as age (Figure 
5-19 and Table 5-13); sex (Figure 5-20 and Table 5-14); ALT at diagnosis (Figure 5-21 
and Table 5-15); being on anti-HBV treatment at the present time (Figure 5-22 and 
Table 5-16); ever being on anti-HBV treatment (Figure 5-23 and Table 5-17); smoking 
(Figure 5-24 and Table 5-18); alcohol (Figure 5-25 and Table 5-19); and diabetes 
(Figure 5-26 and Table 5-20) were significant using univariate analysis. Other 
independent risk factors such as e-antigen status at diagnosis and HBV DNA viral load 
at diagnosis were not statistically significant. 



















Figure 5-19 Age vs decompensated disease in first generation immigrant HBV patients 

















Age <40 651/1026 2/1026 
< 0.001 30.55 7.27 to 128.3 
Age ≥40 341/1026 32/1026 
 
Table 5-13 Univariate statistics for age vs decompensated disease in first generation 






















Figure 5-20 Sex vs decompensated disease in first generation immigrant HBV patients 


















Female 470/1026 4/1026 
< 0.0001 6.75 2.36 to 19.32 
Male 522/1026 30/1026 
 
Table 5-14 Univariate statistics for Sex vs decompensated disease in first generation 























Figure 5-21 ALT vs decompensated disease in first generation immigrant HBV patients 



























Table 5-15 Univariate statistics for ALT vs decompensated disease in first generation 
























Figure 5-22 Treatment now vs decompensated disease in first generation immigrant 





















Not on Rx 
now 
876/1026 17/1026 






Table 5-16 Univariate statistics for treatment now vs decompensated disease in first 

























Figure 5-23 Treatment ever vs decompensated disease in first generation immigrant 
























< 0.001 6.69 
3.33 to 




Table 5-17 Univariate statistics for treatment ever vs decompensated disease in first 

























Figure 5-24 Smoking vs decompensated disease in first generation immigrant HBV 





















< 0.001 9.03 4.45 to 18.32 
Smoker 131/993 20/993 
 
Table 5-18 Univariate statistics for smoking vs decompensated disease in first 

























Figure 5-25 Alcohol vs decompensated disease in first generation immigrant HBV 





















< 0.001 3.93 1.82 to 8.47 
Alcohol 92/993 10/993 
 
Table 5-19 Univariate statistics for alcohol vs decompensated disease in first 

























Figure 5-26 Diabetes vs decompensated disease in first generation immigrant HBV 





















< 0.001 8.55 
4.10 to 
17.82 
Diabetic 67/1026 13/1026 
 
Table 5-20 Univariate statistics for diabetes vs decompensated disease in first 
generation immigrant HBV patients of all ethnicities 
 
As age group, sex, ALT group, smoking, alcohol, and diabetes were significant from 
univariate analyses, they were used for multivariate analysis. As mentioned before, 
treatment, either currently or in the past, was not utilised because of its uncertain 
clinical significance. A binary logistic regression using the forced enter method was 




Unlike with the multivariate analysis of cirrhosis, in this case age >40, smoking and 
the presence of diabetes were significant predictors of decompensated liver disease 
even when the other factors were controlled for. Age group was the most statistically 
significant, with the highest odds ratio but also had a very wide 95% confidence 
interval. This suggests that the odds ratio is not a very accurate estimate of the true 





95.0% CI for EXP(B) 
Lower Upper 
Age group <.0001 18.69 4.29 81.32 
Sex .13 2.44 .77 7.77 
ALT .11 1.90 .87 4.15 
Smoking <.001 4.00 1.73 9.24 
Diabetes <.02 2.85 1.24 6.54 
Alcohol .23 1.79 .69 4.67 
 
Table 5-21 Logistic regression showing significant variables for predicting 
decompensated disease with odds ratio and confidence intervals in first generation 
immigrant HBV patients of all ethnicities. 
 
5.4.2 African chronic HBV patients 
5.4.2.1 Demographics 
Africa is a vast continent made up of a number of individual countries. 417 patients 
originated from at least 24 countries. To delineate as clearly as possible where in 
Africa, these patients came from, the continent was arbitrarily divided into 5 regions 
which are shown in Figure 5-27. Central Africa referred to countries such as 
Cameroon, Chad, Democratic Republic of Congo and Nigeria. Eastern Africa referred 
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to Ethiopia, Kenya, Somalia and Uganda. Northern Africa referred to Egypt, Morocco 
and Syria. Southern Africa referred to Angola, Namibia, South Africa and Zimbabwe. 
Western Africa referred to Gambia, Ghana, Liberia and Sierra Leone. In 126 cases, the 
exact African country of origin could not be identified from the notes. The majority of 




















Figure 5-27 Distribution of first generation African immigrant patients with chronic 
HBV attending clinics 
 
5.4.2.2 Risk factors for cirrhosis 
For the sake of comparison with first generation immigrant Bangladeshis and 
Pakistanis studied in Chapter 4, the same risk factors for cirrhosis were also analysed 




This section shows the 2x2 contingency tables, p values, odds ratio and 95% 
confidence intervals of the statistically significant various risk factors associated with 
cirrhosis in the first generation immigrant African patients seen in the hepatology 
clinics. Risk factors such as age (Figure 5-28 and Table 5-22); sex (Figure 5-29 and 
Table 5-23); and ALT at diagnosis (Figure 5-30 and Table 5-24) were significant using 
univariate analysis. Being on anti-HBV treatment at the present time and ever being 
on anti-HBV treatment were also statistically significant but as mentioned before the 
clinical significance of this is uncertain and so they are not displayed graphically. 
Smoking, diabetes and alcohol were not significant risk factors for cirrhosis, along 
with e-antigen status at diagnosis and HBV DNA viral load at diagnosis.  
Only 1 patient with liver cancer did not have underlying cirrhosis and for the purposes 
of this analysis he was not included in this section.  
 








































<40 282/417 6/417 
<.001 9.14 3.59 to 23.26 
>40 108/417 21/417 
 










































Female 238/417 5/417 
<.001 6.89 2.55 to 18.59 
Male 152/417 22/417 
 























Figure 5-30 ALT vs cirrhosis in first generation immigrant African patients 
 














Low (≤40) 283/386 11/386 





Table 5-24 Univariate statistics for ALT vs cirrhosis in first generation immigrant 
African patients 
 
As age group, sex, and ALT group, were significant from univariate analyses, they 
were used for multivariate analysis. As mentioned before, treatment, either currently 
or in the past, was not utilised because of its uncertain clinical significance. Binary 




Table 5-25 shows that being both age over 40 and having elevated ALT are significant 
predictors for developing cirrhosis in chronic HBV in first generation immigrant 









<.001 5.53 2.06 14.87 
Sex .111 .41 .14 1.23 
ALT <.011 3.32 1.32 8.35 
 
Table 5-25 Logistic regression showing significant variables for predicting cirrhosis 
with odds ratio and confidence intervals in African patients.  
 
5.4.2.3  Risk factors for decompensated disease 
Below are the 2x2 contingency tables, p values, odds ratio and 95% confidence 
intervals of various significant risk factors associated with decompensated disease in 
the first generation immigrant African patients. Risk factors such as age (Figure 5-31 
and Table 5-26); sex (Figure 5-32 and Table 5-27); ALT at diagnosis (Figure 5-33 and 
Table 5-28); smoking (Figure 5-34 and Table 5-29); and alcohol (Figure 5-35 and Table 
5-30) were significant using univariate analysis. Being on anti-HBV treatment at the 
present time and in the past were also significant independent factors for 
decompensated disease, but for the aforementioned reasons these were not 
displayed graphically. Other independent risk factors such as diabetes, e-antigen 










































<40 287/417 1/417 
<.001 18.98 2.35 to 153.4 
≥40 121/417 8/417 
 
Table 5-26 Univariate statistics for age vs decompensated disease in first generation  











































Female 242/417 1/417 
<0.01 11.66 1.44 to 94.17 
Male 166/417 8/417 
 
Table 5-27 Univariate statistics for sex vs decompensated disease in first generation 


















































Table 5-28 Univariate statistics for ALT vs decompensated disease in 1st degree 













































0.02 6.82 1.61 to 28.77 
Smoker 27/404 3/404 
 
Table 5-29 Univariate statistics for smoking vs decompensated disease in first 














































0.02 7.40 1.75 to 31.37 
Alcohol 25/404 3/404 
 
Table 5-30 Univariate statistics for alcohol vs decompensated disease in first 
generation immigrant African patients 
 
The significant univariate predictors of decompensated disease: age group, sex, ALT 
group, smoking, and alcohol, were analysed using multivariate analysis. Again, binary 
logistic regression using the forced enter method was adopted (see Table 5-31). Only 
age >40 was statistically significant but with a very wide 95% confidence interval 







95% Confidence Interval 
for EXP(B) 
Lower Upper 
Age group <.03 12.50 1.47 106.37 
Sex .42 2.55 .26 25.12 
ALT .10 3.65 .80 16.65 
Smoking .46 1.93 .34 11.10 
Alcohol .18 3.30 .57 19.15 
 
Table 5-31 Logistic regression showing significant variables for predicting 
decompensated disease with odds ratio and confidence intervals in African patients. 
 
5.4.3 Far Eastern chronic HBV patients 
5.4.3.1 Demographics  
For the purposes of this study, the Far East was deemed to include all Asian countries 
North and East of the Indian Subcontinent (see Figure 5-36). Chinese patients made 
up half of this cohort of chronic HBV patients who attended outpatients. Along with 















Figure 5-36 Distribution of first generation Far Eastern immigrant patients with 
chronic HBV attending clinics 
 
5.4.3.2 Risk factors for cirrhosis  
This section shows the 2x2 contingency tables, p values, odds ratio and 95% 
confidence intervals of the various significant risk factors associated with cirrhosis in 
the first generation immigrant Far Eastern chronic HBV patients. Unlike the African 
patients the only significant risk factors found using univariate analysis were age 
(Figure 5-37 and Table 5-32) and sex (Figure 5-38 and Table 5-33). Being on anti-HBV 
treatment at the present time and in the past were also statistically significant but as 
mentioned before the clinical significance of this is unclear. Smoking, alcohol, 
diabetes, ALT group, e-antigen status and HBV DNA viral load at diagnosis were not 
statistically significant  
Four patients with liver cancer did not have underlying cirrhosis and for the purposes 








































<40 99/183 5/183 
<0.01 5.03 1.75 to 14.41 
≥40 63/183 16/183 
 








































Female 96/183 6/183 
<0.001 3.64 1.34 to 9.86 
Male 66/183 15/183 
 
Table 5-33 Univariate statistics for sex vs cirrhosis in first generation immigrant Far 
Eastern patients 
 
As before, multivariate analysis using logistic regression with certain factors was 
performed to see if a model for developing cirrhosis could be developed. Unlike 
African patients, only age group and sex were significant from univariate analyses, 




Table 5-34  shows that both being male and age over 40 are significant predictors for 
developing cirrhosis in chronic HBV in the 1st degree immigrant Far Eastern patients. 
The lower limits of the confidence intervals are greater than 1 which gives us 











<.0001 5.26 3.06 9.04 
Sex <.0001 4.74 2.56 8.80 
 
Table 5-34 Logistic regression showing significant variables for predicting cirrhosis 
with odds ratio and confidence intervals in Far Eastern patients.  
 
5.4.3.3  Risk factors for decompensated disease 
This section shows the 2x2 contingency tables, p values, odds ratio and 95% 
confidence intervals of the various risk factors significantly associated with 
decompensated disease in the first generation immigrant Far Eastern chronic HBV 
patients. Unlike the analysis of cirrhosis, sex was not a significant risk factor for 
decompensated disease, but age (Figure 5-39 and Table 5-35), smoking (Figure 5-40 
and Table 5-36) and diabetes (Figure 5-41 and Table 5-37) were. In addition to these, 
being on anti-HBV treatment, either at the present time or at any time in the past 
were also significant risk factors. ALT, alcohol, e-antigen status and HBV DNA viral 
load were not statistically significant.  
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<40 103/183 1/183 
<0.01 11.61 1.42 to 94.89 
≥40 71/183 8/183 
 
Table 5-35 Univariate statistics for age vs decompensated disease in first generation 













































<0.001 10.89 2.57 to 46.22 
Smoker 27/183 6/183 
 
Table 5-36 Univariate statistics for smoking vs decompensated disease in first 












































0.04 9.66 1.59 to 58.78 
Diabetic 5/183 2/183 
 
Table 5-37 Univariate statistics for diabetes vs decompensated disease in first 
generation immigrant Far Eastern patients 
 
Unlike Africans and Indian Subcontinent patients, where male sex and alcohol were 
significant risk factors, now only age group, smoking and diabetes were found to be 
significant and were used for multivariate analysis. A forced enter binary logistic 
regression was performed.  
Table 5-38 shows that all 3 factors were statistically significant predictors for 
developing decompensated disease. However in each of the 3 cases (age >40, 
smoking and the presence of diabetes), there were large 95% confidence intervals 









Table 5-38 Logistic regression showing significant variables for predicting 
decompensated disease with odds ratio and confidence intervals in Far Eastern 
patients 
 
5.4.4 Eastern European chronic HBV patients 
5.4.4.1 Demographics  
Although not as large as Africa, Europe and especially Eastern Europe has recently 
undergone political upheaval that has resulted in the formation of a number of new 
independent states. For the purposes of clarity in describing where these patients 
originated from, patients from the former Soviet states (Azerbaijan, Moldova, Ukraine 
and Uzbekistan) and the former Yugoslav states (Bosnia, Kosovo and Macedonia) 
were grouped together (see Figure 5-42). In 16 of the 87 cases, the exact country of 










<.0001 19.61 4.54 84.68 
Smoking <.0001 6.49 3.08 13.68 
















Figure 5-42 Distribution of first generation Eastern European immigrant patients with 
chronic HBV attending clinics 
 
5.4.4.2 Risk factors for cirrhosis 
The 2x2 contingency tables, p values, odds ratio and 95% confidence intervals of the 
various risk factors significantly associated with cirrhosis in first generation immigrant 
Eastern European chronic HBV patients are shown below. The only significant risk 
factors are age (Figure 5-43 and Table 5-39) and smoking (Figure 5-44 and Table 
5-40). Being on anti-HBV treatment in the past was also statistically significant but not 
currently being on treatment. Other independent factors like sex, ALT, alcohol, 
diabetes, e-antigen status and HBV DNA viral load at diagnosis were not statistically 
significant. Only 1 patient developed liver cancer and that was on a background of 
underlying cirrhosis; he was included in the analysis of cirrhosis here.  
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<40 74/87 0/87 
<0.01 49.67 2.39 to 1032 
≥40 10/87 3/87 
 
Table 5-39 Univariate statistics for age vs cirrhosis in first generation immigrant 











































0.03 16.83 0.84 to 339.0 
Smoker 23/82 3/82 
 
Table 5-40 Univariate statistics for smoking vs cirrhosis in first generation immigrant 
Eastern European patients 
 
The 2 risk factors associated with cirrhosis, age and smoking, were analysed further 
using logistic regression to see if a model for developing cirrhosis could be predicted.  
A force enter binary logistic regression was performed but it showed that neither 




5.4.4.3  Risk factors for decompensated disease 
In the first generation immigrant Eastern European chronic HBV patient group, only 
one patient had decompensated disease and that was due to liver carcinoma. 
Therefore it is unlikely to be very meaningful to display contingency table of these risk 
factors with this condition. Through univariate analysis, only treatment ever and 
diabetes were statistically significant. Since only 2 patients were diabetic and one of 




5.4.5 British chronic HBV patients 
5.4.5.1 Risk factors for cirrhosis 
The only significant risk factor for developing cirrhosis in White-British chronic HBV 
patients was smoking (see Figure 5-45 and Table 5-41). Treatment at present was also 
statistically significant but this has already been discussed previously. The other risk 
factors of age, sex, ALT at diagnosis, alcohol, diabetes, eAg status and HBV DNA viral 
load at diagnosis were not significant. Because of the lack of other significant risk 









































0.033 5.30 1.15 to 24.43 
Smoker 11/46 7/46 
Table 5-41 Univariate statistics for smoking vs cirrhosis in British patients 
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5.4.5.2 Risk factors for decompensated disease 
As with the risk factors for cirrhosis in British patients, the same risk factor, smoking, 
was associated with the development of decompensated disease (see Figure 5-46 and 
Table 5-42). Treatment ever was also associated with the development of 
decompensated disease. The other risk factors of age, sex, ALT at diagnosis, alcohol, 
diabetes, e antigen status at diagnosis, and HBV DNA viral load at diagnosis were not 










































0.002 28.41 1.49 to 541.90 
Smoker 12/46 6/46 
 





5.5.1 Prevalence of HBV in all ethnic groups 
This study has given estimates of the prevalence of diagnosed HBV being seen in the 
two local, secondary care hospitals. Table 5-1 shows the disparity between the 
numbers of patients being reviewed in hospital compared to the potential numbers 
who are in the local community unaware that they are carrying HBV. Of the 1209 CHB 
patients being followed up in hospital, we estimate there are another 6220 (84%) 
who are undiagnosed in the community and not having outpatient care. A proportion 
of these will have cirrhosis, because stable disease doesn't cause any specific 
symptoms. However, very few of the undiagnosed HBV individuals are likely to have 
decompensated liver disease because this would manifest itself as ascites, variceal 
bleeding, encephalopathy, jaundice or HCC and would likely cause most patients to 
seek medical attention.  
Determining HBV prevalence from clinic attendance is bound to under-estimate the 
true figure because the values are dependent on clinic and local population numbers. 
In the Central Asian group, 37 patients from a relatively small population of 1098 gave 
a prevalence of 3.4% which is much higher than the high endemic regions of the Far 
East and Africa, which we calculated as having 2.1% and 1.5% respectively. Whilst 
3.4% may be a relative accurate calculated prevalence for this region, the calculated 
values for the Far Eastern and African patients are very low when compared to the 
derived infection prevalence back home. Clinic patients are a self-selecting group in 
that they choose to attend their hospital appointment for investigation and 
management of their condition. GP referrals would give a more accurate result but it 
still is dependent on the patient seeing their doctor to have the necessary blood tests. 
Pregnant women and blood donors have their blood screened automatically for HBV 
but only represent part of the population and are still "volunteering" to have the 
blood test. Only by screening everybody could you get the true prevalence of HBV. 
With time the prevalence of CHB in other countries will decrease because of the 
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universal perinatal HBV vaccination programme, which should reduce the pool of HBV 
available to infect others.   
At the time of this study I did not record the patient's source of the referral or 
whether they already knew they had underlying HBV at the time of their first clinic 
appointment. In a number of cases this information was not recorded and so it is not 
possible to comment on why they presented to hospital services when they did. 
However from clinical experience referrals typically come from 3 sources: GPs, 
antenatal service and genito-urinary clinics. Most patients who get referred from GPs 
are asymptomatic and HBV is diagnosed either because another family member or 
partner has been diagnosed with HBV, or because the patient has some derangement 
of the liver function tests and the GP has followed this up by performing hepatitis 
serology testing. All pregnant women are automatically tested for HBV, HIV and 
rubella unless they specifically object to having these tests done. A proportion of 
these may be having their 2nd or more child and so HBV would (hopefully) have been 
detected in their 1st pregnancy. Only patients with HBV mono-infection would have 
been referred from genito-urinary clinics as they tend to manage the HIV-HBV co-
infected patients. A considerable number of patients are referred but did not attend 
hospital. In this study we only included those patients who attended as then we could 
determine their socio-demographic and disease status. 
There is speculation as to whether the health of migrants is the same as the 
population that they have emigrated from. It may well be that migrants are 
"healthier" than non-migrants and so the prevalence of HBV might be less in this 
population than back home. The healthy migrant effect and our population based 
study confirm that this applied to people from the Indian sub-continent and is likely 
to apply to the ethnic groups described here.172 However, individuals from Eastern 
Europe typically have a lower standard of living, including worse healthcare and job 
prospects, back in their home country compared to the UK. In this case, economic 
reasons may mean that poorer, and possibly less healthy, people migrate and bring 
their underlying conditions with them. Because their countries are part of the 
European Union, they are entitled to free NHS healthcare and so maybe keener to 
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engage with health services than other ethnicities. This could help explain why more 
of a proportion of this group is seen in the clinics. Cultural beliefs such as stigma and 
understanding of what the infection is and its sequelae can be huge obstacles to 
being screened, getting referred, having treatment and vaccinating the rest of the 
family.209;231  
Eighty-eight out of 1209 patients had cirrhosis confirmed by histology or radiology. 
The ethnic groups with the highest numbers of cirrhotics were patients from Africa 
(27), Indian Subcontinent (31), and the Far East (21). Of note, around a quarter of 
Caucasian British patients being followed up in the clinic had cirrhosis (10/47). The 
Caribbean and British groups had relatively high proportions of cirrhosis although 
small total numbers of patients attending the clinics. Given the size and population of 
the respective countries compared to densely populated regions such as Africa and 
Asia, this would suggest that these patients tend to seek medical help sooner rather 
than being associated with worse disease. Univariate analyses looking at immigrants 
of all ethnicities showed that age, sex, ALT, smoking and diabetes were all 
significantly associated with the development of cirrhosis. When multivariate 
analyses were employed age over 40, male sex and raised ALT appeared to predict 
cirrhosis even when controlling for the other variables. 
Thirty-four out of 1209 patients had decompensated disease as shown by cirrhosis 
with complications or HCC; the latter need not necessarily occur in cirrhotic patients. 
Again the ethnic groups with the highest numbers of decompensated disease came 
from Africa (9), the Indian Subcontinent (14) and the Far East (9). Six British patients 
had decompensated disease. As in chapter 4, the statistically significant variables for 
decompensated disease were the same: age, sex, ALT, smoking, alcohol and diabetes. 
Using multivariate statistics in the form of binary logistic regression age over 40, 
smoking and presence of diabetes were predictors of decompensated disease. 
The presence of diabetes was significantly associated with cirrhosis and 
decompensated disease on univariate analysis. HBV is not a commonly recognised 
risk factor for the development of diabetes unlike the association between hepatitis C 
 238 
 
and diabetes. A recent meta-analysis has shown that diabetes that develops after 
HBV has been diagnosed is linked with cirrhosis and decompensated disease.232 
Unfortunately our study could not determine the temporality of the diabetes to the 
infection. 
 
5.5.2 Cirrhosis and decompensated disease in African immigrants 
There were 417 first generation African immigrants seen in hospital. Although 24 
countries were represented, individuals from Ghana, Nigeria and Somalia made up 
over half of this population.  Collectively they have the highest proportion of hepatitis 
B patients seen in the outpatient clinics. Most of the countries represented have high 
endemicity rates greater than 8% but our study suggested that the prevalence of HBV 
was 1.5%. As has been proposed before, it may be that the more affluent persons are 
the type to leave the original country and that these people may be relatively 
healthier which is why the prevalence is less than back in their home country.   
 
Of this cohort 6.5% had cirrhosis. The risk factors for cirrhosis in this group were age 
over 40, male sex and high ALT from univariate statistics. Using multivariate statistics, 
age and ALT were significant but with low odds ratios and wide 95% confidence 
intervals.  
Decompensated disease occurred in 2.2%.  There are different risk factors for 
developing decompensated disease: male sex, age >40, high ALT, smoking, and 
alcohol. Only age >40 was statistically significant when the other variables were 
controlled for.  
 
5.5.3 Cirrhosis and decompensated disease in Far Eastern immigrants 
There were 183 first generation Far Eastern immigrants seen in the clinics. As with 
individuals from Africa, although a number of countries are included in this region, 
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certain countries are more represented than others in the outpatient clinics. China 
makes up more than half of the patients, Vietnam about a quarter and the Philippines 
about 10%. Countries such as Indonesia and Japan have larger populations than 
Vietnam and the Philippines but have only about 1% of the outpatient attendance. In 
this way outpatient attendance is more of a reflection of net immigration to the UK 
than population back in the home country.  As with other ethnicities, the estimated 
prevalence is dependent on those patients who have been identified and attending 
clinic. As mentioned before, language difficulties and cultural differences may mean 
that individuals from an ethnic Chinese background may prefer to attend another 
centre further afield if they can bypass the usual referral routes and can speak to 
someone in their language rather than via an interpreter224. 
In this group 11.5% had cirrhosis. The only risk factors for cirrhosis were age and sex, 
which were also statistically significant at multivariate level. Although the odds ratios 
are fairly low, the corresponding 95% confidence intervals are not too wide.  
 
Decompensated disease was found in 4.9% of this cohort. Unlike the risk factors for 
cirrhosis, sex was not a significant risk factor but, smoking and diabetes were along 
with age. All of these were also statistically significant at multivariate level. 
 
5.5.4 Cirrhosis and decompensated disease in Eastern European immigrants 
Approximately 8.5% (87) of the total number of patients seen were first generation 
Eastern European immigrants. Albanians, Romanians and Poles make up the 
predominant ethnicities identified. The smaller numbers than expected to come to 
the clinic are the same as for the other ethnic groups and due to language difficulties 
predominantly. 
Cirrhosis was seen in 3.4% of this cohort. Only age and smoking were significant risk 




Only 1 patient developed decompensated disease, in this case HCC, and so univariate 
statistics were not used as they would be unlikely to be statistically or clinically 
significant. 
 
5.5.5 Cirrhosis and decompensated disease in British patients 
Forty-seven Caucasian, British patients with chronic, mono HBV infection were being 
followed up in the hepatology clinic. Unlike the other ethnic groups, the UK is 
regarded as a country of low prevalence. It may be that infection in this group is more 
likely to be due to horizontal transmission through sex or via blood (illicit drug use, 
operations and needlestick injuries) and less likely through maternal or childhood 
transmission. 
Ten (21.2%) patients had cirrhosis and 6 (12.7%) had decompensated disease. In both 
cohorts smoking was the only significant risk factor. Unlike other cohorts neither age 
nor sex had any bearing on the development of advanced disease (cirrhosis or 
decompensation). If the disease was transmitted horizontally rather than vertically 
then it may be that there has been less time for the disease to progress compared to 
individuals from more endemic countries. Significantly more patients with cirrhosis 
and decompensated disease are on treatment and this is most likely an attempt to 
prevent further sequelae occurring. 
 
5.5.6 Bias and confounding 
Determining the prevalence of HBV in these ethnic groups was reliant on primary care 
referring infected patients to the hospital. Case finding is very difficult in patients who 
are asymptomatic206. Patient reluctance to be seen or primary care perceptions that 
this is a disease that is either benign or incurable may have had an impact on referral 
patterns, and ultimately numbers being seen in clinic. Other sources of referral 
include maternity and attendees of genito-urinary clinics, where all mono HBV 
infections should be referred for specialist follow up. These latter patients can bypass 
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their general practitioners and can self-refer themselves; they may not necessarily be 
seen in the hepatology clinic unless the patient and consulting physician agree to do 
so.  
Figure 5-6 shows that 135 patients, including all the White British patients, were born 
in the UK. As mentioned in Chapter 4, routine screening of mothers for HBV was not 
fully implemented until April 2000207 and so it cannot be said with total certainty 
whether the second generation immigrants and British patients were born with the 
disease or got it transmitted to them horizontally. Also it is not possible to say 
whether they acquired their disease because of vaccine failure unless they were 
specifically vaccinated as a baby. 
Figure 5-8 shows a preponderance of young females of all ethnicities (age 16-39) 
being seen in the clinic. This is probably a reflection of them being detected through 
antenatal screening which is automatically done by 20 weeks gestation. All women 
who screen positive for HBV are referred to hepatology services. It makes sense that 
if more women are screened, then there will be a higher detection and referral rate, 
and by inference, increased clinic attendance rate. 
The accuracy of all retrospective studies is dependent on the results of patient notes 
and records. This will have a subsequent impact on the significance of proposed risk 
factors. ALT, HBV DNA and e-antigen status were all taken from the earliest recorded 
visit that the patient made to the hospital but the recorded results may have been 
taken from a much later visit because the test was not requested at first visitation. 
Similarly, the effects of the amount and duration of smoking and alcohol or the 
severity of diabetes were not possible to elucidate from some of the notes. 
Again the role of anti-viral medications on disease progression is hard to estimate. 
Treatment could have been initiated to halt disease that was already progressing or 




5.5.7 Comparison with other studies 
Along with other studies, we have used clinic attendance as a surrogate marker for 
determining the prevalence of the disease. The problem with this is that it relies up 
on the patient seeking medical help in order to calculate the scale of the problem. A 
European report suggests that 90% of carriers don't know that they have viral 
hepatitis and that only 21% know what that means.231 Our study estimated the 
prevalence in the Far Eastern population (including Chinese) to be 2.1% but other 
studies have quoted much higher values in Chinese immigrants. A study looking at 
patients attending genito-urinary clinics in London, where no external referral is 
necessary, estimated the prevalence to be 12.8%.224 A Central London health centre 
that has Chinese speaking doctors and purely deals with patients of Chinese origin 
quotes similar numbers (personal communication). Even though healthcare in the UK 
is free, patients' perception of their disease and their ability to relate to someone 
who understands their language can affect their attendance. However such studies 
may give an indication of numbers of patients who are HBsAg positive but don't 
report any more about the prevalence of cirrhosis and decompensated disease.  
A recent study by McPherson et al did look at HBV screening and disease severity in 
Chinese immigrants in North East England using DBS from volunteers attending health 
centres and churches. They found 53/606 tested positive for HBsAg but only 31 
accepted the invitation for outpatient review and investigation. Three patients were 
found to have active disease and started on treatment, but none had cirrhosis or 
decompensated disease.173  
In the SIMIT cross-sectional study, all the HBV outpatient attendances over a 5 month 
period to 74 centres in Italy were analysed. Of 3760 patients included, about a 
quarter were immigrants. Most of the immigrants were from Central Italian centres, 
which would have included the capital Rome, whilst the Italian cases were distributed 
more in the South and North. Most studies looking at immigrants typically show that 
immigrants seem to prefer to live in the metropolitan cities and capitals. Asia and 
Eastern Europe were the predominant regions of origin. The immigrants were 
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younger, predominantly female, less likely to be co-infected with HCV, HDV or HIV, 
less likely to be HBeAg positive, and were less likely to have cirrhosis or HCC.226 
However, the study period was short, significantly more immigrants presented on 
only 1 occasion and fewer of this group had had liver biopsies, meaning that it would 
be difficult to establish the true stage of the disease if the patients did not continue 
their follow up. The same applies to treatment as it is very unlikely treatment would 
have been started on the first outpatient visit unless the patient was known to have 
active HBV infection. At the time of our study the routine testing of HDV was not 
common place and so it is possible that we may have had more HDV co-infections had 
we tested for it.  
The CUSHI-B study involved analysing 698 demographics, clinical details and blood 
samples of CHB patients referred from 15 centres over a 2 year period. Patients were 
born in 61 countries, with most coming from the Commonwealth countries of Asia 
and Africa, which generally reflects the ethnic mix of UK. Sixty percent were men and 
aged between38-50. Like the SIMIT study, genotype analysis was performed and 
showed good correlation between ethnicity and genotype. At the time of our study 
genotype analysis was not routinely done on all patients with HBV infection. The 
study does suffer from referral bias as immigrants may well be over-represented. Our 
study looked at all attendances to two hospitals in East London (neither of which 
were included in the CUSHI-B study), rather than look at a selection of cases of 




The results of this study show that there is massive under-diagnosis of CHB in 
immigrants in East London and as such we are probably under treating this disease. 
As shown in chapter 4, various factors are associated with progression to 
decompensated disease (decompensated cirrhosis and HCC). Allowing us to predict 
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disease progression will help us plan and develop adequate services for the future as 
well as trying to reduce morbidity and mortality. 
Further studies need to examine the strength of the correlates of this association. For 
example, the role of different genotypes was not explored and this may well have a 
role to play; different ethnicities are associated with different genotypes which are 
also associated with varying rates of HCC incidence.233 Similarly the roles of smoking 
and diabetes have not been explored very much in the past and yet are significant 







6.1 Summary of findings 
The purpose of this thesis was to investigate chronic hepatitis B infection in the 
immigrant communities of East London. Chapters 3, 4 and 5 deal with prevalence and 
the risk factors for cirrhosis and decompensated liver disease (decompensated 
cirrhosis and HCC) in the Bangladeshi & Pakistani and other immigrant groups. 
Chapter 2 details the preliminary work done by myself in collaboration with others in 
validating an OMT method for diagnosing CHB infection. This was necessary in order 
to calculate the prevalence of HBV in the Bangladeshi and Pakistani populations as 
described in chapter 3. 
The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-
Hepatitis B Virus (REVEAL-HBV) study is the landmark study looking at the natural 
history of CHB infection. Approximately 90,000 residents from 7 townships in Taiwan 
were offered screening for HBV, of which about 24,000 accepted. Of these, 4155 
were HBsAg+ but 3653 individuals were included in the study. Over an 11 year period 
and without being given antiviral treatment, they showed that CHB infection was 
associated with increased mortality from all causes of liver disease, HCC, chronic liver 
disease and cirrhosis. The study authors proposed that elevated HBV DNA (>104 
copies) at baseline was the most important predictor of developing HCC and was 
independent of HBeAg, ALT, genotype status and even the presence of cirrhosis (on 
ultrasound).50;234 This is a ground breaking study that, for obvious ethical reasons, 
cannot be repeated. However, the study does provide an insight into the factors that 
should be incorporated into future models and we have used these factors in a cross 
sectional analysis of patients with chronic hepatitis B living in East London.   
The REVEAL study examined only patients from SE Asia. The UK as a whole has low 
prevalence for HBV, but in East London there are multiple, diverse ethnic 
communities with a high prevalence of CHB. Since patients of different ethnicities 
living in a Western society have not been studied in detail and as our clinical 
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impression was of slow disease progression in patients of Bangladeshi and Pakistani 
origin, we studied the epidemiology and natural history of CHB in our local 
community.172 As many immigrants originate from Bangladesh and Pakistan we 
conducted a detailed analysis of this population and also studied other communities 
where data was available. A number of assumptions were made in our study. We 
assumed that representative people from Bangladesh and Pakistan would attend 
local mosques (allowing the community prevalence to be estimated from studies in 
local religious centres) and because healthcare is provided free, we assumed that 
those with severe disease would attend the local hospitals. Although these 
assumptions could be challenged we believe that they are reasonable and an on-
going study involving testing in primary care will allow some of these assumptions to 
be examined in further detail. Our study targeted this immigrant group to see if the 
same risk factors found in the REVEAL study also applied here.  We looked at hospital 
attendance and the development of advanced disease (cirrhosis and decompensated 
liver disease) over a 2.5 year period whilst analysing socio-demographic, biochemical 
and virological factors.   
The major findings of this study are summarised below: 
1. In the Bangladeshi and Pakistani populations, cirrhosis is significantly 
associated with older age (≥40), male sex, elevated ALT (>40) at diagnosis, 
smoking and diabetes. The same factors and alcohol are associated with 
decompensated liver disease at a univariate level. At multivariate level, age 
and sex are statistically significant predictors of cirrhosis and smoking is a 
predictor of decompensated disease. HBeAg status, HBV DNA and genotype 
are not associated with either condition. Only men over the age of 40 were 
admitted to hospital with decompensated liver disease. The calculated annual 
admission rates were 1.4% for Bangladeshis and 2.7% for Pakistanis. 
2. Looking at all immigrant groups together, the same variables, at univariate 
level, for developing cirrhosis and decompensated liver disease were noted. 
With multivariate analysis, older age, male sex and elevated ALT are 
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predictors for cirrhosis, and older age, smoking and presence of diabetes are 
predictors for decompensated disease.  
Age and smoking were significant predictors in all the ethnic sub-groups at 
univariate level. 
 
6.2 Unexpected findings 
The most surprising finding of this thesis was that baseline HBV DNA and HBeAg 
status had no predictive value for the development of cirrhosis or decompensated 
liver disease in this population or any of the ethnic sub-groups. The original REVEAL-
HBV study showed that high viral loads (>106 copies/ml) were significantly associated 
with HCC and cirrhosis over time, but that low viral loads (<104 copies/ml) could also 
be linked with these same complications.50;65 The study authors imply that high levels 
of circulating virus are responsible, to a degree, for disease progression.  This idea is 
endorsed by international consensus guidelines for initiating antiviral treatment.47;157 
The problem is that the REVEAL-HBV authors and others do not explain what happens 
to viral load once these complications have occurred. It may be that with cirrhosis 
and HCC, the ensuing advanced hepatocyte damage leads to clearance of the virus 
from the liver and a corresponding drop in circulating virus. As the viral load 
decreases it would typically be associated with HBeAg negativity. The liver damage 
associated with HBV infection is immune-mediated because HBV is not directly 
cytopathic as shown by the immune tolerant phase, where there are high viral loads, 
HBeAg positivity and normal ALT levels. This is followed by an immune 
active/clearance phase, where there is liver inflammation associated with elevations 
to ALT, reduction in viral load and HBeAg loss. The duration and extent of this phase 
varies on an individual basis but in some cases may lead to end-stage liver disease 
even with the absence of symptoms. The REVEAL authors do contend that significant 
damage may occur many years after HBeAg seroconversion and this could explain 
why HBeAg is less important in predicting HCC. The REVEAL-HBV study does not 
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mention what happened to HBV DNA levels (or HBeAg) during follow up and it may 
be that with the onset of cirrhosis and HCC these amounts decreased.  
The role of HBV DNA in predicting cirrhosis and HCC is complicated. It is assumed that 
cccDNA transcription correlates with intrahepatic HBV DNA which in turn is reflected 
by serum HBV DNA but this may not necessarily be the case.235 One of the problems 
about using baseline HBV DNA levels is who to screen. In the original REVEAL-HBV 
study, the subjects were aged 30 or older when an elevated HBV DNA would probably 
have been associated with the immune active phase. In our study, the youngest 
patients were age 16 and their elevated viral loads most likely reflected the 
underlying immune tolerant phase. It is impossible to say from the duration of our 
study whether those individuals would have gone on to develop advanced liver 
disease. Viral load is also associated with HBV genotype. Genotype B has been shown 
to cause HCC in younger patients, that do not necessarily have to develop cirrhosis, 
and this can occur with lower viral loads and ALT.236;237 Genotypes and associated 
mutations (such as the basal core promoter mutation A1762T/G1764A) were not 
tested in our study as it was not routinely available and so this could have made a 
difference to our results. In the REVEAL-HBV study, those patients who developed 
HCC with low viral loads tended to be older and drank alcohol. Alcoholic liver disease 
can cause cirrhosis HCC in its own right and the extent to which this played a part 
cannot fully be assessed. It maybe there are different genotypes of HCC and cirrhosis 
to which the role of viral load is still emerging. 
In our study we differentiated HBV DNA into 2 groups: those with viral loads ≤4.0 
versus >4.0 log IU/ml. Young patients with immune tolerant disease typically have 
very high viral loads, are HBeAg positive and have normal ALT. These patients could 
therefore have been put in a separate group with very high viral loads >8.0 log IU/ml 
as they may have been contributing to HBV DNA being statistically insignificant as a 
risk factor for cirrhosis and decompensated disease. However on scrutiny of the data, 
it is not straightforward determining who is in this immune tolerant group. Forty-five 
patients had viral loads >8.0 log IU/ml and were HBeAg positive. Of these only 14 
patients had normal ALT (<40): 9 were Far Eastern, 2 African, 1 Bangladeshi and 2 
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were Europeans. All of these patients were aged between 22 and 41. Five of these 
patients had liver biopsy of which 4 were 0/6 fibrosis but 1 had cirrhosis (6/6). This 
result would appear to justify our decision to keep HBV DNA as 2 groups (high and 
low). 
Our study showed that smoking (or previous smoking) was statistically significant at 
univariate level for cirrhosis and multivariate level for decompensated disease. The 
original REVEAL-HBV study also found smoking to be a significant predictor of 
cirrhosis and HCC but only at univariate level. The same authors have constructed a 
REVEAL nomogram with a REACH-B (risk estimation for HCC in chronic hepatitis B) to 
help predict 3, 5 and 10 year risk of developing HCC, but whilst alcohol consumption 
and ALT, amongst others are included, smoking history isn't.204;238 Up until recently, 
smoking was regarded as "controversial" in the development of HCC due to HBV.239 
This is in spite of the International Agency for Research on Cancer stating that HCC 
was a smoking-related cancer.240 A recent meta-analysis of 9 studies claims that there 
is an additive interaction between CHB and HCC although this link is not as strong as 
the relationship between HCV and HCC. How this happens is not fully understood but 
there are a number of possibilities: tobacco smoke contains a number of toxins and 
carcinogens (such as benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N'- nitrosonornicotine) 
which are metabolised in the liver; liver fibrosis may occur due to increased oxidative 
stress, systemic and tissue inflammation, tissue hypoxia, iron accumulation, 
hepatocellular injury and insulin resistance; or it may be due to the additive (and 
confounding) effects of alcohol which is often taken at the same time.179;241 It is 
possible that smoking acts as an initiator of carcinogenesis and HBV contributes as a 
promoter through liver inflammation and cellular inflammation. Given the results of 
our findings it suggests that more effort should be spent trying to persuade HBV 
patients to stop smoking and see whether this improves their chances of not getting 
HCC. 
One of the unique features about studying HBV in a predominantly Muslim 
population of Bangladeshis and Pakistanis is that because of their religious beliefs, the 
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vast majority (>95%) don't drink alcohol, and so this removes alcohol as a potential 
confounding variable in the development of end stage liver disease. However, we 
know from the treatment of the same population of patients who have been infected 
with HCV, that genotype 3 is their predominant genotype, and this is associated with 
steatosis and diabetes. Diabetes is associated with the metabolic syndrome, 
hyperlipidaemia, excess body weight and obesity and all of these have been 
implicated with the development of cirrhosis and HCC secondary to NAFLD/NASH. 
Another peculiar finding is that this phenomenon occurs when applied to the total 
immigrant population, of whom almost 90% claimed not to drink alcohol. This leaves 
the question as to whether the liver complications are due to diabetes/NASH rather 
than HBV or whether HBV, cirrhosis and HCC cause diabetes. Up until now there has 
been a dearth of studies showing a link between HBV and diabetes in the progression 
of liver disease. A recent, retrospective, nationwide, cohort study from Taiwan looked 
at the incidence of diabetes in patients who had already been diagnosed with CHB to 
see whether they developed cirrhosis or decompensated liver disease over a 9 year 
period. Of 14,523 patients identified with HBV from a national insurance registry, 351 
developed diabetes over the study period and 7886 were followed up as non-diabetic 
HBV controls. The authors found that those patients who developed diabetes tended 
to be older and have more co-morbidities than the controls. In the diabetic cohort 
there was a statistically significant difference in the development of cirrhosis and 
decompensated liver disease, and that the latter complication always followed the 
development of cirrhosis. This work relied on the review of insurance registries and 
the accuracy of the people recording the information, but the authors cite this as 
evidence for diabetes causing cirrhosis.232 Unfortunately our study cannot determine 
the temporality of diabetes to HBV infection and the subsequent development of 
complications. However, if diabetes is the predominant contributor to disease 
advancement it could explain why viral load had no effect in our study. Future studies 
would need to examine the role of diabetes in greater detail: duration, level of 
diabetic control, development of diabetic complications, type of treatment, along 
with other socio-demographic (body mass index, weight, presence of central obesity) 
and biochemical markers (serum lipids). The liver biopsies would need to be 
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examined for the presence of steatosis as well as fibrosis. Until then, we should 
emphasise to CHB patients the importance of good diabetic control and encourage 
developing a healthier lifestyle (by eating less and doing more exercise, reduce 
alcohol and stop smoking), as there is evidence that this can impact on the long-term 
progress of their disease. 
 
6.3 Limitations of this work 
With all retrospective studies, the data generated is heavily reliant on the quality of 
source material. The problem is that patient's may not have the correct blood tests 
either at their initial appointment or their subsequent appointments for a variety of 
reasons: patient refused blood tests; doctor did not order blood tests; blood test was 
not done i.e. due to difficulty of phlebotomy; laboratory did not process blood result; 
or patient had blood test performed at another laboratory and the result was not 
available in the hospital notes. Whilst every effort was made to obtain the hospital 
notes, this was not always possible. Even if the notes were found then in a number of 
cases the quality of the details may have been too sparse to make assumptions. For 
instance in 24 cases it was not possible to establish the patient's ethnicity. These 
patients were seen in general hepatology or gastroenterology outpatient clinics, 
sometimes by junior doctors who, due to lack of experience, may not have known 
what tests to order or the correct questions to ask. A number of patients, especially 
those referred following antenatal screening, presented to the clinic once or twice 
and then did not attend again. If the correct blood tests and demographic details 
were not recorded then it was not possible to get this information. We had not 
sought ethical approval to contact patients by phone and this defect should be 
rectified in future studies of this kind. Because the vast majority of patients were not 
born in the UK, their ability to speak English may have prevented them from coming 
for follow up even if an interpreter was available.  
This prevalence and disease burden modelling of Bangladeshis and Pakistanis relied 
on the data derived from the Mosque study. As with all screening studies we depend 
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on volunteers agreeing to take part and this is affected by their aptitude, knowledge 
of the condition and also their availability to take part in screening. However other 
UK-based studies have indicated that our data is accurate and a very small scale study 
in primary care suggested that the prevalence in primary care was similar to that seen 
in our study indicating that our data is likely to be correct.206;242 We noted that the 
prevalence of HBV in women was less than that seen in men, which is in line with 
previous studies in HBV. However, the prevalence in Bangladeshi women was 5 times 
less than that of Bangladeshi men (0.4% versus 2.0%), whereas the prevalence in 
Pakistani females was 1.6% and was close to the male prevalence of 2.0%. It is 
unclear whether this is a true finding or reflects the relatively few Bangladeshi 
women who agreed to be tested. The stigma attached to viral hepatitis may have 
been too great for some individuals to want to be tested i.e. for an individual 
(especially female) to seek testing in a public place, such as a mosque, may have led 
to aspersions being cast about why that person would consider being tested. This 
point probably applies to all ethnicities but seems to be more of an issue with South 
Asian Muslims. 
The prevalence estimates for patients from the rest of the world depended on 
published data and clinic attendance. Given the wide geographic areas considered 
and the local differences in prevalence our estimates of disease burden can only be 
rough estimates. Nevertheless these data do provide the first insights into the 
possible burden of undiagnosed infection in immigrant communities in the UK. 
Studies to estimate the true prevalence of infection will require community based 
screening projects in these communities and a trial (based in a large part on the work 
presented here) is currently under way in East London.   
Our prevalence calculations are based on data from the ONS 2001 census looking at 
age, sex, ethnicity and country of birth. At the time of the study we asked for detailed 
statistics on the Bangladeshi, Pakistani and Indian populations of London at borough 
level. It is not possible to look at every ethnicity and country of birth for all age groups 
in London, let alone the UK. However, because these 3 ethnicities are quite common 
in the UK, accurate numbers were attainable. Although completion of the census is 
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required by law, it is not legally enforced. It is clear that not everybody completes the 
census accurately or at all, especially if you are not living in the UK legally. The ONS 
collects a plethora of data including the ten yearly census, national insurance number 
(NINo) allocations to foreign individuals, labour force surveys (LFS), international 
passenger survey (IPS) and total international migration (TIM). Each of these gives 
different pieces of data, which are not mutually exclusive; some give total figures 
from one point in time, whilst others are derived from representative samples done 
throughout the year. Pendleton et al in their report on the prevalence of HBV in the 
UK chose not to use the 2001 census because they felt it was out of date.225 They 
instead preferred to use the LFS and data commissioned from the Institute of Public 
Policy Research.243 The LFS is a quarterly survey of 60,000 private addresses in Great 
Britain which will give data including country of birth. However private addresses 
don't include communal establishments like hostels, local authority houses or 
residential and nursing homes. At the time of our study, we felt that the census data 
was the most accurate and widely used but would suffer the same level of 
inaccuracies that other population surveys typically face.  
In the REVEAL study cirrhosis was diagnosed on ultrasound. Ultrasound is a non-
ionising radiation modality that is cheap, safe, effective screening tool but which is 
highly operator-dependent. Even in the hands of experienced radiologists, the 
diagnosis can be over-estimated if there is "coarse echotexture" or "irregular liver 
outline". In their study it was performed by gastroenterologists qualified in 
ultrasound. In our study the diagnosis of cirrhosis was made on liver biopsy (either 
percutaneous or transjugular) or there were confirmatory findings on triphasic CT 
liver or MRI liver and the patient had clinical and endoscopic features of portal 
hypertension (low albumin, low platelets, splenomegaly, and presence of varices or 
ascites). Because the criteria we used to diagnose cirrhosis was more robust than 
theirs, it is possible that both studies (ours and theirs) underestimated subclinical 
cirrhosis. This is because the ultrasound changes may have been too subtle to be 
picked up. AFP is routinely tested but at least 10% of patients with HCC do not secrete 
AFP so there may have been patients with undiagnosed HCC who had normal AFP and 
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relatively normal ultrasounds. If these patients did not attend further outpatient 
appointments or they went elsewhere for their treatment (although there was no 
financial incentive for them to do so) then their condition could have deteriorated 
without us knowing.  
At the time of this study, a number of tests were not routinely available which could 
have affected the outcome of the results. Genotype testing was done on small 
number of patients. Delta virus screening was also not routinely done then. This small 
RNA virus, which only occurs in patients with HBV infection, can suppress HBV DNA, 
cause rapid progression of liver damage to cirrhosis and decompensated liver 
disease.244 It is possible that there were more patients with HDV co-infection and at 
the time of the study this test either wasn't available or the patient had ceased to be 
followed up for the test to be done. However we now routinely test all patients for 
delta virus and, of note, no infected patients have been identified who were born in 
the Indian Subcontinent.  Quantitative measurement of HBsAg wasn't routinely 
available. There is growing evidence that this variable may give more insight into who 
will progress to HCC. It has been proposed that quantitative HBsAg levels give a more 
accurate marker of cccDNA transcription than HBV DNA and that it gives a marker of 
response to interferon treatment. Those patients with low HBsAg levels <1000 IU/ml 
probably have inactive disease and levels <100 IU/ml may have a better chance of 
spontaneous HBsAg seroconversion.245;246  
 
6.4 Future studies 
This work has provided as many questions as it has tried to answer. We are still trying 
to find the most effective and efficient way of determining the prevalence of CHB. 
Our HIV colleagues are getting their disease under more control. There is better 
screening, testing is done quicker and the result relayed to the patient faster. If the 
test is positive then assessment and treatment can be offered quickly. As a result the 
development of AIDS in the UK is declining. A similar approach needs to be adopted 
with HBV (and HCV). We need to develop a quick, reliable, valid test for HBsAg and 
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HBcAb that does not need to be administered in hospitals. Once patients are 
identified then the disease needs to be confirmed. We then need to find ways of 
making sure patients are followed up.  
The next step is to identify those markers which will determine who will progress to 
cirrhosis and/or decompensated liver disease. Genotype, delta and quantification of 
HBsAg are variables that should be measured in future to see if this will improve 
diagnosis of current disease but improve prediction of disease advancement. The 
original REVEAL-HBV authors have already proposed a nomogram that will give 3, 5 
and 10 year predictive scores but this has only been tested in Taiwan and Korea with 
very homogenous populations.247 Patients with acute HBV may not be truly "acute" 
and instead may be having a reactivation of their CHB, in which case they may benefit 
from treatment. It has been proposed that one way of differentiating between the 
two conditions is HBcAb avidity but a test for this is not routinely available.248 If this 
were to be developed it would help our understanding and management of these 
patients.   
 
6.5 Conclusion 
Our study, the first to evaluate the burden of disease due to HBV in immigrant 
communities living in the UK clearly shows that there is a very large burden of 
undiagnosed disease in the immigrant communities living in East London. Although 
the retrospective approach used here and the difficulties in accessing all patient 
records may reduce the confidence in the magnitude of the burden there can be no 
doubt that this work has highlighted a significant diagnostic shortfall. Our initial 
hypothesis that different ethnic groups would have different risk factors for disease 
progression has not been confirmed by our study. The previously identified risk 
factors for disease progression were confirmed in our analysis. However we did not 
find an association between viral load and advanced liver disease that has been 
reported by others but we believe this is due to the well described decline in viraemia 
with advanced disease. Of note our work highlights the importance of smoking and 
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diabetes in disease progression in patients with chronic HBV and more attention 
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7 APPENDIX  








The World Health Organization estimates that there are about 350 million people 
with chronic HBV and about 180 million with chronic HCV. Of these, there are about 
600,000 deaths due to HBV annually and 350,000 deaths due to HCV. It has been 
suggested that only about 10% of patients infected with Mycobacterium tuberculosis 
actually develop clinical tuberculosis and less than 1% of those infected with malaria 
die of the disease.249 2 fundamental questions that form the cornerstones of the 
management of chronic disease are who will get “bad disease” and who will respond 
to treatment. Currently we cannot predict either and we know that genotypic disease 
does not necessarily predict phenotypic disease.  
 
There are many proteins that have been implicated as biomarkers of disease. For 
example, alpha fetoprotein (AFP) has been used in the diagnosis of HCC. However it 
has only moderate sensitivity and specificity in screening for this disease.250 Another 
option is to look at the components of the immune system as this plays an important, 
but not altogether fully understood, role in the pathogenesis of disease. One of the 
components of this is the cluster of differentiation (CD) antigens that exist on the 
surface of leukocytes and other cells. CD antigens are glycoproteins that were named 
because they act as receptors and ligands for various monoclonal antibodies. At the 
9th International Workshop and Conference on Human Leukocyte Differentiation 
Antigens in 2010, there were 360 known CD antigens.251 The CD antigens provide a 
number of functions such as providing a receptor for various antibodies, such as CD4 
with HIV and CD35 for complement, cell signalling and cell adhesion.  
 
Immunophenotyping using CD antigens provides the basis of differentiating between 
types of acute leukaemias and diagnosing subgroups (i.e. M0-M7 subgroups of acute 
 284 
 
myeloid leukaemia).252 In the past this has been done using flow cytometry of cells to 
identify the CD antigens involved which was very time consuming. However, 
Woolfson et al, have developed a new approach involving direct measurement of 
serum CD antigens that are presumably released by cells of the immune system. The 
detection system involves multiple testing for multiple antigens whereby a number of 
monoclonal antibodies are arranged in a grid-like array. In each site there is a specific 
antibody, delivered there robotically, that will react with specific CD antigens. The 
amount of capture for each antibody gives an indication of the CD antigen expression 
in the patient's peripheral blood. This technique was used in a number of patients 
with different types of leukaemia and lymphoma and the consensus rate with 
established criteria was 94% with peripheral blood and 98% with bone marrow 
samples. It has also been studied with patients with different types of HIV infection: 
long term non-progressive patients not on treatment, those being maintained on first 
line treatment, and patients requiring salvage treatment. Compared to healthy 
controls, the HIV positive patients had decreased expression of CD60, CD102 and 
CD126 and increased expression of HLA-DR and CD20. Hence this new technique 
offers a rapid, serum based assessment of immune system function and we speculate 
that this approach may be diagnostically useful. 
 
There is evidence that CD antigens change in viral hepatitis. It has been suggested 
that HBV may protect hepatoma cells from complement dependent cytotoxicity by 
up-regulating CD46.253 Whilst with HCV, interferon appears to down-regulate CD81 
and those patients that ultimately go on to have SVR had lower circulating levels of 
CD81.254;255  
 
By identifying the amount of expression of the different types of CD proteins in the 
blood it may be possible to determine who will develop progressive viral hepatitis and 
who will develop stable disease. Furthermore it is possible that these assays may 





1) Different viral infections of the liver are associated with different CD antigen 
profiles in serum – thus patients with acute HBV infection will have a different profile 
from patients with chronic HBV infection that will differ from that seen in acute and 
chronic HCV infection. 
2)   The CD profiles of patients with different phases of chronic HBV infection will 
differ.  
3)   The CD antigen profile in patients with HBV and HCV infection differs in those 




This was a retrospective study using blood samples from patients with HBV and HCV. 
The samples were taken from HBV, HCV and a control group that consisted of non-
viral hepatitis patients with varying stages of disease as shown in Table 1. Numbers 




HBV HCV Controls 
HBeAg- patients with low viral load & 
normal LFTs  
25 Rapid virological 
response patients  
17 Patients with normal 
LFTs  
22 
HBeAg- patients with high viral load & 
raised LFTs  
9 Early virological response 
patients  
19 Patients with raised 
LFTs  
17 
HBeAg+ patients with high viral load but 
normal LFTs  
11 Patients who relapsed on 
treatment  
11   
HBeAg+ patients with high viral load but 
raised LFTs  
12 Patients who did not 
respond to treatment  
8   
Patients with HBeAg seroconversion with 
PEG-IFN  
2     
HBeAg+ patients who failed to respond to 
PEG-IFN (5) 
     
Patients who cleared HBsAg spontaneously 
(7) 
     
Patients who cleared HBsAg with treatment 
(2) 
     
 
 Table 1  Patient samples collected for CD antigen study. Numbers are samples collected and sent to the reference laboratory.
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In the HBV cohort, the first four rows correspond to the different stages of HBV 
carriage described in chapter 1. HBeAg positive patients with high viral load and 
normal LFTs correspond to the immunotolerant phase. HBeAg negative patients with 
low viral loads and normal LFTs correspond to the immunosurveillance phase. HBeAg 
positive patients with high viral loads and deranged LFTs represent the immunoactive 
phase. HBeAg negative patients with high viral loads and elevated LFTs signify the 
immunoescape phase. The other four HBV rows correspond to patients who have 
either had treatment or spontaneously lost circulating HBsAg.  
 
In the HCV cohort, the top two rows correspond to patients who were cured of their 
HCV. Rapid virological response (RVR) means that their viral load was undetectable 
following 4 weeks of treatment. Early virological response (EVR) means that they had 
a ≥2 log10 reduction from baseline HCV RNA by 12 weeks of treatment. Both of these 
groups went on to achieve sustained virological response (SVR) whereby HCV RNA 
was not detected six months after the end of treatment. Relapser means that there 
was undetectable viraemia during and/or at the end of treatment but the virus was 
detectable once the treatment stopped. Non-responders are patients who had 
detectable HCV RNA throughout their treatment.  
 
In the control group, none of these patients were infected with HBV or HCV. Patients 
with normal LFTs are patients who had no history of chronic liver disease and also 
happened to have normal LFTs. Patients with deranged LFTs are patients with non-
alcoholic fatty liver disease (NAFLD) but had elevated ALT. 
 
Once samples from the patients had been obtained they were sent to a commercial 
laboratory in Cambridge, ProteinLogic Ltd, for processing and analysis. This study was 
approved by the local ethics committee (See Appendix 2). 
 




Identifying suitable HBV and HCV patients was a labour intensive task as no patient 
databases existed at BLT.  Using the electronic patient record at the Royal London 
Hospital it was possible to view all patients who were attending the hepatology clinics 
as well as those who had attended previously. Only data on clinic attendees was 
readily available and no diagnosis was available in the out-patient listing. After 
discovering who was attending the clinics, I checked the pathology results to 
determine which patients had HBV and HCV. Following this I consulted patient notes 
and clinic letters and cross checked these with the pathology results to determine at 
what stage of the disease each and every patient was. This took a number of months 
to accomplish. Whilst identifying the patients, I also recorded their socio-
demographic data (such as ethnicity, gender, age and medical co-morbidities) along 
with their biochemical and virological parameters. Particular note was made of those 
patients who had been given treatment for their condition and when this was started. 
As treatment either with oral anti-viral agents or pegylated interferon could have an 
effect on the CD antigen profile it was essential to get samples from patients before 
they started treatment. The dates when treatment was started were recorded in the 
notes and were confirmed with the hepatitis nurse, who also kept details of the 
outcomes of treatment for HCV patients. 
 
The next step was identifying the correct sample. The RLH pathology system records 
all the sample numbers of all the patients. All virology samples are kept for two years 
in the departmental freezers. Because of the volume of samples, there is not enough 
physical space to keep samples beyond two years. It is for this reason that I had to 
identify HBV and HCV patients as soon as possible. The serum samples were stored at 
-30°C, whilst the plasma samples were stored in a separate freezer at -80°C. Using 
appropriate handling equipment, I located and retrieved as many suitable samples as 
possible. Ideally all the samples would have been either plasma or serum but because 
of the difficulty finding suitable patients and then tracking down their sample, it was 
necessary to acquire a mixture of plasma and serum samples. Ethical approval had 
been given for 300 samples to be studied but in the end 167 samples were included in 




No supplementary consent from the patients was required. Patients attending the 
hepatology clinics had already given consent to having their blood taken for routine 
analysis and under the Human Tissue Act samples surplus to diagnostic purposes 
could be used in research projects as long as they were anonymous to the researcher. 
The samples were to be coded before being sent to the reference laboratory. Each of 
the samples stored in the virology freezers could hold 2ml, however in many cases 
there was often less than 500μl and so not enough for analysis. For the study, 500μl 
was extracted from the original virology sample. This was then put in another vial, 
sealed with parafilm, coded and stored in another freezer at -80°C. 
 
Before the samples could be sent, a material transfer agreement was agreed. The co-
investigator, Dr Adrian Woolfson, had originally planned to examine the samples at 
the  ProteinLogic laboratories in Cambridge. However, for operational reasons the 
laboratory service transferred to the USA (Gentel Biosciences Inc, Finchberg, 
Wisconsin). As the samples were now being sent to the USA a substantial amendment 
was required to ensure that it was ethical to send samples outside the EU and 
approval was needed from CDC for the transportation of hepatitis samples. Once 
these had been granted, the samples were sent by courier and transported on dry ice 
to keep them at -80°C. The costs of transportation were borne by the hepatology 




This was carried out by Dr Woolfson's team at Gentel Biosciences. The procedure 
used was the same as the method described in his previous study with HIV 
samples.256  
 
In order to "train" their computer, the research team requested that 98 of the 167 
samples be unblinded: 41 HBV, 34 HCV and 23 controls. These unblinded samples 
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were a mixture of plasma and serum samples. Only the underlying condition was 
revealed and not the disease stage. When the analysis was finished then all the 




Of the 167 samples sent for analysis, 96 were analysed: 46 HBV, 35 HCV and 15 
controls. 
 
Figure 1 shows the scatter plots for the different CD antigens comparing controls to 
HBV. There appears to be down regulation of CD antigen expression with the HBV 
samples.  
 
Table 2 shows the sensitivity and specificity these CD antigen profiles comparing 
controls and all other samples to HBV. The table shows that there is very low 
specificity comparing HBV with controls suggesting that CD antigens are very poor at 




Figure 1 Scatter plot comparing control and HBV samples for various CD antigens and 
their cell surface expression 
 
 Sensitivity Specificity 
Control/HBV 93% 0.78% 
All/HBV 85% 90% 
 
Table 2  Predictive accuracy of CD antigens in differentiating between controls and 




Figure 2 shows the scatter plots for the different CD antigens comparing controls to 
HCV. Unlike with HBV, the scatter plot for HCV CD antigens is very similar to that for 
the controls.  
 
Table 3 shows the sensitivity and specificity these CD antigen profiles comparing 
controls and all other samples to HCV. Whilst there is good sensitivity, the specificity 




Figure 2 Scatter plot comparing control and HCV samples for various CD antigens and 




 Sensitivity Specificity 
Control/HCV 92% 63% 
All/HCV 65% 91% 
 
Table 3 Predictive accuracy of CD antigens in differentiating between controls and 





Although the data is not shown, the researchers at ProteinLogic doing the analysis 
compared the best CD antigens at distinguishing controls with HBV and HCV samples 
and analysed them by disease phase. Unfortunately there were no differences seen. 
The results of this study show that there are no statistically significant specific CD 
antigen profiles associated with HBV or HCV, and that none of these can discriminate 
between the different phases of the infections. 
 
The procedures done in this study were similar to that adopted in other studies using 
HIV and leukaemia patients as it involved the same researcher (Adrian 
Woolfson).256;257 In the HIV study, although there was up and down-regulation of 
certain CD antigens between HIV patients and normal controls, there were no 
significant CD antigen patterns between the 3 HIV subgroups (long term non-
progressors, first line treatment  and salvage treatment patients).256 Compared to 
that study, we used far higher numbers of patients for the test groups and for the 
subgroups. In that study they had 4 controls and between 6 and 10 patients in each of 
the 3 groups. We used 73 HBV, 55 HCV and 39 control samples. Although there are at 
least 360 known CD antigens, at the time of the previous study, the array could only 
test for 84. There is always the possibility that HBV and HCV samples, in varying 
stages of their disease, may be associated with different CD antigens that were not 
tested for in this study.  
 
Although this pilot study did not reveal any major diagnostic markers of clinical value 
only a proportion of the known CD antigens were tested and the data does indicate 
subtle differences between HBV and HCV infections providing encouragement that a 
diagnostic/prognostic CD profile may be detected and further studies in this area are 







7.3 Novel vaccine treatment for chronic hepatitis B 
 
Introduction 
In a significant number of patients, chronic HBV is associated with progressive liver 
inflammation that leads, in some, to cirrhosis. The principles of treatment are to 
prevent transmission of the virus to others, stop further disease progression and 
avert the development of HCC. Current treatments are with immunomodulators 
(PEG-IFN) or with oral nucleosides (i.e. Entecavir) or oral nucleotides (i.e. Tenofovir). 
They target the viral polymerase and viral replication but cannot eradicate the 
infection due to cccDNA remaining in the hepatocytes. The treatments may be life-
long and are prone to the development of drug toxicity and resistance. There is a 
pressing need for a more effective short duration antiviral therapy that will eliminate 
HBV from the majority of patients.  
HBV is not directly cytopathic to hepatocytes and whilst virtually all these cells can 
demonstrate actively replicating virus, there is not necessarily histological or 
biochemical damage.30;258 Instead this damage is immune-mediated and in particular 
due to the adaptive response through a complex interplay between virus-specific 
CD4+ and CD8+ T cells. Those individuals who clear the virus mount a forceful, 
polyclonal response with cytotoxic T cell lymphocytes (CTLs) that enter the liver, 
identify the antigen, destroy infected hepatocytes and lead to the secretion of IFNγ to 
inhibit HBV gene expression. Where HBV infection persists, the CD4 response is not 
triggered early enough and there is induction of functionally impaired, narrowly 
focused CD8 cells which can lead to tissue damage but are not vigorous enough to 
clear the virus.259;260 These T cell defects are thought to be related to continued, large 
scale exposure of viral antigens such as HBsAg and HBeAg over time and can lead to 
long term "exhaustion", which results in loss of functions like cytokine production 
(TNFα and IL-2), cytotoxicity and cell propagation. How this occurs is not fully 
understood but may be due to the over-expression of receptors such as programmed 
death-1 (PD-1) on HBV-specific T cells which, inhibit the production of IFN and 
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prevent the production of memory cells.57;261-263 Manipulation of the immune system 
appears to be a viable strategy to achieve sustained resolution of this chronic 
infection.  
The principle of vaccination is to introduce an inactivated pathogen that will stimulate 
the immune system to mount a response should it encounter that pathogen again. 
The current HBV vaccine is a recombinant HBsAg that is given on at least 3 occasions 
via an intramuscular (im) injection. However, over the past 3 decades, there have 
been attempts to use the standard HBsAg vaccine as treatment of CHB. One of the 
first attempts was carried out by Pol et al. Patients were given 3 standard 
recombinant HBV vaccination injections im and the HBV DNA load was noted to be 
undetectable in 31% of patients at the end of 6 months follow up. However, in this 
small study, the authors do not mention whether HBsAg loss also occurred.264 Other 
pilot studies using vaccines with HBsAg also failed to show any significant 
improvement in viral load, HBeAg or HBsAg seroconversion. A large multi-centre 
study looking at patients given im HBsAg recombinant vaccine in combination with 
lamivudine also failed to show any significant clinical treatments outcomes when 
compared to patients treated with lamivudine alone.265 The rationale being that 
reducing the viral load would also stimulate T cell responsiveness, but this was not 
maintained either in this or other studies.266 One of the reasons for varying degrees 
of "success" of using HBsAg as a therapeutic vaccine may be because of the variability 
of HBV disease progression. Spontaneous clearance of the virus does occur, albeit not 
very often, but is more likely to happen during the active phase when there is raised 
ALT and elevated HBV DNA rather than in the inactive carrier state due to inaction by 
the immune system. If the study used patients in the active phase, then in order to 
detect a clear difference there would need to be larger numbers in the control arms.  
It now appears that it is HBcAg rather than HBsAg or HBeAg which is associated with 
stimulating the immune response into clearing the virus.267-269  Patients who clear 
acute HBV infection or whose CHB disease progression is kept in check, have more 
HBcAg-specific cytotoxic T lymphocytes (CTL) than those patients who have 
uncontrolled viral loads and progressive liver damage. An early multicentre HBcAg-
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based epitope vaccine study was performed by Heathcote et al in which they 
administered various im doses of the vaccine into patients on a number of occasions. 
Unfortunately there were no significant treatment responses and the CTL responses 
were weaker in HBV patients than in healthy volunteers.270  
HBV vaccine is a recombinant DNA vaccine produced by inserting the gene for the S 
envelope protein into yeast or mammalian cells where they are grown and purified. 
The problem with subunit and recombinant vaccines is that they require an adjuvant 
to enhance the specific immune response against the antigen. There are a number of 
different adjuvants, but the most common used ones are aluminium based (either 
aluminium phophate or hydroxide). Aluminium adjuvants have been used in vaccine 
treatments in humans against CHB but with only limited success and no long term 
loss of virus.271 There are other possible adjuvant systems such as other mineral salt 
adjuvants (salts of calcium, iron and zirconium), adjuvant emulsions, carbohydrate 
adjuvants (inulin), bacterial adjuvants, and cytokine adjuvants (granulocyte colony 
stimulating factor, PD-1 antagonists and IL-2) but most have not been tested against 
hepatitis B and even then not with human subjects in vivo. 272-275 
DNA vaccines derived from plasmids are another alternative to recombinant vaccines 
and that can induce both cytotoxic and Th1 responses.276;277 There have been some 
promising results, albeit in trials with small numbers. One study showed that even 
with patients who had experienced virological breakthrough with lamivudine some 
patients displayed HBeAg seroconversion, there was induction of IFNγ-secreting T 
cells and increased production of specific NK but that this effect was only 
temporary.278 Another study showed that a DNA vaccine encoding for multiple HBV 
antigens combined with IL-12 adjuvant and lamivudine treatment over 12 months 
reduced viral load, and in some cases suppressed it completely up to 3 years post 
cessation of treatment, but still didn't eradicate HBsAg.279 
Bacteria could potentially be used as an adjuvant to carry the vaccine and so 
stimulate the immune system. Salmonella typhi (S.typhi) is a serovar of Salmonella 
enterica, a gram negative bacterium, which can lead to the systemic disease in 
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humans called typhoid fever. When ingested it can cross the gastrointestinal mucosa 
via the M-cells and can colonize in the gut-associated lymphoid tissue.280;281 S.typhi 
specifically targets immune cells and triggers a variety of cellular, humoral, and 
mucosal immune responses. It is this broad immune response which makes S.typhi 
attractive as a possible vector for antigens. For S.typhi to work as a vaccine it needs to 
retain its immunogenicity but not cause bacteraemia. Various studies have shown 
that at least 2 deletions are necessary for this to happen: aroC- (which limits bacterial 
growth) and ssaV- (which prevents bacteriaemia and toxicity).282-284 The authors of 
these studies have carried out clinical trials using various, single doses of this 
particular avirulent S.typhi in healthy volunteers. They found that the oral 
preparation was well tolerated, there were very few adverse events (and none of 
these were serious) but that the vector was highly immunogenic generating profound 
Th1 responses.285;286  
In the present study, the S.typhi strain described before (S. typhi (Ty2 aroC- ssaV-) 
M01ZH09, Emergent Biosolutions, Wokingham, UK) was modified to have ssaG-HBcAg 
promoter-gene fused to it and to generate HBcAg; the modified vaccine was named 
M04NM11. A phase 1 study utilised healthy volunteers who were given 2 doses of 
M04NM11 and showed it to be safe and well tolerated. It also showed that subjects 
mounted a Th1 response as evidenced by a rise in IFNγ in T cells removed and 
challenged with HBcAg. The question is whether M04NM11 would be safe and 
tolerable in patients with CHB as well as show an increase in Th1 T cells. 
 
Aims 
The principal aim of this study was to assess and compare the safety profile of a new 
investigational medicinal product (IMP), called M04NM11, to a placebo drug in CHB 
patients both during treatment and 6 months after completion of vaccination. The 
secondary aims were to assess the effects of the treatment on the patient's immune 
response and HBV viral load after 6 doses of vaccine and, in particular to monitor 
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conversion of HBeAg positive to negative; development of anti-HBe; drop of HBV DNA 




This was a multi-centre, randomised, double-blind, placebo-controlled, dose-
escalation trial. It was sponsored by Emergent Biosolutions (Wokingham, UK) and 
involved one centre in the UK (Royal London Hospital, RLH) and 4 centres in Serbia. 
The study had been given REC and Medicines and Healthcare products Regulatory 
Agency (MHRA) approval for using the IMP (see Appendix 3).  
Each patient would receive 6 doses of either M04NM11 or placebo. M04NM11 
consisted of live-attenuated Salmonella enterica serovar Typhi (S.typhi) bacteria (S. 
typhi (Ty2 aroC- ssaV- ssaG-HBcAg) RSC5) which had been genetically modified to 
carry HBcAg to stimulate the immune system but not induce Typhoid fever. The first 
dose was given within 28 days of screening and consisted of 10^8 colony forming 
units (CFU). The second dose was 10^9 CFU and the third 10^10 CFU. If the dose was 
safely tolerated then the patient would be given the next higher dose at the next visit 
according to the schedule (see Table 1) with a maximum of 4 doses of 10^10 CFU in a 
6 month treatment trial. 
There were 3 study groups of chronic HBV patients each consisting of a maximum of 
15 patients: 
Group 1: HBeAg positive with low ALT (≤2 x ULN) and HBV DNA load ≥ 10^6 copies/ml 
Group 2: HBeAg positive with high ALT (>2 x ULN and ≤5 x ULN) and HBV DNA load ≥ 
10^6 copies/ml 




For men the normal range for ALT was defined by the reference laboratory (Simbec 
laboratories, Merthyr Tydfil) as 13-67 U/L and for women this was 9-33 U/L.  
Once 9 patients in group 1 had reached dose 3 a safety review committee would 
meet and assuming there were no significant safety issues, recruitment of patients 
into groups 2 and 3 could begin. As raised ALT is a marker of liver dysfunction and as 
there were concerns that the vaccine might induce a severe, liver threatening, 
‘hepatic flare’, the trial was designed so that patients with less inflamed livers (group 
1) and who would not normally undergo anti-HBV treatment should be tried first with 
the test drug.  
Safety and tolerability were assessed clinically to see if patients had experienced any 
adverse events and by analysis of blood, urine and stool tests at an initial screening 
visit and then 19 other dosing and safety visits as per the schedule in the table below. 
At each visit routine blood tests were performed for full blood count, urea & 
electrolytes, LFTs and clotting. Urine analysis was also undertaken and if there was 
significant proteinuria or the presence of nitrites this was to be sent for microscopy, 
sensitivity and culture. Virological tests such as HBeAg and HBeAb status and HBV 
DNA were done on selected visits (see table). All analytical tests were undertaken by 
an independent central laboratory, Simbec laboratories, Merthyr Tydfil, and samples 

















Day - 0 3 7 14 28 35 42 56 70 
Virology x     x  x x x 
 
Visit No 10 11 12 13 14 15 16 17 18 19 
Visit 
type 
Dose 4 S Dose 5 S Dose 6 S S S S S 
Day 84 98 112 126 140 154 168 196 252 308 
Virology x x x x x x x x x x 
 
Table 1 Schedule of trial visits and dates of virology testing. x denotes when virology 
testing occurred. 
 
Because the study used a genetically modified organism (GMO) that could potentially 
cause Typhoid fever, the Department of the Environment, Food and Rural Affairs 
(DEFRA), on the advice of the Health and Safety Executive (HSE), maintained that all 
testing had to be done in an isolated unit. Even though a phase 1 study using GMO 
S.typhi had shown that there was no shedding of the bacteria in faeces by day 7, 
subjects had to remain within England for 14 days post dosing.  
All visits occurred in a separate building called the clinical research centre (CRC), 
which is a dedicated building for running clinical trials and walking distance from the 
Royal London Hospital (RLH). Prior to giving the 1st dose, the study investigator rang 
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Clinphone, an independent organisation, who assigned the subject a randomisation 
number. This number was then taken to the pharmacy department where the 
medication (either M04NM11 or placebo) was reconstituted, prepared and then 
dispensed. After fasting, the subject was given a solution containing 150ml water and 
an effervescent tablet that was allowed to dissolve and containing 2.6g sodium 
bicarbonate, 1.65g ascorbic acid and 30mg aspartame (to act as a buffer against 
gastric acid). The study medication was then added to this solution. This was drunk 
within 30 minutes of preparation. On the dosing visits, the patients had to arrive 
fasted for at least 90 minutes and be kept in a separate, enclosed room with the 
study investigator for at least 60 minutes post ingestion to see if there were any 
immediate adverse events like anaphylaxis. If there were any adverse events post 
dosing or there were abnormal laboratory results then unscheduled visits and further 
analysis and investigations could be initiated after discussion with the principal 
investigator, medical monitor and trial sponsor. 
By the time of start of the trial I had been trained in good clinical practice methods. 
My role was to identify and recruit suitable patients; conduct all the screening, dosing 
and safety visits, including taking history, physical examination and carrying out the 
blood tests; design and implement the standard operating procedure for out of hours 
medical cover and un-blinding of patients; and to assess, record and report all 




Trial candidates were selected from the patients attending the hepatology clinics in 
RLH and could be included if they had: chronic HBV infection (shown by 2 positive 
HBsAg samples at least 6 months apart); were aged over 18; had stable LFTs and PT; 
had a liver biopsy within 2 years; and were able to attend all scheduled visit days. 
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Because of the use of GMO and the possible implications to public health there were 
a number of stringent exclusion criteria: they must not work as commercial food 
handlers (i.e. butchers and the catering trade) because of the risk of spreading 
S.typhi; work with or be in regular contact with immuno-compromised individuals 
(HIV/HCV/HDV co-infected patients); have cirrhosis or decompensated liver disease; 
be pregnant or breast-feeding women; or be with children aged under 2 or adults 
aged over 70; have hypersensitivity to trimethoprim-sulfamethoxazole and 
ciprofloxacin (in case they needed to be treated with antibiotics if they developed a 
typhoid like illness) or anaphylaxis to the ingredients M04NM11; have a recent 
infection that necessitated antibiotic use within 7 days of dosing; have significant 
derangement of liver function shown by ALT >5.1 x ULN, PT >1.25 x ULN or  bilirubin 




Patient recruitment occurred between December 2006 and September 2008. A total 
of 10 patients were screened: 9 patients for group 1 and 1 for group 2. There were 4 
patients who failed screening and all of these were for group 1: one because of 
elevated ALT, one because of newly diagnosed HIV co-infection, and two because 
their viral loads were too low. 
The demographics of the 6 patients involved in the trial at RLH are shown in Table 2. 
Patients 1-5 were in group 1 and patient 6 was in group 2. Three patients were given 
the actual test drug (patients 2, 3 and 6) and three were given placebos (patients 1, 4 
and 5). The identities of the test drug were not revealed until the whole trial had 
finished and the results were analysed. None of the patients withdrew from the study 
before the scheduled end of the trial nor did any adverse events necessitate the need 




Patient Age Sex Ethnicity Genotype Screening Final Trial drug 
1 41 M Ghana E 19/12/06 13/11/07 M04NM11 
2 47 M Bangladesh D 20/12/06 14/11/07 Placebo 
3 19 M Philippines A 19/12/07 21/11/08 M04NM11 
4 20 M Somalia D 12/01/08 08/12/08 Placebo 
5 36 F China B 23/01/08 19/12/08 Placebo 
6 24 F Poland D 22/05/08 20/04/09 M04NM11 
Table 2 Demographic details, initial screening and end visit dates, and test drug given  
 
Figure 1 and Figure 2 show the variation of ALT and HBV DNA throughout the 19 
visits. Two patients (patient 1 and patient 5) had fairly stable ALT values throughout 
the trial. Both of these patients had the placebo medication. The other 4 patients all 
suffered flares in their HBV, in that the ALT went up many fold but the patients 
themselves were clinically well. Again one of these patients (patient 4) had the 
placebo medication but his flare appeared right at the end of the trial and so was 
unlikely to be associated with the test medication.  
Patient 2 had a flare soon after dose 1 and as result had extra unscheduled visits. He 
was not dose-escalated at visit 5 and instead was given another 10^8 CFU (and not 
10^9) dose as his second dose. 
Patient 3 had two big peaks in his ALT - 343 U/L occurring at visit 8 when he had dose 
3 and 665 at visit 17. However both "flares" had a fairly long duration period: 56 and 
84 days respectively, but only with the second flare was there a corresponding drop 
in HBV DNA from more than 8 log IU/ml to 5.84 log IU/ml. In the trial, analysis of HBV 
 306 
 
DNA was recorded in copies/ml but throughout this research period (and clinical 
practice) I have used IU/ml with a conversion rate of 1 IU/ml = 5.5 copies/ml. 
None of the other patients had a significant drop of HBV DNA from baseline by the 
end of the trial period. Patient 1 did have a drop in his viral load to 5.24 log IU/ml at 
week 14 but this was not sustained. Unfortunately due to problems with 
transportation and analysis of his samples there were no virology results at visits 13 
and 15 so it is not possible to establish the full extent of this viral load drop. He was 





























































































Figure 2 Graph showing variation of HBV DNA with each of the trial visits and in relation to dosing for each of the trial patients 
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As with all treatment trials, patients can suffer adverse events. In this study, some 
patients did experience these and they are shown in Table 3. Adverse events are defined 
as any unexpected events that occur in a subject who has been given a medicinal product 
and include occurrences that are not necessarily caused or related to the original 
product. The event can be classed as serious or not serious. According to the MHRA, 
serious adverse events (SAE) are associated with death, or life-threatening injury, or with 
the subject requiring hospitalisation, or can result in persistent or significant disability, 
clinical anomaly or birth defect. Based on this definition, the post-tonsillectomy bleed 
that occurred with patient 2 was classed as a SAE. This is because the patient attended 
the A&E department of RLH at 2200 three days after his tonsillectomy, and was seen by a 
doctor at 2315 but subsequently discharged at 0040 of the next day. As the event had 
transcended beyond midnight it was classed as an overnight hospital admission even 
though the actual admission had lasted less than a few hours. The bleed per se was most 
likely due to the patient not adhering to the post-operative instructions given to him 
rather than due to the study drug. As per the protocol, this SAE was reported 
immediately to the sponsor and the details carefully documented. No specific treatment 
was necessary and the patient was given appropriate advice.  
The enlarged tonsil of patient 2 and the haematuria of patient 4 (due to pre-existing 
kidney stones) were deemed unlikely to be associated with the study drug as they were 
both noted at the time of screening.  
Patient 3 was trekking in the Pyrenees Mountains of Spain and was bitten multiple times 
by mosquitoes. Although insect bites were the most likely cause of his rash, as it 
happened whilst he was still enrolled in the trial, albeit after he had finished all his doses, 
it was still counted as an adverse event possibly related to the study drug. 
Patient 5 was working on a market stall when she sustained a laceration to her head 
from a falling overhead pole. This accident was unlikely to be due to the study drug and 
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she only required sutures to the wound but not antibiotics (thereby invalidating the 
study). 
None of the patients developed a fever or diarrhoeal symptoms suggestive of Typhoid 
fever and there were no positive bacteraemias or positive urine cultures.   
 
Patient Adverse event Action plan Relation to trial drug 
2 Enlarged right tonsil 
ENT referral & 
tonsillectomy 
Unlikely to be related 
2 Post-tonsillectomy bleed Observation Possibly related 
3 Skin rash following insect bites Observation Possibly related 
4 Painless haematuria 
Urology referral & 
Ultrasound 
Unlikely to be related 
5 Laceration to head Sutures to wound Unlikely to be related 
 
Table 3  Adverse events, action plan and relationship to trial drug. 
 
Discussion 
This study achieved its primary aim by showing that both M04NM11 and the placebo are 
safe and well tolerated. Unfortunately none of the secondary aims were achieved. None 
of the patients seroconverted from HBeAg positive to HBeAg negative, nor did the HBV 
DNA drop significantly after the sixth dose. The viral load of patient 3 did drop by 2 log10 
by the end of the trial from baseline but it is unclear whether this was related to 
medication or to the natural fluctuations of chronic HBV infection. One aim was to see 
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what effect M04NM11 had on the immune system by looking at IFNγ production from 
Th1 cells. The (unpublished) phase 1 study had shown that M04NM11 did cause 
increased production of IFNγ. Unfortunately the samples were taken and were due to be 
analysed by University College London but to the best of our knowledge this analysis has 
not been completed and the company involved in the study has now ceased trading 
suggesting that further data is unlikely to be available.  
The study was supposed to have 15 patients in each of the three groups. Within the 2 
year time period, 16 patients had been recruited into group 1, 3 into group 2 and 5 into 
group 3. Of the 1161 mono-infected HBV patients that I found to being followed up in 
the RLH and NUH clinics, only a fraction were known at the time of recruitment. The 
strict trial inclusion criteria made it very difficult to even find patients for group 1: have 
high viral loads (>6 log10 copies/ml), normal ALT values, HBeAg positive, mono-infected, 
liver biopsy within 2 years of screening and not have been on any form of treatment 
within the last year. Most of these patients would typically be young patients in the 
immuno-tolerant phase of the disease. Because they are generally asymptomatic, a lot of 
potential subjects declined screening because of the fear that the test drug would make 
their condition worse. Immuno-tolerant patients typically don't get started on treatment 
because the immune system is not thought to be very active, which is highlighted by 
their normal ALT values. This might explain why none of the secondary aims were 
achieved. Although it is interesting to see that in the three young patients (3, 4 and 6) all 
experienced transient rises in their ALT despite being asymptomatic. A recent study by 
Kennedy et al has suggested that the immunotolerant phase seen in young adults and 
children may be more complicated than first thought. Their T cell profile shows some 
characteristics of "exhaustion" through expression of PD-1, although less than in adult 
patients. Also a proportion of patients with persistently normal ALT showed evidence of 
fibrosis on liver biopsy.49 This would suggest careful follow up of such patients may 
identify more active disease than is currently believed.  
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Recruitment for groups 2 and 3 were possibly lower because patients in these two 
groups (high ALT, high viral load and HBeAg positive and negative respectively) are 
candidates for treatment. The rationale would have been to start them on treatment 
rather than wait until recruitment of these groups began in early 2008.  
All the patients we recruited were non-British immigrants and had a multitude of 
genotypes, which is probably different to the patients enrolled in Serbia where there is 
medium endemicity (UK is low) and possibly more uniformity of genotype. From the 
overall results only 1 patient had a significant, sustained drop in HBV DNA during the trial 
and he/she was in group 3 and from Serbia. Without the immunology results it is not 
possible to say what the Th1 and IFNγ responses are. Before the study began we were 
told that the trial would be published but as the company no longer exists we have not 
been able to insist on the data being entered into the public domain.  This study was 
carried out before the creation of the clinical trials database (www.clinicaltrials.gov) 
which was designed to prevent this from happening in the future.  
To date there are no other similar trials where a bacterial vaccine has been used to 
stimulate the immune system to treat HBV in CHB patients. Most of the studies using 
Salmonella sp vaccine have been about the development of a single dose, oral HBV 
vaccine. They have used modifications to either a Salmonella typhimurium serovar in 
mice or S. typhi in humans and have looked at the CTL response. They have found that a 
variety of routes can be utilised such as oral, rectal and nasal with varying degrees of 
success.280;282-284;287 None have attempted to treat patients who already have CHB.   
By giving an oral vaccine, the rationale is to enhance the mucosa-associated lymphoid 
tissue (MALT) humoral and cellular response against infection as that is where 80% of 
immune cells are located.288 However enterally delivered vaccines have to negotiate the 
same obstacles faced by microbes: gastric secretions and acid, mucus gel and epithelial 
barriers.289 All these may have contributed to the failure of M04NM11 to treat CHB. 
There is also the possibility of mucosal tolerance whereby the MALT does not respond to 
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the perceived threat of the vaccine. Because there are no immunology results from this 
study it is impossible to know what the Th1 response was. Possibly increasing the dose 
may have resulted in different results.  
 
In conclusion, the study drug was shown to be safe but at the doses delivered it was not 
shown to be effective at treating CHB. The closure of the company involved in the study 
sadly precluded further meaningful information being derived from this trial.  
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